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Introduction: Cerebral small vessel disease (SVD) is responsible for a third of 
strokes and is the most common cause of vascular dementia. It is characterised by 
white matter lesions and more diffuse damage outside of the lesions. Despite its 
importance, the mechanisms causing white matter damage are incompletely 
understood. Both increased blood-brain barrier (BBB) permeability and inflammation 
have been suggested to play a role. We hypothesised that BBB permeability and 
microglia activation would be increased in SVD and explored the relationship 
between these processes and other imaging, cognitive and blood markers.  
Methods: A PET/MR system was used to acquire simultaneous dynamic contrast 
enhanced MRI with Patlak modelling to measure BBB leakage, and [C11]PK-11195 
PET to assess microglia activation. We recruited 20 sporadic SVD patients, 20 
monogenic SVD patients (CADASIL) and 20 healthy controls to this study.  
Results: BBB permeability in the white matter of the sporadic SVD group was 
significantly higher than control (p=0.001), with a significantly higher volume of 
focal hotspots (p=0.010). The focal hotspots of activated microglia also had a 
significantly higher mean in the white matter (p<0.001). The role of BBB 
permeability and PK binding in CADASIL was less clear, with no difference in 
permeability but a significantly higher mean of focal hotspot of activated microglia in 
the CADASIL white matter, compared to control (p=0.015). In the sporadic SVD and 
CADASIL groups, the number of voxels containing both significant permeability and 
microglia activation was significantly lower than expected (p<0.001).  
Conclusion: Areas of focal increase in both BBB permeability and microglia 
activation occur in SVD and therefore may have a role in the pathophysiology of 
white matter damage. In this cross-sectional dataset, the two processes were spatially 
independent of one-another. However, we cannot exclude a temporal relationship, 
where one process may precede another, without follow-up data. Further research is 
needed to see if these markers predict white matter damage in longitudinal studies, 
and whether they can be altered therapeutically.  
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Chapter 1: Introduction to the Pathogenesis of 
Cerebral Small Vessel Disease 
 
1.1 Imaging Features of Cerebral Small Vessel Disease 
 
1.1.1 Cerebral Small Vessel Disease 
Cerebral small vessel disease (SVD) refers to a group of pathological processes which 
affect the small vessels in the brain (Pantoni, 2010). SVD spans the fields of stroke, 
dementia and ageing, and is a highly diverse and heterogeneous disease. Our 
knowledge of SVD is still very limited and there are no treatments that target the 
underlying mechanism. This is largely due to a lack of understanding of the basic 
pathophysiology.   
 
SVD accounts for approximately one-third of symptomatic strokes including lacunar 
stroke (Fisher, 1982) and parenchymal brain haemorrhage (Greenberg, 2006). SVD is 
the leading cause of vascular dementia, which make up around 15% of all dementia 
cases (O'Brien and Thomas, 2015).  Together, vascular dementia and Alzheimer’s 
disease make up 70-75% of total dementia cases (Gorelick et al., 2011). Many of the 
dementia patients actually have both dementias to a certain degree, with vascular 
comorbidity present in 30-60% of Alzheimer’s disease patients and Alzheimer’s 
disease pathology present in 40-80% of vascular dementia patients (Attems and 
Jellinger, 2014, Wallin et al., 2018). SVD is also thought to contribute towards age 
related cognitive decline. SVD is frequently seen on the magnetic resonance imaging 
(MRI) scans of brains of cognitively healthy elderly individuals (van der Flier et al., 
2005). Therefore, the reality is that the prevalence of SVD is actually much higher 
than our current statistics would suggest (Hachinski, 2008).   
 
Like many countries, the UK has an ageing population, meaning that the prevalence 
of SVD will only continue to rise over the coming years (Kuller and Lopez, 2016). 
The disease is not only life-changing for patients affected and their families, but also 
has large economic implications for health service providers (Poggesi et al., 2011), 
making research into this area even more important.  
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1.1.2 Application of MRI 
MRI is a versatile tool used throughout the field of neurology for imaging of the 
brain. MRI utilises the differing water composition of tissues to create contrast in 
images. In the brain, this is mainly used to discriminate between grey matter (GM), 
white matter (WM) and cerebrospinal fluid (CSF); plus showing up any pathology.  
 
Since imaging the small vessels themselves in the brain is not possible with current 
techniques, other imaging markers are used for diagnosis, tracking disease 
progression and research end-points. Features of SVD on neuroimaging include recent 
subcortical infarcts, lacunes, white matter lesions (WMLs), perivascular spaces, 
cerebral microbleeds (CMBs) and brain atrophy (Wardlaw et al., 2013c). These 




Figure 1.1: Characteristic MRI markers of SVD. Example images (upper), schematic 
representations (middle) and MRI features (lower) for the individual markers. DWI= 
diffusion-weighted imaging, FLAIR=fluid-attenuated inversion recovery, GRE = 
gradient-recalled echo. Reproduced with permission from (Wardlaw et al., 2013c). 
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1.1.3 Lacunar Infarcts 
Lacunar infarcts (or lacunar strokes) are key feature of SVD. Lacunar infarcts are 
small strokes (3-15mm in diameter) in the deep cerebral WM, deep GM nuclei and 
brainstem, which are thought to result from the occlusion of a single small perforating 
artery (Wardlaw, 2005). Acute lacunar infarcts are easily detected on diffusion-
weighted imaging (DWI) if imaged within a few weeks of the acute event, where they 
appear as a region of hyperintensity.  
 
After the initial acute phase of the infarct, most lacunar infarcts will then cavitate to 
become a fluid filled cavity known as a lacune. Lacunes can be imaged as a 
hypointense region on both T1 and T2-fluid attenuated inversion recovery (FLAIR) 
scans. However, lacunar infarcts do not always cavitate into lacunes. Recent studies 
have shown that 1/3rd of recent infarcts do not lead to cavity formation within a 2-year 
period and will either disappear completely or become part of a WML (Okazaki et al., 
2015). These studies have led to the suggestion that counting lacunes probably 
substantially underestimates the real burden of lacunar infarcts (Loos et al., 2012). 
 
Lacunar infarcts have various clinical symptoms depending on lesion location, but 
around 30% of patients with lacunar stroke are left dependent (Bamford et al., 1991). 
Lacunar infarcts are associated with cognitive decline and dementia onset during 
follow-up (Samuelsson et al., 1996). Lacunes are also found in the brains of around 
20-50% of the healthy elderly population (Vermeer et al., 2007). They are often 
termed ‘silent’ brain infarcts, but they have been shown to correlate with subtle 
deficits in physical and cognitive function, suggesting they are clinically relevant 
(Schneider et al., 2007, Choi et al., 2012, Vermeer et al., 2007).  
 
Lacunar strokes have a 22.4% recurrence rate and 25% mortality rate at five years 
(Norrving, 2003). This suggests our current preventative treatments are not good 








WMLs are another key characteristic of SVD seen on MRI. They are thought to 
represent a reduction in tissue, gliosis and a loss of myelin and axons due to chronic 
diffuse injury (Gouw et al., 2011). WMLs appear as a region of hyperintensity on T2 
and T2-FLAIR scans. WMLs tend to be bilateral and symmetrical and are found 
mainly in the periventricular and deep WM regions (Wardlaw et al., 2013c). They can 
also be found in the subcortical GM structures and brainstem.  
 
WML burden has been correlated with cognitive function, mood, mobility, depression 
and urinary problems in cross-sectional studies (Pantoni, 2008). They have been 
associated with both cognitive decline and dementia in longitudinal studies (Pantoni 
et al., 2007). Studies have also investigated the effect of WMLs on recurrent stroke 
risk and have found that presence of WML during first stroke increases the risk of 
having a second stroke (Miyao et al., 1992).  
 
WMLs are commonly seen as an incidental finding on MRI scans of the cognitively 
healthy elderly (Ylikoski et al., 1995). Up to 90% of patients over 65 years present 
with some degree of WMLs on MRI (Schmidt et al., 2011). As with silent lacunes, 
when these healthy elderly individuals are tested for cognitive impairment, there is a 
correlation between extent of WML and cognition (Nylander et al., 2018). This 
cognitive impairment, which can be associated with WML, is often at a sub-clinical 
level but can still impact the daily lives of these individuals. 
 
There is evidence that WMLs in the periventricular or deep WM should be 
differentiated in studies (Griffanti et al., 2018). Studies have reported that there is a 
greater association between perivascular WMLs and cognitive performance 
(Bolandzadeh et al., 2012), whereas deep WMLs are more associated with mood 
disorders (Krishnan et al., 2006, de Groot et al., 2000). Postmortem studies have also 
shown there seems to be an anatomical difference in the lesions. Smooth perivascular 
WMLs predominantly show demyelination and gliosis; whereas deep WMLs and 
irregular periventricular WMLs show increased axonal and tissue loss suggesting 
infarction, in addition to demyelination and gliosis (Fazekas et al., 1998, Kim et al., 
2008). It has also been suggested that the two types may have different underlying 
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pathologies; smooth periventricular WMLs could be attributed to increased blood-
brain barrier (BBB) permeability whereas deep WMLs and irregular periventricular 
WMLs are a result of hypoperfusion. However, this is likely an oversimplified model. 
Additionally, in severe SVD it can be difficult to differentiate between deep and 
periventricular WML, as the extent of the damage means that the WMLs extend all 
the way from the ventricles out into the deep WM. Therefore, despite this 
differentiation, most studies still measure WML volume in its entirety.  
 
It is generally accepted that WMLs increase over time (Schmidt et al., 2016); 
however, the growth rates vary widely between studies. In the normal aging person 
with confluent WMLs, the mean rate of progression ranges from 0.23-1.33cm3/year 
(Sachdev et al., 2007). This WML growth does not seem to be random; a recent study 
estimated that around 80% of incident WMLs occurring over four years represented 
extensions of pre-existing lesions (Maillard et al., 2012). WMLs have also been 
shown to expand from the periventricular WM, where they tended to be most 
prevalent, toward the subcortical WM (Duering et al., 2013). They grew along the 
trajectories of small perforating arteries, suggesting WMLs are prone to growing in 
the vascular end zone.  
 
The progression of WMLs has been associated with cognitive decline, dementia, 
incident stroke, gait dysfunction and depression (Schmidt et al., 2016). WMLs have 
been associated with both general cognitive decline and a decline in information 
processing speed (PS) (van Dijk et al., 2008). Greater WML load at baseline has also 
been shown to predict both conversion from normal ageing to mild cognitive 
impairment (Smith et al., 2008) and functional decline and disability (Inzitari et al., 
2009).  
 
Some studies have demonstrated that WML burden appears stable or even decreases 
over time. Early reports of this were put down to a measurement error (Schmidt et al., 
2003, Sachdev et al., 2007).  However, multiple case reports then emerged, 
suggesting there can be regression of WMLs after ischaemic stroke (Moriya et al., 
2009, Durand-Birchenall et al., 2012), hepatic encephalopathy treatment (Minguez et 
al., 2007, Rovira et al., 2007) and carotid artery stenting (Yamada et al., 2010). 
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Following this, more recent studies have revalidated this finding in larger sample 
sizes of SVD patients, showing there does indeed seem to be regression of WMLs in 
some patients, suggesting these WMLs are far more dynamic than originally thought 
(Cho et al., 2015, Ramirez et al., 2016, van Leijsen et al., 2017). Interestingly, the 
retraction of WML was found to be associated with no change in cognition, but rather 
it is associated with stable SVD (van Leijsen et al., 2019).   
 
The progression of WMLs, and their relationship to cognition and clinical endpoints, 
means that WML volume is commonly used as a trial end-point. Studies using blood 
pressure lowering medication and statins have shown this to reduce WML growth 
compared to placebo (Dufouil et al., 2005, Mok et al., 2009), suggesting that the 
process is both modifiable and influenced by cardiovascular risk factors. This 
dynamic nature of the WMLs has led researchers to wonder about whether WML 
reversal with therapeutics is potentially possible, whereas previously the best outcome 
was thought to be slowing WML progression. New therapeutics will look to both 
slow down progression and reverse these WMLs, in the hope to slow down the 
progression of clinical symptoms.   
 
 
1.1.5 WM Microstructural Changes 
In addition to the WMLs seen in SVD, there is more widespread tissue damage to 
WM microstructure that cannot be detected through T2-weighted or FLAIR imaging.  
 
Diffusion tensor imaging (DTI) allows assessment of the microstructural integrity of 
whole WM by measuring the direction and magnitude of water diffusion in the 
intracellular compartment of the axons (Pierpaoli et al., 1996). It provides two main 
scalar parameters: mean diffusivity (MD), which is a measure of the magnitude of 
diffusion of water averaged in all spatial directions, and fractional anisotropy (FA), 
which provides information about the directionality of water diffusion. DTI measures 
correlate with markers of myelin integrity, and axonal damage and density (Shereen et 
al., 2011, Gouw et al., 2008). A reduction in FA and increase in MD are believed to 




DTI has been shown to significantly correlate with cognitive performance in SVD 
patients (van Norden et al., 2012, D'Souza et al., 2018). Studies have also correlated it 
with the risk factor hypertension in SVD patients (Gons et al., 2010).  Looking 
longitudinally, DTI has been shown to predict faster cognitive decline (Jokinen et al., 
2013) and a decrease in the Rankin score (Holtmannspotter et al., 2005).  
 
Longitudinal studies have suggested that DTI is the most sensitive measure to 
ongoing changes in SVD patients; Nitkunan et al. reported a 2.96% increase in MD 
and 2.13% decrease in FA in SVD patients over one year, despite an unchanged 
lesion load and brain volume (Nitkunan et al., 2008). Further, thalamic FA was found 
to predict WML accrual four years on, suggesting that these underlying WM 
microstructural changes are pathological (Cavallari et al., 2014). 
 
The strong evidence for the clinical relevance of DTI to SVD has led to the 
incorporation of DTI into clinical trials with MD and FA used as primary end-points 




CMBs are small hypointense regions present on T2* weighted or susceptibility-
weighted sequences (Wardlaw et al., 2013c).  They are small (usually 2-5mm in 
diameter) and generally cannot be seen on FLAIR, T1-weighted or T2-weighted 
sequences. CMBs are seen in 5 to 15% of the elderly population (Cavalieri et al., 
2012) and in 85% of patients with vascular dementia (Seo et al., 2007).  
 
CMBs have been associated with lacunar infarcts and WMLs (Vernooij et al., 2008, 
Gao et al., 2014, Cordonnier et al., 2007, Wardlaw et al., 2006). In longitudinal 
studies, subjects with CMBs at baseline showed more than five times higher risk for 
newly occurring CMBs compared to those without (Poels et al., 2011). 
 
The clinical relevance of CMBs is still poorly understood. Meta-analyses of the 
studies showed that patients with CMBs had a higher incidence of cognitive 
impairment, lower scores of cognitive functions from the Mini Mental State 
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Examination (MMSE) and Montreal Cognitive Assessment (MoCA) and conversion 
to dementia (Li et al., 2017b, Charidimou et al., 2018). Follow-up studies have 
associated an increasing number of CMBs with a decline in global cognition (GC) 
(Liem et al., 2009, Akoudad et al., 2016) and executive function (EF) (Meier et al., 
2014, Gregoire et al., 2012). However, not all studies have shown a relationship 
between CMB and cognitive decline (Jimenez-Balado et al., 2019). Therefore, more 
studies are required to confirm the pathological association with CMBs before they 
are used as common practice clinically and as research end-points. 
 
 
1.1.7 Enlarged Perivascular Spaces 
The human brain contains a lymphatic drainage system for interstitial fluid from the 
brain along perivascular spaces around the arteries, arterioles, veins and venules. 
Perivascular spaces are microscopic in the healthy brain; however, larger spaces can 
be seen using MRI (Groeschel et al., 2006). Enlarged perivascular spaces have similar 
signal intensity to CSF on all sequences; they follow the blood vessels so they will 
appear linear if imaged parallel to the vessel and circular if imaged perpendicular to 
the vessel (Wardlaw et al., 2013c). It can be difficult to discriminate between enlarged 
perivascular spaces and lacunes as they both appear hypointense on T2-weighted or 
FLAIR imaging; so the general rule is that if it is <3mm and does not have a rim or 
area of high signal intensity around it, then it is an enlarged perivascular space. T2* 
can also be used to check there is no evidence of hemosiderin in its wall to distinguish 
it from a CMB (Ding et al., 2017).   
 
Enlarged perivascular spaces are commonly found in SVD, particularly in the basal 
ganglia, centrum semiovale and midbrain (Wardlaw et al., 2013a). They have been 
associated with WMLs and lacunar infarcts (Doubal et al., 2010, Loos et al., 2015). 
Some studies have shown there to be a relationship between cognitive decline and the 
number of perivascular spaces in the basal ganglia (Huijts et al., 2014, Arba et al., 
2018, Maclullich et al., 2004) and total number (Passiak et al., 2019, Ding et al., 
2017). However, not all studies have shown this association (Benjamin et al., 2018, 
Riba-Llena et al., 2016, Yao et al., 2014). Therefore, the clinical significance of 
perivascular spaces remains controversial. 
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1.1.8 Brain Atrophy 
Brain atrophy is common in diseases that affect the brain and in normal ageing (Fjell 
et al., 2009). Brain volume is calculated from T1 MRI scans, which can be used to 
determine the volume of the GM, WM and CSF. Normalising these measures for 
intracranial volume (ICV) accounts for head size and reduces interindividual variation 
(Whitwell et al., 2001). Brain volume can be tracked over time and brain atrophy can 
be calculated.  
 
Within vascular disease, brain atrophy is thought to include neuronal loss, cortical 
thinning and WM reduction (Wardlaw et al., 2013c).  Cross-sectionally, brain volume 
is lower in SVD compared to controls and is associated with reduced EF (Nitkunan et 
al., 2011). Longitudinally, brain atrophy has been shown to occur in SVD and 
correlate with cognitive decline (Nitkunan et al., 2011, Jokinen et al., 2012). 
 
Many studies have shown an association between brain volume and WMLs 
(Appelman et al., 2009, Aribisala et al., 2013, Godin et al., 2009, Lambert et al., 
2015), but until recently it was unclear as to whether these processes had a common 
pathogenesis or just shared risk factors. More recent work has suggested that WML 
progression is associated with accelerated brain atrophy, suggesting that atrophy is a 
secondary mechanism in WML degeneration (Lambert et al., 2016). Aribisala et al. 
also showed a focal thinning in GM regions connected to subcortical infarcts 
(Aribisala et al., 2013). Therefore, brain atrophy is thought to be a pathological and 
clinically relevant process in SVD, resulting from the underlying changes occurring in 
the WM. If treatments could reduce the progression of WMLs and appearance of 
lacunar infarcts then this would hopefully also slow down brain atrophy and reduce 




1.2 SVD Subtypes 
 
1.2.1 Sporadic SVD 
Sporadic SVD is prevalent within our population, associated with a variety of genetic, 
cardiovascular and environmental risk factors, which all increase the risk of it 
developing. The single biggest risk factor for SVD is age, which has led some to 
conclude that SVD may be a natural consequence of living beyond our physiological 
means (Thompson and Hakim, 2009).  
 
Hypertension is the major modifiable risk factor associated with SVD.  Longitudinal 
studies have consistently shown that blood pressure correlates with the likelihood of 
WMLs being present, and also the severity of them, in both SVD patients and in the 
elderly population (Guo et al., 2009, van Dijk et al., 2004, Liao et al., 1996, Godin et 
al., 2011). Long-term hypertension has been shown to result in lipohyalinosis of the 
media and thickening of the vessel walls, which leads to narrowing of the lumen of 
the arterioles and small perforating arteries (Pantoni and Garcia, 1995). Further it has 
been shown to increase blood vessel fibrosis and alter the distribution of collagen and 
other extracellular matrices to result in stiffness of the vessel walls and reduced 
cerebral blood flow (CBF) (Faraco and Iadecola, 2013). Other cardiovascular risk 
factors have also been associated with SVD: female sex, smoking, and high baseline 
WML load were all significantly associated with SVD progression and a decline in 
cognitive function (van Dijk et al., 2008).  
 
Both twin and family history studies suggest that SVD has a heritable element 
(Carmelli et al., 1998). Twin studies have shown there is a WML concordance rate of 
61% in monozygotic pairs and 38% in dizygotic pairs (Carmelli et al., 1998). 
Candidate gene and genome-wide association studies (GWAS) have attempted to 
uncover which genes may be mediating this effect. Rannikmae et al. found that 
genetic variations in COL4A2 and HTRA1 are associated with lacunar stroke 
(Rannikmae et al., 2017), whilst Traylor et al. found that variations in PLEKHG1 are 
associated with WMLs (Traylor et al., 2019). Further, genetic variants in the VCAN 
gene have been associated with FA and MD, suggesting they may have a role in the 




Treatment of risk factors is still the primary treatment used for SVD, predominantly 
with anti-hypertensives and statins; there are currently no therapeutics that target the 
underlying mechanism of SVD.  
 
 
1.2.2 Monogenic SVD (CADASIL) 
There are several single-gene disorders known to cause SVD. Cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy (CARASIL), COL4A1-related SVD, retinal vasculopathy with 
cerebral leukodystrophy (RVCL) and Fabrys disease are all examples (Choi, 2015).  
 
CADASIL is the most common form of hereditary stroke disorder. The disorder is 
thought to have a prevalence of between 2 and 5 in 100,000 but may vary between 
populations (Di Donato et al., 2017). It is caused by mutations in the Notch3 gene on 
chromosome 19q12 (Joutel et al., 1996).  The Notch3 receptor protein is 
predominantly expressed in adults by vascular smooth muscle cells and pericytes. The 
initial symptom of CADASIL tends to be migraine, with onset at around 20-30 years 
old (Tan and Markus, 2016). Transient ischaemic attacks (TIAs) and strokes are 
reported in around 85% of symptomatic patients (Dichgans et al., 1998), with mean 
age at onset being 45-50 years old (Opherk et al., 2004).  
 
CADASIL patients show extensive WMLs and lacunes on T2-weighted and FLAIR 
scans. WM changes can often involve the anterior temporal lobe, external capsule and 
superior frontal gyrus (Auer et al., 2001); this differs from the pattern seen in sporadic 
SVD. These WM changes can be seen in presymptomatic CADASIL patients, from 
the age of 20-30 onwards (Singhal et al., 2005). Life expectancy is also reduced to 
64.6 years in men and 70.7 years in women (Opherk et al., 2004). 
 
In CADASIL, arterioles and venules accumulate granular osmiophilic material within 
the vascular smooth muscle cell membrane (Yamamoto et al., 2013). The vascular 
smooth muscle cells gradually undergo degeneration with mural fibrosis which results 
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in stenosis of the arteries and a loss of the ability to autoregulate (Stojanov et al., 
2015). Recent evidence has shown that the accumulation of Notch3 protein also 
affects the capillary pericytes, affecting CBF and BBB permeability (Dziewulska and 
Lewandowska, 2012).  
 
In CADASIL, cardiovascular or environmental risk factors are not required for 
manifestation of the disease. However, the same risk factors as sporadic SVD are still 
known to accelerate the disease pathogenesis (Adib-Samii et al., 2010). Hypertension 
and smoking have been associated with earlier onset of stroke (Singhal et al., 2004) 
and an increased likelihood of progression to dementia (Chabriat et al., 2016).  
 
Similarly to sporadic SVD, current treatments for CADASIL include treatment of the 
risk factors, such as anti-hypertensives and statins, and treatment of the symptoms, 
such as migraine medication. There are no treatments that target the underlying 





1.3 Clinical Features of SVD 
 
The vessel pathology in SVD leads to many changes in the brain, which manifest as 
clinical symptoms. SVD is fairly unique in the sense that the symptoms seen will 
progress in both a slow and a sudden way; the gradual build up of brain pathology due 
to chronic damage leads to a gradual symptom increase, which will then be mixed 
with acute damage from strokes, leading to a more sudden increase in symptoms 
specific to the stroke.  
 
 
1.3.1 Cognitive Symptoms  
SVD is the most common cause of vascular cognitive impairment and vascular 
dementia (Pantoni, 2010, Wardlaw et al., 2013a).  It has also been shown to worsen 
the symptoms of other dementia disorders, such as Alzheimer’s disease. 
 
Cross-sectional studies have characterised the profile of the cognitive impairment 
seen in SVD. SVD patients show early impairments in PS and EF, with long-term 
memory (LTM) mostly spared (Lawrence et al., 2013). Similarly, CADASIL patients 
show a deficit in PS and EF, although they also seem to have a deficit in both working 
memory (WoM) and LTM (Charlton et al., 2006b).  
 
Studies have then looked at cognition longitudinally over a three-year period; 
Lawrence et al. found that average cognitive change declined most for the domains 
that were most impaired at baseline but noted that in most individuals, the declines 
were slow and were only statistically significant for EF (Lawrence et al., 2015). 
Comparably, the rate of cognitive decline seen in SVD is higher than seen for healthy 
aging (Charlton et al., 2006a). However, the rate of cognitive decline is less than 
reported for Alzheimer’s disease and mild cognitive impairment, but with more 
variability in disease progression (Bennett et al., 1994, Wallin et al., 2018). 
 
SVD can exist alone or in combination with other dementias. Studies have 
investigated the severity of dementia in community-dwelling elderly cohorts, 
exploring the presence of Alzheimer’s disease, SVD and Parkinson’s disease/Lewy 
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body dementia (Eggink et al., 2019). Schneider et al. found that in persons with 
dementia, over 50% had multiple diagnoses, whereas, in persons without dementia, 
over 80% had either one or no diagnosis; suggesting that these diseases working in 
combination had the largest contribution to dementia (Schneider et al., 2007). The 
presence of lacunar infarcts was also found to increase the prevalence of dementia and 
worsened cognitive function in Alzheimer’s disease patients, suggesting SVD lowers 
the threshold for dementia in these patients (Snowdon et al., 1997, Toledo et al., 
2013).  
 
Alzheimer’s disease and SVD share various risk factors, including age, hypertension, 
diabetes, smoking, hypercholesterolemia, hyperhomocysteinemia and APOE4 
isoforms (Santos et al., 2017). Chronic hypertension in an animal model of 
Alzheimer’s disease shows accelerated amyloid deposition, BBB dysfunction, 
microglial activation and subsequent neuronal loss and cognitive impairment (Kruyer 
et al., 2015). There are also other underlying biological mechanisms shared by 
Alzheimer’s disease and SVD including oxidative stress, inflammation, mitochondrial 
disruption and metabolic dysfunction (Liu et al., 2018b).  
 
Amyloid peptides are generated by amyloid precursor protein cleavage and can 
aggregate into fibrillar deposits in brain tissue and in vessel walls (Hardy and 
Higgins, 1992).  An association of amyloid-β1-40, but not amyloid-β1-42, with 
WMLs and lacunar infarcts was described in a mixed population of Alzheimer’s 
disease, mild cognitive impairment and CAA patients (Gurol et al., 2006) and in SVD 
patients (Gomis et al., 2009). It is thought that amyloid-β1-40 has a toxic effect on the 
vessel wall.  
 
CMBs were significantly associated with amyloid-β pathology in Alzheimer’s disease 
patients (Liu et al., 2018b). Amyloid-β pathology was also significantly associated 
with WMLs in Alzheimer’s patients but not in normal age-matched controls, 
suggesting there is a negative interaction between the diseases.  
 
However, how Alzheimer’s disease and SVD pathology combine to increase dementia 
is not well understood and the relationship between these diseases remains 
27 
 
controversial. A limiting factor is that there are limited animal models for both 
diseases and so it is difficult to study the mechanisms in vivo.  The link between 
Alzheimer’s disease and SVD could potentially be explained through the BBB, as it 
explains the protein infiltration, perivascular oedema and secondary axonal and 
neuronal damage seen in SVD; plus it could provide a route of entry of amyloid-β and 
inflammatory cells into the brain in Alzheimer’s disease (Biron et al., 2011). 
However, the evidence for this is limited so this is currently just speculative.  
 
 
1.3.2 Psychiatric Symptoms 
The psychiatric symptoms associated with SVD include apathy and depression 
(Staekenborg et al., 2010). Studies have a history of grouping the two together, but 
more recently research has attempted to separate out these two distinct symptoms. In 
sporadic SVD, around 15% have been seen to have apathy, 12% have both apathy and 
depression and 1% have only depression (Lohner et al., 2017). Studies investigating 
apathy and depression have found that apathy, but not depression, is associated with 
impaired EF and with WM network disruption (Tay et al., 2019, Hollocks et al., 
2015). Depression has, however, been associated with WML volume (de Groot et al., 
2000).  
 
In CADASIL, psychiatric disturbances are present in 20-41% of patients, with apathy 
and depression being the main psychiatric symptoms seen (Valenti et al., 2008). 
 
 
1.3.3 Motor Symptoms 
Gait and balance disturbances and related falls are a major symptom of patients with 
SVD, and are an important cause of morbidity and mortality in the elderly (Issac et 
al., 2015). SVD motor deficits can present in many different ways, including 
unsteadiness of gait and impaired balance on walking, all leading to increased fall 
risk. Studies have shown WMLs correlate with walking speed, balance and physical 
activity in an SVD cohort (Baezner et al., 2008). Lacunar infarcts in the frontal lobe 




1.3.4 CADASIL-specific Symptoms 
Migraine is often the earliest feature of CADASIL, present in about 55-75% of 
Caucasian cases (Tan and Markus, 2016). The migraine experienced by CADASIL 
patients is predominantly with aura. Encephalopathy is a rarer symptom of 
CADASIL, described in around 10% of patients (Drazyk et al., 2019). 
Encephalopathy is also known as ‘CADASIL coma’ and is an acute event of altered 
state of consciousness in a CADASIL patient, manifesting as signs of brain 
dysfunction. History of migraine increases the risk of encephalopathy, suggesting a 






1.4 Pathogenesis of SVD  
 
1.4.1 Anatomy 
Most often, SVD is thought of as a disease of the small arteries and arterioles, 
however, it technically encompasses all of the small vessels including the capillaries 
and small veins (Pantoni, 2010).  
 
Anatomically, small arterial vessels stem from two origins. Superficially, they stem 
from medium sized arteries, which have originated as larger arteries (Pantoni, 2010). 
Deeper in the brain, they stem directly from the large arteries as arterial perforators. 
These penetrating arteries run through the cortical layers perpendicular to the brain 
surface and enter the WM along the myelinated fibres (Pantoni and Garcia, 1997). 
These two types of small arterial vessels converge in the deepest areas of the 
subcortical WM. The vessels measure 20-50mm in length and have a diameter of 
around 40-200µm, but have been shown to become more tortuous and longer with 
ageing (Spangler et al., 1994).  These vessels are the terminal end of the blood supply, 
known as the watershed area (Pantoni and Garcia, 1997). If there is impaired 
circulation within the brain, it is the watershed areas that suffer first and foremost.  
 
Early pathological descriptions of these vessels came from C. Miller Fisher in the 
1950s and 1960s; he carried out various experiments on post-mortem brains. He 
observed that occlusion of the small penetrating arteries occurred by two main 
pathologies: either a diffuse arteriopathy with hyaline deposition (termed 
lipohyalinosis) or atherosclerosis (Fisher, 1968). He reported that the lipohyalinosis 
affected smaller arteries (200-800µm) and atherosclerosis affected the larger 
perforating arteries near their origins (Lammie, 2000). Later studies have suggested 
that the lipohyalinosis of the smaller arteries leads to multiple small infarcts with 
WMLs, whereas atherosclerosis of the larger perforating arteries leads to isolated 
larger lacunar infarcts, and that differing risk factors may affect these subtypes (Khan 
et al., 2007).   Examples of this pathology can be seen in Figure 1.2.  
 
Our understanding of the anatomical vessel pathology has not progressed greatly 
since Fisher’s experiments and the cause of these changes in the vessels at early 
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stages of the disease is largely unknown. The main limitation in furthering our 
understanding of the vessel pathology is the difficulty imaging them in vivo due to 
their size. However, even if we could image the vessels in vivo, features of SVD often 
develop slowly and silently until the damage reaches clinical levels, making it 
difficult to research into the early stages. Post-mortem studies are possible, but 
lacunar stroke has a low mortality rate compared to other stroke causes (Lund, 2014), 
meaning that there are few post-mortem studies available from patients in early stages 
of the disease.  
 
 
Figure 1.2: Pathological features of SVD. A) Lipohyalinosis in the basal ganglia 
(x100). B) Microaneurysm in the right thalamus (x25). C) Microatheroma in the basal 
ganglia (x20). D) Atheroma in the basal ganglia (x20). D) Fibrinoid necrosis in the 




There is evidence for a reduction in CBF in SVD (Marstrand et al., 2002, O'Sullivan 
et al., 2002). A meta-analysis of the literature found that CBF does seem to be lower 
in subjects with higher WML volume, when measured globally and in the GM and 
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WM regions separately (Shi et al., 2016). WMLs also commonly occur in the 
watershed regions of the brain, which provides further evidence for a role of CBF and 
oxygen delivery in the pathology.  
 
Longitudinal studies have had conflicting results about whether this reduction in CBF 
is causative or consequential of the underlying problems in the microvasculature. 
Studies have shown an increase in WML growth in patients with higher CBF at 
baseline, suggesting that CBF has a role in the pathogenesis of WML formation 
(Bernbaum et al., 2015, ten Dam et al., 2007). However, the largest longitudinal study 
in the literature suggested that high WML volume at baseline was associated with 
falling CBF over time, suggesting CBF is a result of underlying WM damage (van der 
Veen et al., 2015). This research would suggest that potentially there is a role for CBF 
in both the initiation of SVD, and later down the line as a secondary effect, although it 
is unclear.  
 
A potential explanation for the discrepancies within the literature comes from more 
recent work investigating capillary dynamics and their relationship with oxygen 
extraction factor (OEF) (Jespersen and Østergaard, 2012). The theory behind this 
body of work is that heterogeneity in the transit time of red blood cells through the 
capillaries leads to variation in how much oxygen can be extracted, which means CBF 
cannot be simply measured to determine the amount of oxygenation in the brain. In 
SVD, capillary dysfunction can mean that, even when high amounts of CBF occur, 
the extraction of oxygen may still not be sufficient to supply the tissues (Østergaard et 
al., 2016). Capillary dysfunction has been associated with increased clinical 
symptoms in an Alzheimer’s disease population (Eskildsen et al., 2017) and strongly 
hypothesised to show a similar pattern in a SVD population (Østergaard et al., 2016), 
although this has not yet been directly tested.  
 
Whether a reduction in CBF or OEF is important in the pathogenesis SVD, they 
would both result in a reduction of oxygen and triggering of a hypoxic response in 
both the vessels and the brain. The hypoxia experienced by the vessels is thought to 
lead them to become stiff, impairing cerebrovascular autoregulation (Birns et al., 
2009). The hypoxic response in the brain leads to many downstream mechanisms, 
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including an inflammatory response and increased permeability of the BBB (Martinez 
Sosa and Smith, 2017).  
 
 
1.4.3 BBB permeability and Inflammation 
There is a growing body of evidence suggesting that the BBB increases in 
permeability in SVD and that this is an important component of SVD pathogenesis 
(Farrall and Wardlaw, 2009). Neuropathological studies, CSF studies and MRI studies 
have all shown an increased permeability of the BBB (Wardlaw, 2010) and have 
linked this directly to a decrease in CBF (Wong et al., 2019). There is also evidence 
of endothelial cell dysfunction and damage (Hassan et al., 2003), which is a key 
component of the BBB. Increased permeability of the BBB would allow blood-borne 
substances to enter the brain parenchyma and lead to damage (Farrall, 2009).  
 
Using animal models, a proposed pathway which links the various mechanisms 
together has been hypothesised. The pathway proposes a link between an initial 
hypoxia of the brain tissue leading to production of hypoxia inducible factor-1α (HIF-
1α) and an inflammatory response (Rosenberg, 2018). This inflammatory response is 
thought to lead to activation of matrix metalloproteinases (MMPs), which disrupt the 
tight junctions and extracellular matrix of the vascular endothelial cells and increase 
the permeability of the BBB. This would therefore allow various blood-borne, and 
potentially toxic, substances through into the brain, which would result in damage to 
the brain tissue and further damage to the small vessel wall itself (Wardlaw, 2010). 
The combination of all of this damage could then lead to pathological hallmarks of 
SVD seen on MRI. The hypothesised cascade can be seen in Figure 1.3.  
 
Evidence supporting and opposing this hypothesised pathology will be discussed 
further on, including where there are gaps in the knowledge. Uncovering this 
underlying pathophysiology is vital for our understanding of how SVD progresses and 







Figure 1.3: Schematic of the hypothetical injury cascade in SVD, involving the initial 
insult of hypertension, endothelial dysfunction and genetic factors leading to hypoxia, 
which triggers HIF-1α production. HIF-1α then activates a variety of inflammatory 
mechanisms leading to an opening of the BBB and vasogenic oedema, as well as 
vessel wall fibrosis leading to cell death and the clinical symptoms seen. Reproduced 




1.5 BBB  
 
1.5.1 Anatomy and Function of the BBB 
The BBB is a complex structure that forms the walls of the capillaries within the 
central nervous system (CNS). A schematic is shown in Figure 1.4.  
 
The main physical barrier comes from the endothelial cells, which form tight 
junctions that seal the paracellular diffusional pathway between cells (Luissint et al., 
2012). Surrounding the endothelial cell surface is a basal lamina containing type IV 
collagen, fibronectin, heparin sulphate and laminin, which interacts with integrins to 
act as a molecular weight filter (Rosenberg, 2012). Accompanying the endothelial 
cells in its structure are many other cell types, including pericytes and astrocytes 
(Abbott et al., 2010). Pericytes wrap around the endothelial cells, forming a 
perivascular extracellular matrix. Pericytes are macrophage-like cells with smooth 
muscle properties; they are important as they can regulate blood flow and 
permeability through release of vasoactive substances (Rosenberg, 2012). Foot 
processes from the astrocytes then form around this matrix, which contain proteases, 
neurotransmitters and other essential molecules.  
 
The function of the BBB is to regulate molecules passing into the brain and provide 
neurons with a stable environment for optimal synaptic signalling (Abbott et al., 
2010). The permeability of specific substances through the BBB are regulated by 
transport systems. Only small solutes are able to pass through by diffusion, with 
solute carriers, transcytosis and mononuclear cell migration used for larger molecules.  
 
The CNS does not have a large regenerative capacity, so any amount of cell death can 
have significant consequences. Leakage of blood-borne substances into the brain 
parenchyma can upset neuronal signalling, lead to problems with cellular 
communication and ultimately cause excitotoxic cell death. Further, reactive oxygen 
species (ROS) generation can occur, due to red blood cells depositing iron from 
haemoglobin (Zhong et al., 2008) and fibrinogen activating various intracellular 
pathways (Iadecola, 2013). Blood clots can also occur through the interaction of 
blood with collagen on the damaged endothelial cells; leading to ischaemia of the 
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small vessels, whilst also causing activation of fibrin, thrombin and plasmin, all of 




Figure 1.4: A schematic of the components of the BBB. The endothelial cells form 
tight junctions with pericytes distributed around them, enclosed by the basal lamina. 
Foot processes from astrocytes form a complex network around them. Reproduced 
with permission from (Abbott et al., 2010). 
 
 
1.5.2 Role in Ageing  
Many diseases increase in frequency with age: including heart disease, cancer, 
Alzheimer’s, Parkinson’s and all types of stroke (Erdő et al., 2017). The single 
biggest risk factor for SVD is age (Thompson and Hakim, 2009), leading researchers 
to question what is occurring in the ageing brain that makes it so susceptible to SVD. 
 
Studies spanning from in vitro cell work to in vivo human populations have shown 
that there is an increased permeability of the BBB with ageing (Mooradian and 
McCuskey, 1992, Farrall, 2009, Goodall et al., 2018). Studies investigating 
endothelial cells have found that they undergo both oxidative stress and inflammation 
in healthy older adults, leading to a dysfunction and reduction in the cells (Donato et 
al., 2015). Further, there is decreased expression of tight junctions (Elahy et al., 2015, 
Goodall et al., 2018) and increased thickness of basement membrane (Candiello et al., 
2010). These changes all likely have an impact on the permeability of the BBB with 
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ageing. Therefore, it is important to use age-matched controls in research studies to 
ensure that the BBB permeability changes that occur with normal ageing can be 
differentiated from the increased permeability in disease.  
 
In the healthy ageing brain, BBB breakdown has been shown to start in the 
hippocampus, which has implications for Alzheimer’s disease and cognitive 
impairment (Montagne et al., 2015). It has been suggested that in Alzheimer’s 
disease, the accumulation of amyloid plaques in the brain is due to a lack of amyloid 
clearance across the BBB rather than a lower rate of production (Bateman et al., 
2009).  
 
Although increased BBB permeability is found in ageing and throughout age-
associated disorders, it is difficult to know if it is pathogenic or simply resultant of 
other initiating pathologies. In some situations, extrinsic system factors such as 
infections and autoimmune processes effect blood vessels and initiate damage, whilst 
in others the blood vessels are damaged secondary to the injury through 
neuroinflammatory responses (Rosenberg, 2012).   
 
 
1.5.3 BBB permeability in SVD 
Early indications about an increase in BBB permeability in SVD came from studies 
investigating the CSF/serum albumin ratio. The more permeable the BBB, the more 
albumin will be present in CSF compared to serum and therefore the higher the ratio 
(Blennow et al., 1993, Tibbling et al., 1977). The ratio has been shown to be increased 
in both sporadic SVD (Alafuzoff et al., 1983, Wada, 1998) and CADASIL (Dichgans 
et al., 1999).  
 
Further evidence came from post-mortem studies that can investigate levels of 
plasmas proteins in the CNS. Post-mortem examinations have found increased levels 
of the blood-borne proteins immunoglobulin and fibrinogen in the brains of diagnosed 
SVD patients (Tomimoto et al., 1996) and elderly patients with WMLs (Akiguchi et 
al., 1998). This indicates a disruption of the BBB, allowing these proteins to leak 




MRI has been used to both quantify and map BBB permeability in the brain. Dynamic 
contrast enhanced (DCE)-MRI involves gadolinium contrast agent injection followed 
by periodic imaging of the gadolinium-induced signal change in the brain 
parenchyma, to measure permeability (Armitage et al., 2011). Many studies have 
applied this technique to an SVD population, and there is a fairly consistent finding 
that BBB permeability is higher in SVD patients compared to controls (Hanyu et al., 
2002, Topakian et al., 2010, Taheri et al., 2011a, Huisa et al., 2015). Full details on 
the progression and application of DCE-MRI techniques will be discussed in Chapter 
Four.  
 
BBB permeability can be measured in the whole brain or in specific brain regions 
using DCE-MRI. Studies have mainly focused on the WM, as this is thought to 
contain most of the SVD pathology. BBB leakage has been shown to be higher in the 
WM of SVD patients compared to controls (Taheri et al., 2011a, Huisa et al., 2015) 
and compared to cortical stroke patients (Wardlaw et al., 2009). The amount of BBB 
permeability was not increased in the GM in SVD compared to controls (Zhang et al., 
2019, Zhang et al., 2017) and cortical stroke patients (Wardlaw et al., 2008), although 
an increased leakage volume in the GM was seen in SVD compared to control (Zhang 
et al., 2019, Zhang et al., 2017). In the CSF, increased permeability was seen in SVD 
compared to controls (Topakian et al., 2010) and cortical stroke patients (Wardlaw et 
al., 2008, Wardlaw et al., 2009).  
 
Taking this further, studies have segmented the WM into normal-appearing white 
matter (NAWM) and WML and measured BBB permeability. This can help establish 
whether it is the already damaged WML tissue that has the increased permeability, or 
the seemingly healthy tissue of the NAWM. Studies have shown that there is an 
increase in BBB permeability in the NAWM compared to controls (Topakian et al., 
2010). Leakage volume, but not leakage rate, was also found to be higher in NAWM 
compared to controls (Zhang et al., 2017).  
 
Whether there is increased permeability in the WML of SVD compared to the WML 
of asymptomatic healthy elderly is controversial. Some studies showing that there is 
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increased WML permeability in SVD patients compared to healthy controls (Hanyu et 
al., 2002) whilst others show that the WMLs have the same amount of permeability 
(Topakian et al., 2010, Bronge and Wahlund, 2000). A recent study showed that there 
was higher leakage volume, but not leakage rate, in WMLs of SVD patients compared 
to WMLs of controls (Zhang et al., 2017). The discrepancies here could be explained 
through differences in methodology for quantifying permeability. Further studies are 
required to come to a consensus. 
 
Studies have investigated the associations between BBB permeability and WML 
volume. Associations between BBB permeability in the NAWM and WML volume 
have been seen (Topakian et al., 2010, Wardlaw et al., 2017, Munoz Maniega et al., 
2017, Li et al., 2017c). Other studies have also found that increased BBB permeability 
in the WML is associated with WML volume (Munoz Maniega et al., 2017, Wardlaw 
et al., 2017). However, this is controversial within the literature, with other studies 
showing different results: Zhang et al. showed that larger leakage volume but lower 
leakage rate in the WML was associated with larger WML in SVD (Zhang et al., 
2019), whilst Huisa et al. found no correlation between WML BBB permeability and 
WML volume (Huisa et al., 2015). Huisa et al. then looked longitudinally at BBB 
permeability and WML lesion load; this found that only around 11% of new WML 
voxels had prior abnormal permeability over the previous 1-2 years (Huisa et al., 
2015). 
 
Studies then investigated the relationship beween BBB permeability and cognition. 
Scores on MMSE and MoCA decreased with increasing leakage rate in WML and 
GM (Li et al., 2017c). Higher leakage rate in NAWM was associated with lower 
scores in EF and PS in healthy controls, but not in SVD patients (Zhang et al., 2019). 
Looking longitudinally, poorer cognitive outcome at three year follow-up was 
associated with increased basal ganglia BBB permeability at baseline (Wardlaw et al., 
2013b).  
 
Overall, studies do suggest a role for BBB permeability in SVD, but how it fits in 
with the overall disease pathology in terms of imaging markers and clinical outcomes 
is unclear. Studies have not yet managed to reach a consensus about whether BBB 
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permeability is an initiating mechanism in the pathophysiology of SVD, or whether it 
is just a consequence of the other pathologies occurring. Additional studies are 
required to investigate this further.  
 
 
1.5.4 Endothelial Cell Activation  
Endothelial cells line all of the blood vessels throughout the body. Endothelial cells in 
the brain are unique in terms of their role in the BBB, regulation of CBF and 
interactions with other members of the neurovascular unit. In SVD, endothelial cells 
are seen to survive in histological studies, even in late stages of sporadic SVD 
(Lammie, 2002) and in CADASIL (Craggs et al., 2013). However, despite their 
survival, many functional studies have shown that the endothelial cells are activated 
and are therefore thought to be in a state of inflammation, growth and thrombosis 
(Hainsworth et al., 2015).  
 
Endothelial cell activation results in a change of the expression of surface markers on 
the endothelium. Blood biomarkers of endothelial cell activation have been widely 
studied in SVD and recently reviewed (Poggesi et al., 2016). These circulating 
markers include, but are not limited to, intracellular adhesion molecule-1 (ICAM-1), 
vascular cellular adhesion molecule-1 (VCAM-1), E-selectin and P-selectin. ICAM-1 
and VCAM-1 levels are elevated in patients with lacunar infarcts compared to 
controls (Rouhl et al., 2012). ICAM-1 is also found to be higher in a healthy 
population with silent brain infarcts (Sarchielli et al., 2013).  WMLs have been 
associated with higher levels of ICAM-1, VCAM-1, E-selectin and P-selectin 
(Fassbender et al., 1999, Hassan et al., 2003, Han et al., 2009, Markus et al., 2005, de 
Leeuw et al., 2002). Looking longitudinally, ICAM-1 levels at baseline can predict 
future WML progression seen on MRI at 3 and 6 years in SVD patients (Markus et 
al., 2005), and future silent brain infarcts in a type 2 diabetes population (Umemura et 
al., 2008). 
 
Markers of coagulation and fibrolysis have been investigated in SVD. 
Thrombomodulin is an integral membrane protein found in the vascular endothelium 
of systemic blood vessels; its function is to modulate the prothrombotic molecule 
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thrombin, so that thrombin becomes incapable of generating a fibrin clot from 
fibrinogen, protecting the brain from thrombosis (Fisher, 2012). Once bound to 
thrombin, the complex activates protein C and initiates an anticoagulant pathway. 
High levels of thrombomodulin found in the blood are believed to reflect endothelial 
injury, which would be consistent with a breakdown of the BBB (Hassan et al., 2003). 
One study did show a positive association of thrombomodulin with lacunar infarcts 
(Hassan et al., 2003) whereas two further studies did not see this association 
(Gottesman et al., 2009, Knottnerus et al., 2010). Von Willebrand factor (vWF) is a 
glycoprotein expressed by endothelial cells after tissue damage, leading to thrombus 
formation and blood coagulation (Hassan et al., 2012). It was found to be associated 
with the presence and number of silent brain infarcts (Gottesman et al., 2009) and 
WML volume (Kearney-Schwartz et al., 2009).  
 
Animal models of SVD have also been used to try to uncover SVD pathology 
(Hainsworth et al., 2012). Animal models are particularly important for discovering 
early stage pathology in SVD and whether endothelial cell dysfunction could be an 
initiating mechanism. The most common animal models used are the stroke prone 
spontaneously hypertensive rats (SHRSP) and the spontaneously hypertensive rats 
(SHR), derived from selective breeding. These rats show similar degrees of 
hypertension, SVD-like vessel pathology, focal infarcts, cognitive impairment and 
WM damage, although this varies between the models (Lin et al., 2001). It is 
important to note that no current animal models of SVD completely replicate the 
pathology we see in human SVD, and therefore results should always be treated with 
caution (Hainsworth and Markus, 2008). 
 
SHRSP and SHR rats show endothelial dysfunction, manifesting as BBB impairment, 
histopathologically (Sadoshima and Heistad, 1982, Hazama et al., 1979, Lee et al., 
2007, Braun et al., 2012, Kaiser et al., 2014) and on imaging (Sironi et al., 2004, 
Guerrini et al., 2002). Studies have suggested that endothelial tight junctions occur in 
these rats at the earliest ages, preceding other damage (Bailey et al., 2011) and 
treatment with endothelial cell stabilising drugs can prevent SVD from manifesting 
(Rajani et al., 2018). Further, studies have shown that endothelial function 
deteriorates with an increasing hypertension (Lee et al., 2007, Knox et al., 1980). This 
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evidence, and other evidence from human studies, has lead to debate on the systemic 
vs. localised nature of SVD (Thompson and Hakim, 2009). Is SVD a systemic disease 
or a disease confined to the CNS? 
 
The dysregulation of CBF is an important factor in the pathology of SVD, which has 
been suggested to come from endothelial cell dysfunction. CBF relies on endothelial 
nitric oxide signalling, so a dysfunction of endothelial cells may lead to impaired 
regulation globally. Functional studies have shown that lacunar infarct patients are 
less able to respond to vasodilatory stimuli (Deplanque et al., 2013). Further, SVD 
patients have been seen to have a reduced response to L-arginine and flow-mediated 
dilatation experiments, with the amount of systemic endothelial dysfunction 
paralleled with the WML volume (Zupan et al., 2015, PretnarOblak et al., 2017). 
These experiments suggest a systemic change in vasodilatation, which may be 
mediated by an underlying endothelial cell dysfunction.  
 
Additionally, there are diseases of other blood vessels that seem to associate with 
SVD. Retinopathy has been correlated with poorer cognitive function and greater risk 
of lacunar stroke (Wong et al., 2002). Additionally, patients with chronic kidney 
disease were found to have a greater prevalence of WMLs (Khatri et al., 2007), 
suggesting that there could be a widespread small arteriopathy or endotheliopathy.  
 
Various proteins produced in other organs are associated with SVD pathology. 
Homocysteine is produced in the liver and kidney as a product of metabolism of 
methionine; elevated levels of homocysteine can result from folate deficiency or in 
patients with kidney disease (Cianciolo et al., 2017). Homocysteine is elevated in 
SVD (Hassan et al., 2004) and has been shown to correlate with lower brain volume 
and increased risk of silent brain infarcts (Seshadri et al., 2008). It is also associated 
with WML volume (Rosenberg et al., 2014, Kloppenborg et al., 2014, Nam et al., 
2019). Homocysteine levels have also been found to correlate with cognitive function, 
suggesting a relation with clinical status (Pavlovic et al., 2011). The evidence for an 
involvement of homocysteine in SVD was so strong that clinical trials were carried 
out, to see if lowering homocysteine with vitamins could improve cognition; 




Microalbuminuria is a ratio of urinary albumin to creatinine ratio and is thought to 
reflect early kidney damage or systemic endothelial dysfunction (Abdelhafiz et al., 
2011). It was seen to be a risk factor for silent brain infarcts and WMLs in a healthy 
elderly population (Wada et al., 2007) and hypertensive populations (Delgado et al., 
2014, Knopman et al., 2008).  
 
All of these diseases share common cardiovascular risk factors, so it could be that the 
prevalence is simply due to the shared risk. Further, it is possible that SVD in one 
organ could accelerate the involvement of other organs through the release of certain 
factors; this is something that has been seen in studies but the extent of this effect in 
SVD is unknown (Touyz, 2004). However, evidence suggests that SVD is a 
heterogeneous and multi-factorial disease, which likely impacts other organs with 




Pericytes are known to be an important component of the BBB. Cerebral pericytes are 
contractile and regulate capillary diameter during functional activation (Peppiatt et al., 
2006). Animal models have shown that a loss of pericytes leads to brain vascular 
damage through a reduction in CBF and breakdown of BBB (Bell et al., 2010). Under 
ischaemic conditions, pericytes have been shown to die and remain in a rigor mortis 
state, which restricts the vessels and limits blood flow to those areas (Hall et al., 
2014). Pericyte deficient mice have increased BBB permeability (Armulik et al., 
2010, Reske-Nielsen et al., 1966), which leads to WM changes (Montagne et al., 
2018). 
 
Pericyte loss and basement membrane thickening have been seen in conditions that 
represent major risk factors for SVD, such as ageing (Kalaria, 1996, Bell et al., 2010), 
hypertension (Tagami et al., 1990) and diabetes (Johnson et al., 1982).  Post-mortem 
analysis has shown a reduction in pericyte number in aged brains compared to young 
brains (Stewart et al., 1987) and in Alzheimer’s disease compared to age matched 
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controls (Miners et al., 2018). However, this has not been reported in post-mortem 
SVD brains.  
 
The majority of the SVD pericyte research has occurred in the CADASIL mouse 
model of Notch3 mutation. The CADASIL mouse shows Notch3 aggregation in the 
pericytes leads to a reduction in pericyte coverage of vessels over time (Ghosh et al., 
2015). These vessels are then shown to have increased leakage of albumin, suggesting 
they have a BBB disturbance. This work has been shown in human CADASIL 
patients, with degeneration and loss of pericytes from capillary vessels leading to 
increased permeability of the vessels and disturbances in cerebral microcirculation 




The contribution of astrocytes to maintaining BBB function is not fully understood 
(Erdő et al., 2017). Astrocytes show a number of different morphologies depending 
on their location. There is now strong evidence that astrocytes may upregulate many 
BBB features, including increasing the tightness of the tight junctions, which would 
regulate permeability (Abbott et al., 2006).  
 
Astrocyte end-feet cover over 99% of cerebral capillaries, leading to cell-cell 
interactions that modulate and regulate the BBB (Abbott et al., 2006). Loss of 
astroglial function and astroglial reactivity contributes to aging of the brain and 
neurodegeneration, but it is highly heterogeneous (Rodriguez-Arellano et al., 2016). 
Astrocytes are involved in the production of lipoproteins including Apolipoprotein E 
(ApoE), which has an important role in Alzheimer’s pathology and BBB injury (Erdő 
et al., 2017). However, astrocytic involvement in BBB permeability of SVD has not 
been specifically investigated.   
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1.6 Inflammation  
 
1.6.1 Neuroinflammation 
Microglia are the resident macrophages of the brain, and are rapidly activated in 
response to brain injury (Aloisi, 2001). Microglia activation induces the release of 
pro-inflammatory mediators, such as cytokines, chemokines, ROS and interleukins 
(ILs), which increase the permeability of the BBB. This then allows for subsequent 
infiltration of peripheral leukocytes into the CNS, including T cells and macrophages. 
Therefore, this increased BBB permeability means that peripheral macrophages can 
have a role in neuroinflammatory outcomes, leading to neuronal cell death, releasing 
further neurotoxins and causing further microglial activation as a negative feedback 
loop.  
 
Activated microglia have been described as a double-edged sword, where they can 
have both toxic and beneficial roles. Research now suggests that microglia activate in 
a similar way to macrophages, with both an M1 and an M2 phenotype (Hu et al., 
2015). The M1 phenotype represents a proinflammatory phenotype releasing 
inflammatory mediators such as prostaglandins, tumour necrosis factor-α (TNF-α), 
interleukin-6 (IL-6), interleukin-1β (IL-1β), ROS and glutamate. However, the M2 
phenotype attempts to resolve the inflammation, with release of anti-inflammatory 
mediators such as interleukin-10 (IL-10), insulin-like growth factor 1 and 
neurotrophic factors (Reus et al., 2015).   
 
 
1.6.2 Inflammation in SVD 
Inflammation has been recognised as a key component of cerebrovascular and 
neurological diseases. Inflammatory cell infiltrations in the arteriolar wall and 
perivascular tissue have been noted in the elderly since 1902 (Ferrand, 1902).  
 
In SVD, there is a combination of both acute and chronic inflammation. Acute 
inflammation occurs with the formation of lacunar infarcts due to acute vessel 
blockage, leading to activation of inflammation in response to hypoxia/ischaemia (Fu 
and Yan, 2018). The chronic inflammation is thought to be related to the underlying 
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hypoperfusion and BBB changes and is likely more similar in pathophysiology to 
chronic neurodegenerative diseases such as Alzheimer’s disease. Studies looking at 
both systemic and central inflammatory markers can help discover more about the 
underlying pathogenesis of the disease and potentially uncover biomarkers that can be 
used to track disease severity and treatment effect.  
 
Immunohistochemical techniques can be used to detect specific molecular markers 
that can identify activated microglia. Constitutive expression of ionized calcium-
binding adapter molecule-1 (IBA1) is specific for microglia, irrespective of activation 
state. A marker of M1 microglia phenotype is CD68, mannose receptor CD206 can be 
used as a marker of M2 phenotype. Post-mortem studies have shown there is an 
increase in CD68 positive microglia in the WML in the aged brain compared to 
control WM (Simpson et al., 2007a, Waller et al., 2019). Studies into Alzheimer’s 
disease patients showed a similar pattern of increased CD68 activated microglia in the 
patient brain compared to control (Hopperton et al., 2018). This suggests that in these 
neurodegenerative states there is an increase in activated pro-inflammatory M1 
microglia, but not in the anti-inflammatory M2 microglia.  
 
In recent years, several radioligands have been developed to image the activation of 
microglia in experimental models. The majority of these ligands bind to the 18kDa 
translocator protein (TSPO). Under normal conditions, TSPO levels are low in the 
CNS (Lavisse et al., 2012). However, during neuroinflammation, TSPO is over-
expressed in microglia, representing an activated microglia state (Liu et al., 2014b, 
Venneti et al., 2006, Rupprecht et al., 2010).  
 
By far the most validated PET tracer for TSPO human studies, and therefore most 
commonly used, is [C11]PK11195 (PK) (Chauveau et al., 2008). This method has 
been used previously for detection of microglia activation in ischaemic stroke and has 
showed increased activation around the infarct site (Gerhard et al., 2005). This has 
also been linked to cognition, with a high correlation seen between microglial 
activation in the stroke-affected hemisphere WM and cognitive impairment (Thiel et 
al., 2014). However, to the best of my knowledge, it has not been investigated in 




Inflammation can also be quantified through the measurement of various 
inflammatory biomarkers. Most of them can be detected in serum/plasma samples or 
in the CSF and quantified using various assay techniques. The CSF provides a more 
accurate representation of their concentration within the CNS, but is far more difficult 
to obtain due to the requirement of a lumbar puncture. An ‘index’ can also be 
calculated to distinguish between endogenous and exogenous proteins, through 
measurement of the biomarker in both the CSF and blood to form a ratio (Candelario-
Jalil et al., 2011). Alternatively, levels of these biomarkers can be measured post-
mortem, which allows for the anatomical mapping of their location.  
 
Circulating inflammatory biomarkers in SVD have recently been reviewed in detail 
(Low et al., 2019) and will be discussed in more detail in Chapter Seven. Briefly, the 
most commonly studied systemic inflammatory biomarkers in this field are C-reactive 
protein (CRP) and IL-6 (Vilar-Bergua et al., 2016). C-reactive protein is an acute-
phase reactant synthesised in the liver in response to IL-6, and has been widely used 
as a vascular inflammatory marker. IL-6 is secreted by T cells and macrophages to 
stimulate immune response and by smooth muscle cells of blood vessels as a 
proinflammatory cytokine. CRP and IL-6 have been associated with a variety of 
cardiovascular risk factors including diabetes (Pradhan et al., 2001) and hypertension 
(Sesso et al., 2003). CRP and IL-6 have also been associated with infarcts (Hoshi et 
al., 2005, Yoshida et al., 2009), enlarged perivascular spaces (Aribisala et al., 2014) 
WMLs and brain atrophy (Satizabal et al., 2012). 
 
MMP-2, MMP-3 and MMP-9 are produced by microglia, astrocytes and endothelial 
cells as part of the inflammatory response (Gottschall and Deb, 1996, Asahi et al., 
2001, Rosenberg et al., 2001a). Early stages of hypoxia are thought to activate matrix 
metalloproteinase-2 (MMP-2), which initiates reversible disruption of the basal 
lamina proteins and opening of the tight junction proteins (Yang et al., 2007); this is 
thought to be short lived. However, increasing hypoxia levels activate inducible 
matrix metalloproteinase-3 (MMP-3) and matrix metalloproteinase-9 (MMP-9), 
which causes irreversible degradation to the basal lamina and tight junction proteins 
(Rosenberg, 2016). One study found that MMP-9 levels were elevated in CSF of 
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vascular dementia patients, with no changes in MMP-2 effect (Adair et al., 2004). A 
further study then went on to use the ‘index’ method and found that MMP-9 was 
elevated in both the CSF and blood, meaning no change in the index, whereas MMP-2 
index was reduced, suggesting possible endogenous consumption (Candelario-Jalil et 
al., 2011). This study also showed MMP-3 to be elevated in the CSF of SVD patients. 
An investigation into the differences between SVD and Alzheimer’s disease found 
that MMP-9 and MMP-2 were two of the markers that contributed most to SVD, but 
little to Alzheimer’s disease (Bjerke et al., 2011). Autopsy results showed that 
vascular dementia patients were found to have MMP-2 in macrophages and astrocytes 
near blood vessels and MMP-3 in microglia/macrophage cells around infarctions 







SVD is a highly prevalent disease within our population, leading to vascular dementia 
and stroke. SVD is heterogeneous, with a complex pathophysiology. Our lack of 
understanding of the underlying pathogenesis has limited the discovery of new 
treatments.  
 
Studies have indicated that there does seem to be an increase in BBB permeability in 
SVD patients. There also seems to be a role for neuroinflammation in SVD. However, 
whether these pathologies are causal or consequential of the other damage occurring 
is unclear and requires further investigation.  
 
The emergence of new imaging techniques means that BBB permeability and 
neuroinflammation can now be accurately quantified and mapped in SVD patients. 
Utilising these techniques would allow the role of BBB permeability and 
neuroinflammation to be fully explored to determine if the processes are pathological 
in SVD. 
 
Furthering our understanding of the pathophysiology of SVD would allow for new 
treatments to be tested, which target the underlying mechanisms directly, to reduce 








1.8 Objectives of the Research  
 
The availability of PET/MR imaging allows for simultaneous DCE-MRI for mapping 
of BBB permeability and PK PET imaging of activated microglia, in the same 
patients. The imaging modalities can be overlayed into the same space to determine 
the spatial association between the two. Using sporadic SVD patients, monogenic 
SVD (CADASIL) patients and controls, we can explore the relationship between 
BBB permeability and inflammation in both disease and healthy ageing. 
 
This thesis aims to address the following research questions: 
• Are conventional MRI and DTI markers associated with cognitive decline? 
(Chapter Three) 
• Is there increased BBB permeability in sporadic SVD and CADASIL patients 
compared to controls? Does BBB permeability associate with conventional 
MRI, DTI and cognition? (Chapter Four) 
• Is there increased PK binding in sporadic SVD and CADASIL patients 
compared to controls? Does PK binding associate with conventional MRI, 
DTI and cognition? (Chapter Five) 
• Is there a spatiotemporal relationship between BBB permeability and PK 
binding hotspots? (Chapter Six) 
• Are serum markers of inflammation, MMPs and endothelial cell activation 
increased in SVD? Are they associated with BBB permeability and PK 
binding? (Chapter Seven) 
 
The primary hypothesis of the thesis is:  
BBB permeability and PK binding are increased in sporadic SVD and CADASIL 
compared to control. 
 
The secondary hypotheses of the thesis are:  
• BBB permeability and PK binding are associated with conventional MRI and 
DTI  
• BBB permeability and PK binding are associated with cognition 
• BBB permeability and PK binding are spatially related to each other 
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• BBB permeability is associated with circulating MMPs and markers of 
endothelial cell activation 




Chapter 2: Methods 
 
2.1 Study Set-up 
 
2.1.1 Study Approvals and Support 
The BBB permeability and Neuroinflammation in SVD study ran from January 2017 
and is currently ongoing. It was approved by the East of England – Cambridge South 
Ethics Committee (REC no: 16/EE/0468, IRAS project ID: 212632). Approval was 
also granted by the Administration of Radioactive Substances Advisory Committee 
(ARSAC ref: 999/9000/35589). The study was supported by the National Institute for 
Health Research through inclusion in its Clinical Research Network Portfolio.  
 
The study was funded by an MRC experimental medicine grant (MR/N026896/1).  
 
 
2.1.2 Power Calculations 
Power calculations from preliminary data were used to estimate the sample sizes 
required for this study to allow us to detect a difference in BBB permeability and PK 
binding. For prediction of the DCE-MRI data (n=6), using a similar technique to this 
study, we found a mean BBB permeability in WM of SVD patients of 9 x 10-4 (SD 2 
x 10-4) L/g min. Therefore, we could detect a 20% change in permeability in the 
control group with power 0.8 and p=0.05, using a two-sided test, with 20 participants 
per group. Similarly for the PET data, our pilot data (n=3) found WM binding of 
0.174 (SD 0.04). With a power of 0.8 and p=0.05, a two-sided test can detect a 20% 
change in binding with a sample size of 21 per group. These calculations suggested 










Three groups of 20 participants (60 participants in total) were recruited for this study 
into the following groups: sporadic SVD, CADASIL and healthy control. Patients 
were recruited from the Addenbrooke’s Stroke Service, and from Professor Hugh 
Markus’ national CADASIL clinic. All participants gave written informed consent. 
Participant age ranged from 31 to 90 years old, with a mixture of male and female.  
 
2.2.2 Inclusion/Exclusion Criteria 
Sporadic SVD participants were defined as patients who had clinical evidence of 
lacunar stroke syndrome (e.g. pure motor stroke, pure sensory stroke, sensorimotor 
stroke or ataxic hemiparesis, or clumsy hand dyarthria syndrome) with a 
corresponding lacunar infarct on DWI, for cases imaged within 3 weeks of stroke, or 
an anatomically compatible lacunar infarct on FLAIR/T1 MRI, for cases imaged later 
after stroke (<=1.5cm diameter). They also had to have confluent WMLs on T2 
weighted MRI (Fazekas et al., 1987). Participants were not recruited until at least 3 
months since their last acute infarct, to avoid changes secondary to acute injury. 
These patients had no stroke cause other than SVD and no evidence of cortical stroke.  
 
CADASIL participants were subjects with a confirmed genetic diagnosis as defined 
by a recognised Notch3 mutation. They also had to be at least 3 months from their last 
stroke to avoid changes secondary to acute injury.   
 
Healthy controls were participants with no history of stroke or evidence of other 
major neurological disorder. These were of similar age to the sporadic SVD patients.    
 
The MMSE of all participants had to be >21 for consent purposes. All subjects had to 
have no contraindications for taking part in an MRI study (e.g. pacemaker). Women 
of childbearing age were not allowed to take part due to ethical reasons concerning 
the radioactive ligand injection. The participants also had to have an eGFR 




2.3 Demographics and Clinical Assessments 
 
Participant demographics were collected during the baseline appointment. Date of 
birth, sex, occupation, years in education and ethnicity were all recorded. Height, 
weight and blood pressure were also all measured and recorded. Age and sex were 
required so that analyses could be controlled for any age or sex related differences 
(Mooradian, 1988, Sohrabji, 2007).  
 
The cardiovascular risk factors of hypertension, hyperlipidaemia, type 2 diabetes and 
smoking were also recorded, as they were required to provide additional controls for 
analyses (Becker et al., 2019). Participants were marked as a smoker if they indicated 
that they had ever been a smoker, even if they had since stopped. Additionally, the 
neurological risk factors of history of depression and migraine were noted.  
 
All current medications were listed, with dates the participants began taking them, so 
that these could be controlled for if they were found to have any effect on the primary 
end-points.  
 
For participants who had experienced a stroke, the date of the stroke was documented, 
the age at the stroke, as well as whether they were thrombolysed and a description of 
the clinical symptoms experienced. If the participant had experienced multiple 
strokes/TIAs then these were also documented with the date, age at stroke and the 








2.4.1 Baseline PET/MRI scan 
All participants underwent a PET/MR scan on the GE SIGNA PET/MR scanner (GE 
Healthcare, Waukesha, USA) at the Wolfson Brain Imaging Centre in Cambridge, 
UK. The scanner had a 3.0T MR, which scans simultaneously with PET. The scan 
was carried out using a 32-channel NOVA coil (Nova Medical, Wilmington, USA). 
All subjects were placed in the head coil in a neutral position; minimal head 
movement was ensured during the scan through the use of foam pads.  
 
Total imaging time was 80 minutes. Patients were injected with PK radioligand for 
the PET scan at the beginning of the session; 80 minutes of PET recording then 
occurred. 5 minutes after injection, 45 minutes of non-contrast MRI sequences begun, 
followed by 25 minutes of DCE-MRI.  
 
The DCE-MRI was acquired in a sub-section of the brain, manually chosen by the 
radiographer to include the regions of characteristic SVD damage. All other 
sequences were acquired across the whole brain.  
 
 
2.4.2 Non-Contrast MRI  
Non-contrast MRI was run within the PET bed. These sequences were as follows:  
1. 3D T1 weighted images taken with a fast spoiled gradient echo sequence. Flip 
angle = 12°, TI = 450, field of view (FOV) =28mm, slice thickness = 1 mm, 
number of slices – 192, reconstructed matrix size = 512x512. This sequence 
allows for accurate brain volume measurements and for general structural 
knowledge.  
2. Axial susceptibility weighted imaging. Flip angle = 17°, TR = 40.6ms, TE = 
24.2ms, FOV = 22mm, slice thickness = 2 mm, number of slices = 70, 
reconstructed matrix size = 256x256. This sequence can be used to detect 
CMBs.  
3. Axial T2 FLAIR sequence, angled anterior commissure-posterior commissure 
(AC-PC). Flip angle = 160°, TR = 8800ms, TE = 120ms, TI = 2445ms, FOV = 
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22mm, slice thickness = 5 mm, number of slices = 28, reconstructed matrix 
size = 256x256. This sequence is for identification of WMLs and lacunes.  
4. Axial diffusion tensor imaging (DTI) in 63 directions. TE = minimum, TR = 
15763ms, FOV = 19.2mm, slice thickness = 2 mm, number of slices = 665-
670 depending on slice angulation, reconstructed matrix size = 256x256. This 
sequence can be used to extract MD and FA values that represent WM 
microstructure integrity.  
5. Axial T2 fast spoiled gradient echo sequence in AC-PC angle. Flip angle = 
111°, TE = 85ms, TR = 6000ms, FOV = 22mm, slice thickness = 5mm, 
number of slices = 31, reconstructed matrix size = 1024x1024. This sequence 
is used for identification and counting of CMBs.  
 
 
2.4.3 Contrast MRI 
Following this, gadoterate meglumine (Dotarem) was used to visualise BBB 
permeability. The gadolinium dose was 0.025mmol/kg, a quarter of the dose used 
clinically (Taheri et al., 2011b). The injection flow rate was 6m/s followed by a saline 
flush. T1 was mapped prior to injection, followed by the gadolinium, followed by 25 
minutes of T1 mapping.  
 
The sequence uses a 3D radiofrequency (RF)-spoiled gradient echo imaging sequence 
to obtain T1 relaxation times. 6 flip angles were used (2°, 5°, 12°, 17°, 22°, 27°) to 
calculate each map. 8 post injection maps with temporal resolution of about 2.5 
minutes were collected. TR=6.3ms, TE=1.784ms, resolution = 2x2x3mm 
(reconstructed to 0.94x0.94x3mm) number of slices = 16 and reconstructed matrix 
size = 256x256. There is a B0 mapping sequence for flip angle correction; flip angle = 
15°, number of echoes = 1, receiver bandwidth = 15.63, FOV = 35mm, slice thickness 




An MR localiser was used so that the scanner bed could be translated to locate the 
brain in the centre of the axial PET FOV (25cm).  Prior to PET tracer injection, an 
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MR attenuated correction (MRAC) sequence (2-point Dixon, LAVA-Flex) was 
acquired to provide information utilised for attenuation correction of the PET data.  
 
Following the MRAC sequence, the tracer PK (produced at the Wolfson Brain 
Imaging Centre Radiopharmaceutical Unit) was injected over approximately 30s and 
list-mode PET data were acquired for 75 minutes. The effective/target tissue dose per 
administration was 2.6mSv with proposed activity of 500MBq. The median injected 
activities were 438 (IQR 400-482) MBq with corresponding injected mass values of 





2.5 Non-Contrast MRI Analysis 
 
2.5.1 WMLs 
WML were quantified as the presence of signal abnormalities or hyperintensities from 
the WM of the periventricular and subcortical regions on the axial FLAIR T2 
sequence. Both hemispheres were marked for WML volume by a single trained rater 
(JW) using the semi-automatic contouring technique Jim analysis software version 
7.0.5 (Xinapse Systems Limited, http://www.xinapse.com/j-im-7-software/). Whole 
brain WML maps were generated.  
 
To assess inter-rater reliability, ten of the FLAIR scans were remarked in a 
randomised, blinded setting. They were marked for the second time by JW and once 
by a second experienced rater (DT). The inter-rater and intra-rater reliability 
coefficients were 0.988 and 0.993 respectively. An example WML marked T2-FLAIR 




Figure 2.1: Example image of a T2-FLAIR scan marked for WMLs (white).  
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All areas of hyperintensity on the FLAIR scan were included unless they were: 
• Surrounding an established infarct unless this infarct is with an area of 
confluent white matter hyperintensity 
• A narrow band around the ventricles that you would consider normal clinically 
• Midline high signal streaks as these are likely to be artifact 
• Small punctuate of only moderate intensity 
• Infratentorial 
• Established lacunes i.e. seen as dark on T1 
• Acute infarcts i.e. seen as bright on DWI 
 
 
2.5.2 Lacunar Infarcts 
Lacunes were defined as CSF filled cavities at least 3mm in diameter. They were 
marked on FLAIR images manually by a single neurologist (AD). T1, T2 and FLAIR 
scans were all used to identify and confirm the lacunes. The neurologist had training 
in distinguishing them from perivascular spaces. The lacunes were defined as a lesion 
occurring in the subcortical and deep white matter regions of the brain, likely supplied 
by a single small vessel. Location, size, shape (round or oval shape) were all 
considered in order to distinguish lacunes from other mimics such as perivascular 
spaces or CMBs.  
 
The lacunes were both counted and drawn around using semi-automatic contouring 
with Jim analysis software version 7.0.5, in a similar way to the WMLs.  The 




CMBs were defined as focal areas of very low signal intensity on the T2* weighted 
images. They were manually counted by a neurologist (AD) and the neurologist 
recorded the number of CMBs for each participant. The neurologist was blinded to 





2.5.4 Brain Volume 
T1 images were used to calculate the brain volumes. The FLAIR image was 
registered to the T1 image using a rigid body transformation in Advanced 
Normalization Tools (ANTs, http://stnava.github.io/ANTs/). The resulting 
transformation was used to resample the WML mask from the FLAIR image to the T1 
image using nearest-neighbour interpolation. 
 
T1 images were processed using the ‘segment’ routine in SPM12 
(https://www.fil.ion.ucl.ac.uk/spm/software/spm12/). This segmentation alternates 
between image registration, bias correction and tissue classification. Image 
registration aligns the two images together. Bias correction corrects the bias field 
signal caused by magnetic field inhomogeneities. Tissue classification assigns a 
probability value for GM, WM and CSF for every voxel in the brain. This is 
conditional based on a previously-defined population template (Ashburner and 
Friston, 2005). The process alternates between these steps to create the best 
segmentation possible.  
 
Segmentation provides tissue probability maps for every subject, where every voxel 
has an assigned probability of belonging to a certain tissue class. Volumes for each 
tissue class were calculated as the sum of all voxels that have a probability of >0.5 of 
belonging to that class, after having WML voxels removed. Total brain volume is the 
sum of the GM and WM volumes, and ICV is the sum of the total brain volume and 
CSF volumes. 
 
All segmentations and registrations were visually inspected for errors.  
 
 
2.5.5 WM Microstructure 
DWI is a variant of conventional MRI based on the tissue water diffusion rate. DWI 
refers to the contrast of the acquired images, whilst DTI is a specific type of 
modelling using the DWI datasets, which allows for modelling of WM microstructure 
(Soares et al., 2013). DW images are made sensitive to the movement of water 
molecules within a tissue by the application of gradients, which ‘measure’ how far the 
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water molecules have moved in a certain time. This movement will differ amongst 
directions depending on the tissue type, integrity, architecture and presence of 
barriers. Applying the diffusion gradients in a specific direction sensitises your 
images to diffusion in that direction so by acquiring multiple images you can obtain 
information on the ease and directionality of diffusion in the tissue. There are two key 
parameters that are taken from DTI imaging: MD is the molecular diffusion rate, or a 
measure of the ease of diffusion, and FA is a measure of the directional dependence 
of diffusion. Within WM, diffusion tends to be easier along the axons than across it, 
so is anisotropic; in GM it is less anisotropic and in CSF it is unrestricted in all 
directions, so is isotropic.  
 
DTI analysis was carried out in the same way it has been described previously (Croall 
et al., 2017). Briefly, FSL software ("FDT"; FMRIB’s Diffusion 
Toolbox, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDT) was used for DTI preprocessing. 
Scans were corrected for eddy current and a binary brain mask in DTI space was 
calculated. FA and MD maps were then calculated from this data. Voxels with MD 
values above 2.6 x 10-4 mm2s-1 were removed from analyses as these likely contain 
CSF. Likewise, voxels with FA>1 were also removed. For each participant, FMRIB 
Linear Image Registration Tool was used to register the T1 weighted image to the B0 
image, which could then be used to create a transformation of FLAIR to DTI. These 
were all manually checked. Tissue probability maps and WML masks were then 
transformed into DTI space. The tissue and WML masks were then used to create 
tissue specific diffusion parameter maps.  
 
Histogram analysis was performed on the FA and MD maps in WM, NAWM and 
WML. Normalised histograms with 1000bins (FA range: 0-1, bin width: 0.001; MD 
range: 0-4 x 10-3 mm2s-1, bin width: 0.004 x 10-3 mm2s-2) were computed and median, 
peak height, peak location, skew and kurtosis were extracted. These metrics were 







2.5.6 Freewater  
Freewater (FW) maps and FW adjusted FA and MD maps were estimated using a 
non-linear regularised minimisation process implemented in Matlab (Pasternak et al., 
2009) and were carried out in a similar way to previously described (Duering et al., 
2018). Briefly, each voxel was fitted to a two-compartment model, which included a 
FW compartment (isotropic tensor with fixed diffusion constant of water at 37°C) and 
a tissue compartment (FW corrected tensor). The estimated parameters were the 
fractional volume of the FW compartment and the tensor of the tissue compartment. 
The FW measure ranges from 0 to 1 and expresses the relative contribution of FW in 
each voxel. The tensor of the tissue compartment reflects the tissue microstructure 
with the signal from FW removed. Following this, MD and FA were recalculated 
using the histogram analysis described above.   
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2.6 Contrast MRI analysis 
 
2.6.1 Data Processing 
Permeability maps were created as detailed in the previous literature (Taheri et al., 
2011b). The T1 maps from the contrast MRI can be used to calculate estimations of 
gadolinium concentration in the tissue, assuming a linear relationship.  
 
As described above, T1 values are calculated using a variable flip angle technique 
with 6 flip angles (2°, 5°, 12°, 17°, 22°, 27°). We obtained one map prior to injection 
then 8 post contrast injection maps with at temporal resolution of about 2.5 minutes. 
The T1 values can be calculated from the multiple flip angles (α) by fitting the data to 
the equation below to the data.  
 
 
The relationship between the pre- and post-contrast longitudinal relaxation rate 
difference at any point in time (Δ(1/T1(t)) and the concentration of contrast agent at 
that time point (C(t)) is assumed to be linear, with k as the constant of proportionality. 
 
 
The concentration of gadolinium over time can then be used to calculate the level of 
permeability, using the Patlak modelling technique (Patlak and Blasberg, 1985). The 





Ctiss(t) is the concentration of the tracer in the tissue at time t (L/g of tissue), Cpa(t) is 
the concentration of the tracer in the plasma (L/g of plasma), Vp is the fraction of total 
volume occupied by the blood volume (L/g) and Ki is the blood to tissue transfer 
constant of gadolinium per gram of tissue per minute (L/g min). The same equation 
can be used to calculate Ki directly from the T1 values, by replacing the 
concentrations with T1 relaxation rates, scaled by the proportionality constant k.  
 
Dividing both sides of the equation with Cpa(t) allows Ki to be determined by linear 
regression. Cpa(t) is the arterial input function (AIF), designed to represent the 
concentration of gadolinium measured in arterial plasma. Ideally, this would be an 
artery as the model requires an AIF, but there is no artery in the FOV. Therefore, the 
sagittal sinus is used, corrected by the factor (1-haematocrit) as this is assumed to be 
representative of the arterial concentration of contrast agent (Taheri et al., 2011b). 
The sagittal sinus is obtained through semiautomatic segmentation using ITK-snap to 
get the mean activity in the sagittal sinus. Ki can then be determined for every voxel 
in the image across the time of the experiment.  
 
 
2.6.2 Global BBB permeability 
The T1 weighted images were then registered using ANTS to the FLAIR images and 
the tissue segments and WML mask used to create the WM and NAWM masks. We 
then eroded the masks by 3mm using fslmaths (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki), 
to ensure there was no ventricular or GM contamination.  
 
Global values of BBB permeability in the WM (sum of NAWM and WML), NAWM 
and WML were calculated as mean Ki values for every voxel in that region.  
 
 
2.6.3 Hotspot BBB permeability 
Hotspots were classified as voxels with a value greater than the 95th centile of the 
permeability distribution from the NAWM of the control population. The tissue 
segments and the parameter maps were then used along with this threshold to generate 
the hotspot maps using the fslmaths threshold and mask features. The mean value and 
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2.6.4 Penumbra BBB permeability  
The penumbra was defined by taking the lesion mask and dilating this by 3mm in all 
directions using fslmaths. The lesion mask was then subtracted from the dilated image 
to give the penumbra. This was further masked using the CSF and GM segments to 





2.7 PET analysis 
 
2.7.1 Image Reconstruction 
List-mode PET data were histogrammed into 55 time frames and then reconstructed 
into images (128 x 128 x 89 matrix; 2.0 x 2.0 x 2.8 mm voxel size) using time-of-
flight ordered subsets expectation maximisation (Hudson and Larkin, 1994) with 16 
subsets, 6 iterations and no smoothing. Attenuation correction was applied using an 
attenuation coefficient map produced offline from the combination of non-patient 
object templates and a pseudo-CT generated from the T1-weighted MR image 
acquired during PET data acquisition. The multi-subject atlas method was used to 
generate the pseudo-CT (Burgos et al., 2014), which was converted to linear 
attenuation coefficient at 511 keV using a transformation (Carney et al., 2006). Image 
reconstruction also included corrections for random coincidences, dead time, 
normalisation, scattered coincidences, radioactive decay and sensitivity.  
 
2.7.2 Global PK binding  
SPM12 was used to realign each dynamic image series and hence reduce the impact 
of head motion. A mean realigned PET image was then used to co-register each 
realigned dynamic PET image series to the BBB MR image from the same scan via 
the T1 image mentioned above and the FLAIR images. 
 
To estimate specific tracer binding, PK PET data were analysed with the simplified 
reference tissue model (SRTM) to quantify binding potential relative to a non-
displaceable compartment (BPND) (Lammertsma and Hume, 1996). The WM 
reference region was estimated with supervised cluster analysis for PK (Yaqub et al., 
2012) with the library data determined from control scans of another PK project on 
the GE SIGNA PET/MR with the same acquisition and processing protocol 
(BIODEP; PI Prof ET Bullmore). Correction for vascular binding was also applied to 
the PK data (Yaqub et al., 2012).  
 
For regional analysis, NAWM and WML regions of interest (ROIs) were delineated 
on the FLAIR MR image and subsequently transformed to PET space via the BBB 
MR image. To reduce the impact of differential atrophy and ventricle size, the time-
66 
 
activity curve (TAC) of each ROI was corrected for CSF contamination through 
division with the mean sum of GM and WM probabilities in the ROI, with both 
SPM12 probability maps smoothed to PET spatial resolution. SRTM was then applied 
to the CSF-corrected ROI TACs. A basis function implementation of SRTM was used 
for parametric mapping due to its robustness at the higher noise levels found at the 
voxel level (Gunn et al., 1997). A 4mm full width at half maximum Gaussian was 
applied to the dynamic images prior to parametric mapping.  
 
For comparison with the BBB permeability data, only PET data from the tissue that 
corresponds to the BBB data was analysed.  
 
 
2.7.3 Hotspot PK binding 
PK binding was calculated for every voxel in the brain, which could then be 
segmented into NAWM and WML using the methods specified previously. Further, 
hotspots were classified in the same way as for BBB permeability, using the control 
population to define a value of ‘significant’ binding. 
 
 
2.7.4 Penumbra PK binding 
Penumbra values were calculated in the same way as documented above for BBB 








2.8 Cognitive tests 
 
2.8.1 Cognitive Test Battery 
A battery of cognitive tests that had been previously established for an SVD cohort 
was used to provide an assessment of cognitive function (Lawrence et al., 2013). 
Premorbid IQ was estimated using the restandardised National Adult Reading Test 
(NART, 2nd Edition) (Nelson and Willison, 1991).  Assessment was usually on the 
same day but always within 2 weeks of the PET/MRI scan. The tests took around 1 
hour in total.  
 
The tasks were divided into EF, PS, WoM and LTM. The specific tasks used to 
calculate each of these cognitive indices can be found in Table 2.1. Further, a GC was 
produced which summarised performance on all the tasks.  
 
To construct each index, task measures were transformed into z-scores using 
psychometric standardisation using the best available age-scaled normative data. The 
exception to this was the modified Wisconsin Card Sort Test (mWCST), where a 
published study was used to select normative data with comparable age and gender 
distribution (Nagahama et al., 2003). Task z-scores were then averaged to create the 
cognitive index scores.  
 
All participants were able to take part in the cognitive testing, but in some cases 
participants were not able to finish individual tests. In these cases, the minimum 







Task & Normative Data 
reference 




Trail making test 
(Mitrushina et al., 2005) 
Time to complete Part B (number-
letter switching)  
 
Verbal Fluency (Delis et 
al., 2001)  
Total number of Correct Words 
generated 
 
Modified Wisconsin Card 
Sort Test (Nagahama et 
al., 2003) 




BMIPB Speed of 
Information Processing 
(Coughlan et al., 2007) 
Total correct, adjusted for motor 
score & errors (%)* 
 




Grooved Pegboard Task 
(Dawson et al., 2010)  









WMS-III Logical Memory 
(Wechsler, 1997b) 






Total Score: Immediate Recall & 
Delayed Recall* 
*Composite scores used for multiple task measures 
Table 2.1: Summary of tasks making up the various cognitive indices and references 






2.8.2 Trail Making Test 
The Trail Making Test contained two parts: Part A required the participant to draw 
lines that sequentially connected numbers 1-25 on a sheet of paper. For Part B, the 
task was similar, but the participant had to alternate between numbers and letters (e.g. 
1, A, 2, B, 3, C). If the participant made a mistake, they were stopped and told to 
return to the previous correct point. The time taken to complete the task was recorded. 
To calculate our cognitive indices, we were only interested in the time taken to 
complete part B.  
 
 
2.8.3 Verbal Fluency 
The verbal fluency assessment used in this study was letter fluency. Participants were 
given 60 seconds to produce as many words as possible for a letter. They were 
instructed that none of the words could be names of people, names of places or 




The mWCST is a simplification of the Wisconsin Card Sorting Test, which consists 
of only two sets of 24 cards (Nagahama et al., 2003). In this test, six consecutive 
correct responses were required to complete a category. In the mWCST, the 
“categories completed” and “perseverative errors” are the parameters thought to 
categorise ability most accurately (Cianchetti et al., 2005), so a composite score was 
created from these parameters.  
 
 
2.8.5 BIRT Memory and Information Processing Battery 
The BIRT Memory and Information Processing Battery (BMIPB) is a collection of 
seven psychological tests that measure various aspects of cognitive function. The 
Speed of Information Processing required the participant to recognise and draw a line 
through the second highest number in a row of numbers. They did this for 4 minutes, 
and the amount they managed to complete was recorded. They were then also tested 
for their speed and were given a page of figures; they had to cross through these 
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figures as quickly as possible and the number completed in the given 25 seconds was 
recorded. A composite score was then created combining both parts of the task.  
 
 
2.8.6 Digit Symbol Substitution 
Digit symbol substitution is a test of psychomotor performance; participants were 
given a key grid of numbers and corresponding symbols and a test sheet with numbers 
and empty boxes. The participant had to fill in as many of the boxes with the 
matching symbol as possible within two minutes (Rosano et al., 2016).   
 
 
2.8.7 Grooved Pegboard Task 
The Grooved Pegboard Task involved a board with pegs and grooves. The grooves 
were at random rotations across the board, requiring the participant to rotate the pegs 
around in their hand in order to fit them in. The task was done firstly with the 
dominant hand and then with the non-dominant hand. We took the best score from 
either hand to minimise the effect of post-stroke disability on the score.  
 
 
2.8.8 Digit Span Task 
The Digit Span Task involved reading out a series of numbers that the participant had 
to repeat; they started short but got longer throughout the task. The task finished when 
the participant got two of the same length wrong. The second part of the task involved 
the tester reading another line of the numbers, which the participant then had to repeat 
backwards. Again, this started short and got longer with time and stopped when the 
participant got two of the same length wrong.  
 
 
2.8.9 Logical Memory 
Logical memory was taken from the Weschler Memory Scale 3rd edition (WMS-III), 
which involved reading a story to the participant and then asking them to immediately 
recall everything they could remember about the story. A further story was then read 
to the participants and they were again asked to tell everything they could remember. 
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This same story was then read again and the task was repeated. 25-35 minutes later, 
they were then further asked to remember everything they could from the stories.  
 
 
2.8.10 Visual Reproduction 
Visual reproduction was also taken from WMS-III. This involved showing the 
participant designs. They got 10 seconds to look at the design before the design was 
covered and they were asked to draw it in the booklet. There were a total of five 
designs. 25-35 minutes later the participants were asked to draw any of the designs 






2.9 Blood Biomarkers 
 
2.9.1 Blood Sampling and Storage 
Blood samples were taken from all participants at baseline. 10ml of whole blood was 
collected in serum separator tubes. The blood was left to clot for 30 minutes at room 
temperature before being centrifuged for 15 minutes at 1000g. ~4ml of serum was 
then pipette and aliquot into 50µl eppendorfs. These were stored in a -70°C freezer 
until they were sent for analysis.  
 
 
2.9.2 Sample Analysis 
Olink Proteomics (https://www.olink.com/) is an analysis service for targeted protein 
biomarker discovery. The panel chosen was the Cardiovascular Disease III panel 
measuring 92 cardiovascular disease related human protein biomarkers 
simultaneously (https://www.olink.com/products/cvd-iii-panel/). 
 
Olink uses Proximity Extension Assay technology, where 92 oligonucleotide labelled 
antibody probe pairs bind to their respective target protein present in the sample 
(Assarsson et al., 2014, Lundberg et al., 2011). Full details of the methodology is 
available on their website (https://www.olink.com/content/uploads/2018/03/Olink-
CVD-III-Validation-Data-v2.0.pdf). However, briefly, a polymerase chain reaction 
(PCR) reporter sequence was formed by a proximity dependent DNA polymerisation 
event and was subsequently detected and quantified using real-time PCR. The 
analysis was performed in a homogeneous 96-well format without any need for 
washing steps.  
 
Internal and external controls were used for data normalisation and quality control 
purposes. Internal controls were added to each sample and included two immunoassay 
controls, one extension control and one detection control. The controls were then used 
to normalise the data. The extension control was used to normalise for technical 
variations within one run, whilst the interplate control normalised for between runs. In 
the final step of pre-processing the values were set relative to a correction factor 
which generates a Normalised Protein Expression unit on a log2 scale, where a larger 
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number represents a higher protein level in the sample, with background level around 
zero.  
 
In addition to the Olink analysis, we were interested in C reactive protein (CRP). CRP 
was analysed using an enzyme-linked immunosorbent assay (ELISA) at the Core 
Biochemical Assay Laboratory at Addenbrooke’s hospital using the Siemens 




The specific proteins used in our analysis were chosen based on hypothesis-driven 
methods from the literature. The proteins of interest to us are as follows:  
• Inflammation: Tumour necrosis factor receptor 1 (TNF-R1), Tumour 
necrosis factor receptor 2 (TNF-R2), FAS, Interleukin-1 receptor type 1 (IL-
1RT1), Interleukin-6 receptor subunit α (IL-6Rα), Interleukin-18 binding 
protein (IL-18BP), C-reactive protein (CRP) and Chitinase-3-like protein 1 
(CHI3L1) 
• MMPs: MMP-2, MMP-3, MMP-9 and Metalloproteinase inhibitor 4 (TIMP-
4) 
• Endothelial Cell Activation: E-selectin, P-selectin, Integrin β2 (ITGB2), 
vWF Cadherin-5 (CDH5), Junctional adhesion molecule A (JAM-A), Platelet 





2.10 Statistical analysis 
 
All statistical analysis was carried out using R (version 3.3.1 2016, R Foundation for 
Statistical Computing, Vienna, Austria). The statistical tests used for each analysis are 




Chapter 3: Demographics, Conventional MRI, DTI 
and Cognition 
 
3.1 Subject Numbers 
 
There were a total of 60 participants recruited to this study, which formed three 
groups (20 sporadic SVD, 20 CADASIL and 20 control).  
 
However, all patients did not complete every aspect of the study (Figure 3.1). 
Cognitive data and serum samples were collected for every participant. Non-contrast 
structural MRI was collected for all but one participant for whom there was a 
technical scanner problem that meant no images could be acquired.  
 
DCE-MRI permeability data was collected for all but two participants, with a third 
subsequently excluded. One participant was the same as above where technical 
problems with the scanner prevented images being collected. A second subject 
encountered a radiographer error where the gadolinium line was not attached to the 
participant’s cannula. A third subject exhibited significant motion meaning that the 
permeability data could not be analysed. PET yielded the lowest n numbers, with a 
total of twelve patients who did not receive PET. This was due to problems with 
producing the ligand or failure to meet quality control after production, meaning 
injection could not go ahead.   
 
Total recruited n=60 
Control n=20 Sporadic SVD n=20 CADASIL n=20 
Non-contrast MRI n=19 Non-contrast MRI n=20 Non-contrast MRI n=20 
DCE-MRI n=19 DCE-MRI n=19 DCE-MRI n=19 
PK PET n=17 PK PET n=17 PK PET n=14 
Cognition n=20 Cognition n=20 Cognition n=20 
Serum n=20 Serum n=20 Serum n=20 
 
Figure 3.1: Final subject numbers for the end-points collected. 
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3.2 Patient Demographics and Medical History 
 
3.2.1 Statistical Analysis 
The demographic data consisted of frequency and continuous data. For frequency 
data, chi-squared tests with the false discovery rate (FDR) correction for multiple 
comparison were used to compare between sporadic SVD and control and CADASIL 
and control. For continuous data, a Dunnett’s test was used to compare between SVD 
and control and CADASIL and control.   
 
 
3.2.2 Group Differences  
Demographics and medical history were collected from all patients during their 
baseline visit (Table 3.1).  
 
Age was not statistically significant between the sporadic SVD and control group, but 
it was significantly lower in the CADASIL group compared to control (p<0.001). 
There was no significant difference in the sex ratio between sporadic SVD and control 
or CADASIL and control. Similarly, there was no difference in the years in education. 
The cohort was predominantly White British in all the groups, with no significant 
difference between sporadic SVD and control or CADASIL and control. The groups 
were also of a similar height, weight and BMI.   
 
Systolic blood pressure was no different in sporadic SVD compared to control, but 
was significantly lower in CADASIL compared to control (p=0.037). Diastolic blood 
pressure was similar between the groups. There was an increased prevalence of 
hypertension in the sporadic SVD group compared to control (p<0.001), but not in the 
CADASIL group compared to control.  
 
Hyperlipidaemia, diabetes, depression and smoking status were all similar between 
the groups. Migraine prevalence was significantly higher in CADASIL compared to 
















SIL vs.  
control N=20 N=20 N=20 
Age (years) * 66.35 (6.74) 70.90 (9.01) 51.85 (9.46) 0.167 <0.001 
Sex (total male) ** 13 (65.0)  10 (50.0)  13 (65.0)  0.784 1.000 
Education (years) * 13.40 (3.79) 12.95 (2.93) 14.10 (3.28) 0.878 0.734 
Ethnicity **                0.394 0.407 
White British 9 (95.0)  14 (70.0)  16 (80.0)  - - 
White Irish 0 (0.0)  3 (15.0)  0 (0.0)  - - 
Pakistani 0 (0.0)  0 (0.0)  1 (5.0)  - - 
Any other black 
background 0 (0.0)  0 (0.0)  1 (5.0)  - - 
Any other white 
background 1 (5.0)  3 (15.0)  2 (10.0)  - - 






(8.68) 0.171 0.463 
Weight (kg) * 80.61 (11.76) 80.72 (20.98) 84.71 (15.72) 1.000 0.689 
BMI (kg/m2)* 26.34 (3.33) 27.88 (5.86) 28.80 (4.45) 0.516 0.217 
Systolic blood 






(17.22) 0.183 0.037 
Diastolic blood 
pressure (mmHg) * 81.21 (9.03) 76.89 (13.99) 74.40 (11.22) 0.414 0.128 
Hypertension ** 6 (30.0)  18 (90.0)  8 (40.0)  <0.001 0.741 
Hyperlipidaemia ** 7 (35.0)  11 (55.0)  3 (15.0)  0.341 0.341 
Diabetes ** 1 (5.0)  4 (20.0)  0 (0.0)  0.513 1.000 
Smoking ** 12 (60.0)  11 (55.0)  7 (35.0)  1.000 0.512 
Depression** 7 (35.0)  5 (25.0)  8 (40.0)  1.000 1.000 
Migraine ** 5 (25.0)  5 (25.0)  16 (80.0)  1.000 0.002 
*(mean(SD) displayed with p value from Dunnetts test, **(total (%)) displayed with 
fisher-exact with FDR correction 
 
Table 3.1: Demographics and medical history were collected from patients. P values 
are shown for comparisons between sporadic SVD and control groups, and between 
CADASIL and control groups. Significant p-values are shown in bold. 
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3.3 Conventional MRI markers 
 
3.3.1 Statistical Analysis 
All of the conventional MRI markers had a non-normal distribution. To allow them to 
be analysed with parametric statistics, they were transformed. Brain volume and GM 
volume were both squared. CSF volume, NAWM volume, WML volume, lacune 
volume, lacune count and CMB count were all cube rooted. WM volume was logged 
(base:10).  
 
Analysis of covariance (ANCOVA) tests controlling for age and sex were performed 
between the sporadic SVD and control groups and the CADASIL and control groups. 
ICV was used as an additional control for all volumetric measures. Bonferroni 




3.3.2 Group Differences  
MRI markers were quantified from the various non-contrast MRI scans and mean 
values were calculated for each of the groups (Table 3.2).  
 
There was no significant difference in brain volume between SVD and control, but 
CADASIL had a significantly higher brain volume compared to control (p<0.001). 
Brain volume was then segmented into GM, WM and CSF and compared. GM 
volume was not significantly different between the groups. WM volume was 
significantly higher in sporadic SVD compared to control (p=0.023) and in CADASIL 
compared to control (p<0.001). CSF volume was significantly higher in sporadic SVD 
compared to control (p=0.002), was no different between CADASIL and control. 
 
We then split the WM into NAWM and WML and compared these volumes. NAWM 
volume was no different between sporadic SVD and control, but was significantly 
lower in CADASIL compared to control (p=0.009). WML volume was significantly 
higher in the sporadic SVD group compared to control (p<0.001) and in the 




Lacunes were measured as volume and also as a total count. Lacune volume was 
significantly higher in sporadic SVD compared to control (p<0.001) and in CADASIL 
compared to control (p<0.001). Similarly, lacune count was significantly higher in 
sporadic SVD compared to control (p<0.001) and in CADASIL compared to control 
(p<0.001).  
 
Finally, CMBs were counted. The CMB count was significantly higher in sporadic 
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[626.4, 679.4] 
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Table 3.2: Median values for MRI markers in the control, sporadic SVD and 
CADASIL groups are shown. P values are shown comparing sporadic SVD and 
control groups, and CADASIL and control groups. Analyses were controlled for age 
and sex, with volumetric measures also controlled for ICV. Significant p values are 









      0.00  
[0.00, 5.50] 0.002 0.008 
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3.4 DTI markers 
 
3.4.1 Statistical Analysis 
Some of the DTI variables were normally distributed whilst others were not. Non-
normal variables were transformed so that parametric statistics could be used. FA 
NAWM median and FA NAWM peak location were squared. FA WML median, FA 
WML peak height, MD WML peak height and MD WML peak location were logged 
(base:10). FA WML peak location and MD WML median were square rooted.  
 
ANCOVA tests controlling for age and sex were performed between the sporadic 
SVD and control groups and the CADASIL and control groups. Bonferonni 




3.4.2 Group Differences  
Differences in the DTI parameters between sporadic SVD and control and CADASIL 
and control are shown in Table 3.3.  
 
FA median in the NAWM was significantly lower compared to control in the sporadic 
SVD group (p<0.001) and the CADASIL group (p<0.001). FA peak height in the 
NAWM was similar in the sporadic SVD and control groups but was significantly 
higher in the CADASIL group compared to control (p=0.001). FA peak location in 
the NAWM was lower compared to control in the sporadic SVD group (p<0.001) and 
in the CADASIL group (p<0.001).  
 
FA median in the WML was not significantly different between sporadic SVD and 
control or CADASIL and control. However, FA peak height in the WML was 
significantly lower in the sporadic SVD group compared to control (p<0.001) and in 
the CADASIL group compared to control (p<0.001). FA peak location in the WML 




MD median in the NAWM was significantly higher compared to control in the 
sporadic SVD group (p<0.001) and in the CADASIL group (p<0.001). MD peak 
height in the NAWM was significantly lower in the sporadic SVD group compared to 
control (p<0.001) and in CADASIL compared to control (p<0.001). Similarly, MD 
peak location in the NAWM was significantly higher compared to control in the 
sporadic SVD group (p<0.001) and CADASIL group (p<0.001).  
 
MD median in the WML was significantly higher in the CADASIL group compared 
to control (p=0.009). However, it was not significantly different between the sporadic 
SVD group and control. MD peak height was significantly lower in the sporadic SVD 
group compared to control (p<0.001) and in CADASIL compared to control 
(p<0.001). MD peak location in the WML was significantly higher in the CADASIL 
group compared to control (p=0.017). However, it was not significantly different 


















SIL vs.  
control N=19 N=20 N=20 
FA NAWM Median  0.41  
[0.38, 0.42] 
 0.35  
[0.34, 0.36] 
 0.32  
[0.28, 0.35] <0.001 <0.001 
FA NAWM Peak 
height* 
 2.63  
[2.44, 2.67] 
 2.69  
[2.47, 2.80] 
 2.84  
[2.60, 3.08] 0.482 0.001 
FA NAWM Peak 
location 
 0.40  
[0.37, 0.40] 
 0.32  
[0.30, 0.35] 
 0.30  
[0.26, 0.35] <0.001 <0.001 
FA WML Median  0.20  
[0.17, 0.26] 
 0.24  
[0.22, 0.26] 
 0.20  
[0.18, 0.23] 0.492 0.808 
FA WML Peak 
height* 
 9.62  
[8.16, 16.85] 
 4.77  
[4.38, 5.15] 
 4.68  
[4.23, 5.34] <0.001 <0.001 
FA WML Peak 
location 
 0.12  
[0.11, 0.24] 
 0.20  
[0.15, 0.22] 
 0.14  
[0.10, 0.18] 0.702 0.790 
MD NAWM Median*  0.78  
[0.76, 0.79] 
 0.85  
[0.82, 0.87] 
 0.89  
[0.83, 0.91] <0.001 <0.001 







[9.75,13.08] <0.001 <0.001 
MD NAWM Peak 
location* 
 0.76  
[0.75, 0.77] 
 0.82  
[0.79, 0.84] 
 0.83  
[0.81, 0.87] <0.001 <0.001 
MD WML Median*  0.94  
[0.86, 1.15] 
 1.16  
[1.13, 1.18] 
 1.19  
[1.14, 1.30] 0.060 0.009 




 7.61  
[7.09, 8.80] 
 6.76  
[6.05, 7.38] <0.001 <0.001 
MD WML Peak 
location* 
 0.85  
[0.80, 0.97] 
 1.07  
[1.00, 1.18] 
 1.19  
[0.94, 1.33] 0.067 0.017 
*(x10-3) 
Table 3.3: Median values for the various DTI histogram parameters are shown for 
control, sporadic SVD and CADASIL groups. P values are shown comparing sporadic 
SVD and control groups, and CADASIL and control groups. Analyses were 




3.5 FW corrected DTI 
 
3.5.1 Statistical Analysis 
Some of the FW and FW corrected DTI variables were normally distributed whilst 
others were not. Non-normal variables were also transformed so that parametric 
statistics could be used. FW NAWM peak height, FW NAWM peak location, FW 
WML peak height, FW corrected FA NAWM peak height, FW corrected FA NAWM 
peak location, FW corrected FA WML peak height and FW corrected MD WML peak 
height were logged (base:10). FW corrected MD NAWM peak height was squared.  
 
ANCOVA tests controlling for age and sex were performed between the sporadic 
SVD and control groups and the CADASIL and control groups. Bonferroni 




3.5.2 Group Differences  
FW and FW corrected FA and MD values are shown, with differences between 
sporadic SVD and control and CADASIL and control analysed in Table 3.4.  
 
FW median in the NAWM was significantly higher in the sporadic SVD group 
compared to control (p<0.001) and in the CADASIL group compared to control 
(p<0.001). FW peak height in the NAWM was similar in sporadic SVD and control, 
but was significantly lower in the CADASIL group compared to control (p<0.001). 
Similarly, FW peak location in the NAWM was similar in the sporadic SVD and 
control groups, but was significantly higher in the CADASIL group compared to 
control (p=0.016).  
 
FW median in the WML was significantly higher compared to control in the sporadic 
SVD group (p=0.033) and CADASIL group (p=0.003). FW peak height in the WML 
was significantly lower than control for both sporadic SVD (p<0.001) and CADASIL 
(p<0.001). FW peak location in the WML was significantly higher than control for 




FW adjusted FA median values in the NAWM were significantly lower compared to 
control for both sporadic SVD (p<0.001) and CADASIL (p<0.001). FW adjusted FA 
peak height in the NAWM was similar between sporadic SVD and control groups, but 
was significantly lower in the CADASIL group compared to control (p<0.001). 
Similarly, FW adjusted FA peak location in the NAWM was similar between sporadic 
SVD and control groups, but was significantly lower in the CADASIL group 
compared to control (p<0.001).  
 
FW adjusted FA median values in the WML were significantly higher in sporadic 
SVD compared to control (p=0.032) but were similar between CADASIL and control. 
FW adjusted FA peak height values in the WML were significantly lower than control 
for both sporadic SVD (p<0.001) and CADASIL (p<0.001). FW adjusted FA peak 
location values in the WML were significantly higher than control for both sporadic 
SVD (p<0.001) and CADASIL (p=0.027).  
 
FW adjusted MD median values in the NAWM were significantly lower in the 
sporadic SVD group compared to control (p<0.001) and in the CADASIL group 
compared to control (p<0.001). However, FW adjusted MD peak height values in the 
NAWM were no different between sporadic SVD and control or CADASIL and 
control. Similarly, FW adjusted MD peak location values in the NAWM were no 
different between the groups. 
 
FW adjusted MD median values in the WML were significantly lower than control for 
both sporadic SVD (p<0.001) and CADASIL (p<0.001). FW adjusted MD peak 
height values in the WML were also significantly lower than control for both sporadic 
SVD (p<0.001) and CADASIL (p<0.001). FW adjusted MD peak location values in 
the WML were significantly lower than control for both sporadic SVD (p=0.001) and 
















SIL vs.  
control N=19 N=20 N=20 





[0.30, 0.36] <0.001 <0.001 
FW NAWM Peak 
height* 
 4.44  
[4.29, 4.83] 
 4.04  
[3.68, 5.78] 
 3.63  
[3.16, 4.12] 1.000 <0.001 
FW NAWM Peak 
location 
 0.00  
[0.00, 0.24] 
 0.00  
[0.00, 0.28] 
 0.31  
[0.26, 0.32] 1.000 0.016 





[0.53, 0.63] 0.033 0.003 
FW WML Peak 
height* 





[3.03, 4.14] <0.001 <0.001 
FW WML Peak 
location 





[0.55, 0.70] 0.039 <0.001 





[0.21, 0.25] <0.001 <0.001 
FA NAWM Peak 
height* 
 5.77  
[4.18, 7.57] 
 4.94  
[4.06, 7.07] 
 3.54  
[3.33, 4.06] 1.000 0.001 
FA NAWM Peak 
location 
 1.00  
[1.00, 1.00] 
 1.00  
[0.81, 1.00] 
 0.20  
[0.18, 0.42] 0.675 <0.001 





[0.18, 0.21] 0.032 0.400 




 6.61  
[5.92, 6.96] 
 6.07  
[5.53, 6.52] <0.001 <0.001 
FA WML Peak 
location 
 0.12  
[0.10, 0.16] 
 0.18  
[0.17, 0.20] 
 0.18  
[0.17, 0.19] <0.001 0.027 





[0.48, 0.49] <0.001 <0.001 
MD NAWM Peak 
height* 





[2.21, 2.67] 1.000 0.071 
MD NAWM Peak 
location 





[0.50, 0.50] 0.643 0.144 
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MD WML Median  0.47  
[0.46, 0.49] 
 0.46  
[0.45, 0.46] 
 0.45  
[0.44, 0.46] <0.001 <0.001 
MD WML Peak 
height* 
 6.41  
[4.45, 16.32] 
 2.79  
[2.57, 3.12] 
 2.67  
[2.19, 2.91] <0.001 <0.001 
MD WML Peak 
location 
 0.48  
[0.45, 0.49] 
 0.44  
[0.43, 0.45] 
 0.43  
[0.43, 0.46] 0.001 0.011 
*(x10-3) 
Table 3.4: Median values for the various DTI histogram parameters with FW 
correction are shown for control, sporadic SVD and CADASIL groups. P values are 
shown comparing sporadic SVD and control groups, and CADASIL and control 







3.6.1 Statistical Analysis 
Cognitive scores were normally distributed. ANCOVA tests controlling for age, sex 
and premorbid IQ were performed between the sporadic SVD and control groups and 
the CADASIL and control groups. Bonferroni adjustment was used between the pairs 
of p-values to correct for multiple comparisons.  
 
 
3.6.2 Group Differences  
Mean cognitive scores for each group and comparisons between sporadic SVD and 
control and CADASIL and control can be seen in Table 3.5. GC was significantly 
lower in the sporadic SVD compared to control (p=0.021) and in CADASIL 
compared to control (p=0.011). EF was similar between the groups. PS was 
significantly reduced compared to control in sporadic SVD (p<0.001) and CADASIL 
(p=0.027). WoM was similar between the groups. LTM was similar between sporadic 





Group (Mean (SD)) P value P value 
Control 
Sporadic 




control N=20 N=20 N=20 
GC   0.22 (0.52) -0.16 (0.80) -0.37 (0.96) 0.021 0.011 
EF   0.15 (0.87) -0.28 (1.09) -0.20 (1.44) 0.128 0.649 
PS   0.42 (0.43) -0.58 (1.12) -0.61 (1.85) <0.001 0.027 
WoM  -0.01 (0.76) -0.09 (0.95) -0.36 (0.61) 1.000 0.099 
LTM   0.30 (0.75)  0.30 (0.71) -0.32 (0.78) 1.000 0.007 
 
Table 3.5: Z scores for the various cognitive domains for control, sporadic SVD and 
CADASIL groups. P values for comparisons between the sporadic SVD and control 
groups, and the CADASIL and control groups are shown. Analyses were controlled 
for age, sex and premorbid IQ. Significant p values are shown in bold.  
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3.7 Associations between MRI markings and Cognition 
 
3.7.1 Statistical Analysis 
Multivariate linear regressions were performed to determine if any of the imaging 
markers were significantly associated with cognition. Some of the imaging markers 
were not normally distributed and therefore transformations were performed. Brain 
volume, GM volume, FA NAWM median, FW MD NAWM peak height were all 
squared. CSF volume, NAWM volume, WML volume, lacune volume, lacune count 
and CMB count were all cube rooted. WM volume, FA WML median, MD WML 
peak height and FW MD WML peak height were logged (base:10). 
 
Linear regression models were controlled for age, sex and premorbid IQ. Models 
containing volumetric measure were also controlled for ICV. FDR correction was 
used to correct the p values for multiple comparisons.  
 
 
3.7.2 Group Differences  
The associations between the various MRI markers and cognition are shown in Tables 
3.6-3.10.  
 
Associations with GC are shown in Table 3.6. In the sporadic SVD group, GC was 
significantly associated with GM volume (β=0.557, p=0.003), FA median in the 
NAWM (β=0.485, p=0.025) and FW median in the NAWM (β=-0.464, p=0.022). In 
the CADASIL group, GC was also significantly associated with GM volume (β 
=0.874, p=0.006) and FA median in the NAWM (β =1.015, p=0.003). CADASIL GC 
was also significantly associated with FW adjusted FA median in the NAWM (β 
=1.054, p<0.001). There were no associations in the control group between any of the 
imaging markers and GC.  
 
Associations with EF are shown in Table 3.7. A higher GM volume was significantly 
associated with higher EF in the CADASIL group (β=1.083, p=0.001) (Table 3.7). FA 
median in the NAWM was also significantly associated with EF in the CADASIL 
group (β=1.087, p=0.005). This association was still present using the FW corrected 
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FA values in the NAWM (β=1.077, p=0.004). There was no association between any 
of the imaging markers and EF in the control or sporadic SVD groups.  
 
Associations with PS are shown in Table 3.8. In the sporadic SVD group, there was a 
significant association between PS and FW median in the NAWM (β=-0.689, 
p=0.016). In the CADASIL group, FA median in the NAWM significantly associated 
with PS, both uncorrected (β=0.960, p=0.010) and FW corrected (β=0.997, p=0.003). 
There was no association between any of the imaging markers and PS in the control 
group.  
 
There was no association between any of the imaging markers and WoM or LTM for 










β P  
value 
WML volume -0.176 0.561 0.070 0.808 -0.240 0.664 
Lacunar volume -0.459 0.761 -0.230 0.127 -0.483 0.210 
GM volume -0.370 0.210 0.557 0.003 0.874 0.006 
Lacune count 0.011 0.998 -0.358 0.127 -0.531 0.127 
CMB count -0.126 0.680 -0.210 0.439 -0.334 0.483 
FA median in NAWM -0.017 0.998 0.485 0.025 1.015 0.003 
FA median in WML 0.276 0.439 0.078 0.808 0.133 0.790 
MD peak height in NAWM 0.429 0.263 0.312 0.229 0.606 0.134 
MD peak height in WML 0.205 0.483 0.127 0.708 0.126 0.790 
FW median in NAWM -0.078 0.870 -0.464 0.022 -0.563 0.210 
FW median in WML 0.054 0.892 -0.204 0.472 -0.527 0.189 
FW FA median in NAWM -0.052 0.894 0.422 0.177 1.054 <0.001 
FW FA median in WML 0.416 0.127 -0.086 0.808 -0.064 0.892 
FW MD peak height in NAWM -0.226 0.664 0.390 0.088 -0.274 0.509 
FW MD peak height in WML 0.174 0.561 -0.005 0.998 0.000 0.998 
 
Table 3.6: Linear models of associations between various MRI markers and GC, 
controlled for sex, age, and premorbid IQ. All volumetric measures were also 
controlled for ICV. Table shows standardised β coefficients and p values. Significant 











WML volume -0.231 0.630 0.117 0.668 -0.204 0.669 
Lacunar volume -1.179 0.505 -0.100 0.668 -0.404 0.505 
GM volume -0.432 0.426 0.311 0.492 1.083 0.001 
Lacune count -0.632 0.668 -0.217 0.528 -0.502 0.374 
CMB count -0.267 0.505 -0.097 0.686 -0.320 0.635 
FA median in NAWM 0.062 0.798 0.388 0.210 1.087 0.005 
FA median in WML 0.229 0.635 0.140 0.660 0.124 0.707 
MD peak height in NAWM 0.298 0.635 0.088 0.707 0.713 0.210 
MD peak height in WML 0.327 0.429 0.102 0.687 0.169 0.668 
FW median in NAWM -0.213 0.660 -0.343 0.255 -0.669 0.338 
FW median in WML 0.059 0.798 -0.115 0.668 -0.440 0.505 
FW FA median in NAWM 0.087 0.765 0.582 0.070 1.077 0.004 
FW FA median in WML 0.250 0.630 0.097 0.706 -0.188 0.668 
FW MD peak height in NAWM -0.442 0.505 0.157 0.635 -0.299 0.630 
FW MD peak height in WML 0.188 0.635 0.121 0.668 0.122 0.707 
 
Table 3.7: Linear models of associations between various MRI markers and EF, 
controlled for sex, age, and premorbid IQ. All volumetric measures were also 
controlled for ICV. Table shows standardised β coefficients and p values. Significant 












WML volume -0.048 0.902 0.347 0.445 -0.216 0.803 
Lacunar volume 0.275 0.902 -0.166 0.728 -0.554 0.155 
GM volume 0.105 0.902 0.598 0.157 0.690 0.083 
Lacune count 1.115 0.677 -0.333 0.443 -0.557 0.111 
CMB count -0.034 0.917 -0.347 0.357 -0.223 0.803 
FA median in NAWM 0.032 0.918 0.613 0.083 0.960 0.010 
FA median in WML 0.408 0.468 0.107 0.902 0.198 0.803 
MD peak height in NAWM 0.678 0.267 0.612 0.083 0.573 0.170 
MD peak height in WML 0.063 0.902 0.045 0.902 0.135 0.856 
FW median in NAWM -0.066 0.902 -0.689 0.016 -0.631 0.170 
FW median in WML 0.120 0.902 -0.236 0.677 -0.490 0.261 
FW FA median in NAWM -0.080 0.902 0.404 0.468 0.997 0.003 
FW FA median in WML 0.664 0.083 -0.050 0.902 0.072 0.902 
FW MD peak height in NAWM -0.276 0.832 0.580 0.083 -0.177 0.822 
FW MD peak height in WML -0.049 0.902 -0.104 0.902 -0.065 0.902 
 
Table 3.8: Linear models of associations between various MRI markers and PS, 
controlled for sex, age, and premorbid IQ. All volumetric measures were also 
controlled for ICV. Table shows standardised β coefficients and p values. Significant 
















WML volume -0.182 0.757 0.162 0.720 -0.323 0.720 
Lacunar volume -0.002 0.998 -0.120 0.720 0.138 0.757 
GM volume -0.301 0.720 0.505 0.203 0.539 0.550 
Lacune count 0.051 0.977 -0.187 0.704 0.077 0.909 
CMB count -0.183 0.720 -0.102 0.720 -0.263 0.720 
FA median in NAWM -0.064 0.913 0.157 0.720 0.482 0.655 
FA median in WML -0.186 0.757 -0.116 0.720 -0.121 0.757 
MD peak height in NAWM -0.080 0.913 0.065 0.809 0.228 0.720 
MD peak height in WML 0.046 0.916 -0.072 0.757 -0.026 0.940 
FW median in NAWM 0.180 0.757 -0.134 0.720 -0.164 0.757 
FW median in WML 0.241 0.720 -0.015 0.940 -0.358 0.704 
FW FA median in NAWM -0.085 0.909 0.243 0.704 0.519 0.619 
FW FA median in WML 0.307 0.720 -0.233 0.655 -0.309 0.704 
FW MD peak height in NAWM -0.284 0.724 0.034 0.913 -0.219 0.720 
FW MD peak height in WML 0.230 0.720 -0.071 0.757 0.125 0.757 
 
Table 3.9: Linear models of associations between various MRI markers and WoM, 
controlled for sex, age, and premorbid IQ. All volumetric measures were also 
controlled for ICV. Table shows standardised β coefficients and p values. Significant 












WML volume -0.003 0.988 -0.632 0.204 -0.042 0.988 
Lacunar volume -0.058 0.988 -0.464 0.201 -0.427 0.429 
GM volume -0.261 0.740 0.419 0.645 0.253 0.772 
Lacune count 0.075 0.988 -0.509 0.201 -0.426 0.429 
CMB count 0.166 0.780 -0.115 0.905 -0.318 0.711 
FA median in NAWM -0.067 0.958 0.419 0.429 0.341 0.726 
FA median in WML 0.413 0.429 0.121 0.905 0.052 0.958 
MD peak height in NAWM 0.485 0.430 0.225 0.764 0.135 0.905 
MD peak height in WML 0.097 0.905 0.443 0.392 0.007 0.988 
FW median in NAWM -0.104 0.905 -0.305 0.568 0.081 0.958 
FW median in WML -0.218 0.740 -0.354 0.429 -0.342 0.645 
FW FA median in NAWM -0.103 0.905 0.006 0.988 0.437 0.520 
FW FA median in WML 0.146 0.896 -0.146 0.905 0.099 0.905 
FW MD peak height in NAWM 0.315 0.740 0.562 0.174 -0.207 0.780 
FW MD peak height in WML 0.056 0.958 0.049 0.958 -0.166 0.807 
 
Table 3.10: Linear models of associations between various MRI markers and LTM, 
controlled for sex, age, and premorbid IQ. All volumetric measures were also 
controlled for ICV. Table shows standardised β coefficients and p values. Significant 












Our sporadic SVD and healthy control participants had similar ages, with means of 
70.9 and 66.4 years respectively (Table 3.1). This is similar to the SVD populations 
described in the literature (Lawrence et al., 2014, Croall et al., 2017, van Norden et 
al., 2012, Inzitari et al., 2009). The CADASIL group had a significantly younger 
mean age of 51.9 years. This difference in age therefore needed to be taken into 
consideration when comparing our CADASIL and control groups. We controlled for 
age in both this chapter and subsequent chapters, but this may not have accounted for 
all of the variation and is a limiting factor in this study.  
 
The participants were a well-educated population with similar mean years of 
schooling across all groups (13.4 years for healthy controls, 13.0 years for sporadic 
SVD and 14.1 years for CADASIL) (Table 3.1). They also were a predominantly 
white British population, which may limit the reproducibility of the results across 
other ethnic groups.  
 
The average BMI of the participants was similar across the groups (26.3 for healthy 
controls, 27.9 for sporadic SVD and 28.8 for CADASIL) (Table 3.1). Theses means 
fall into the overweight population. However, the average BMI of UK men in 2014 
was 27.4 and women was 27.0, so these numbers are similar to the UK averages 
(NCDRF, 2016).  
 
The prevalence of the neurological risk factors of depression and migraine were 
recorded (Table 3.1). Depression had similar prevalence across the groups but 
migraine was significantly higher in the CADASIL group. This result is to be 
expected, as migraine is a common symptom in CADASIL (Tan and Markus, 2016). 
 
 
3.8.2 Conventional MRI markers 
Various parameters were taken from the MR images, which characterises the disease 
burden in the participants (Table 3.2). Brain volume was significantly higher in the 
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CADASIL population compared to control, even when taking account of age and sex. 
This finding is in contrast to previous studies, which have either shown no difference 
in brain volume between CADASIL and control (De Guio et al., 2015), or a reduction 
in brain volume in the CADASIL group (Rossi Espagnet et al., 2012). It could be that 
the age-adjustment did not account for all of the age variation between the groups. 
Previous studies have shown there is on average a 5% loss of brain tissue per decade 
(Peters, 2006), so age is an important factor when studying brain volume. 
Interestingly, we did not see any significant difference between the brain volumes of 
sporadic SVD and controls (Table 3.2). This is also inconsistent with previous studies, 
which have shown there to be a lower brain volume in sporadic SVD compared to 
age-matched controls (Nitkunan et al., 2011, O'Brien et al., 2001). It is likely that our 
group numbers were too low to detect a difference.  
 
GM volume was no different between the groups (Table 3.2). This was again in 
contrast to the literature, where studies have shown significantly reduced GM volume 
in SVD compared to control (Li et al., 2017a, Liu et al., 2014a). However, it probably 
has the same explanation as for brain volume, where our participant numbers may 
have been too low to detect a significant difference. CSF was significantly higher in 
the sporadic SVD group compared to control. CSF volume has previously been shown 
to increase with age (Malko et al., 1991) and has recently been suggested that it could 
be used as a simple, but sensitive, imaging marker of brain atrophy due to the close 
association between CSF volume and atrophy (De Vis et al., 2016). Our study would 
provide evidence in favour of this, as we found a significant difference in CSF 
volume between sporadic SVD and control, but not in brain volume or GM volume, 
suggesting it may be a more sensitive measure for brain atrophy.  
 
We found the WM in the sporadic SVD and CADASIL groups to be significantly 
higher than in the control group (Table 3.2). This is probably due to the fact that some 
of the WMLs, for patients with severe SVD, extend into the GM. Therefore, when the 
total WM is calculated from the NAWM and WML; this increases the overall volume 
of the WM. This has been noted in previously in the literature with no definite 
outcome established for this problem (Wardlaw et al., 2013a, Li et al., 2018a). The 
hyperintense regions still represent damaged tissue and are a part of the WML that 
99 
 
originated in the WM and so it is difficult not to include them, even though they 
technically spread beyond the limits of the WM border.  
 
There was significantly higher volume of WML, lacune count and CMB count in the 
sporadic SVD and CADASIL participants compared to control (Table 3.2). These 
features are key neuroimaging features of SVD (Wardlaw et al., 2013c) and therefore 
it is to be expected that our patient groups would have significantly more of these 
markers compared to our healthy control group. The figures reported in Table 3.2 are 
similar to those reported by previous studies, suggesting our sporadic SVD and 
CADASIL groups express the typical features of SVD as seen in previous studies 




3.8.3 DTI  
FA and MD values were extracted using the histogram analysis technique; this 
technique is widely used in the literature and shown to correlate strongly with disease 
severity (Della Nave et al., 2007, Croall et al., 2017).  
 
When comparing sporadic SVD with control, we found a significant difference 
between the FA values for median and peak location, but not peak height, in the 
NAWM. On the contrary, we found a significant difference in the FA peak height, but 
not the median or peak location, in the WML. For MD, there was a significant 
difference in all the parameters in the NAWM, but only peak height in the WML. The 
FA values for NAWM are consistent with previous work, where median and peak 
location, were significantly different in SVD from control (Lawrence et al., 2013). 
MD values are less consistent with previous work, as Lawrence et al. showed all MD 
values to be significantly different from control, whereas we have not seen this. 
However, we did see a trend for all of the MD parameters to be different from control, 
and due to our study having much lower numbers of participants, it is likely that our 




In the CADASIL group, there was a significant difference between all of the FA 
NAWM parameters compared to control. For the FA values in the WML, the finding 
mirrored the sporadic SVD group, where only peak height was significantly different. 
With regards to MD, all of the parameters for NAWM and WML were significant in 
CADASIL compared to control. This closely reflects the previous literature, where all 
of the histogram parameters were found to be significantly different from control 
(Molko et al., 2002). 
 
We then investigated the FW corrected DTI values and extracted them using the same 
histogram technique; values are shown in Table 3.4. In the sporadic SVD group, the 
FW median value in the NAWM was significantly higher compared to control. All of 
the FW parameters from the WML were significantly different from control. In the 
CADASIL group, all of the FW parameters in the NAWM and WML were 
significantly different from control. This is similar to the result of Duering et al., 
where FW was significantly higher in sporadic SVD and CADASIL compared to 
control (Duering et al., 2018).    
 
The FW adjusted FA values followed a similar pattern to the non-adjusted values in 
the sporadic SVD group: FA median in the NAWM was still significantly different 
from control, with all of the FA values in the WML found to be significantly different 
from control. In the CADASIL group, the FW adjustment meant that all of the FA 
parameters in the WML were now significantly different from control.  
 
The FW adjusted MD values were also similar to the non-adjusted values. The same 
pattern existed for sporadic SVD and CADASIL groups, where only the median value 
in the NAWM was now significantly different from control, but all of the WML 
parameters were significantly different from control.  
 
This is the first time the histogram analysis has been applied to FW corrected DTI 
values, and therefore the specific values cannot be compared with the literature. 
However, it would seem that even with FW correction, there is still a significant 
difference in many of the DTI parameters of FA and MD in sporadic SVD and 
CADASIL compared to control, suggesting that if you remove the FW component 
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and leave only the component representing ultrastructural WM, you still see a 
difference from control. Therefore, is likely ultrastructural WM damage occurring in 
sporadic SVD and CADASIL. Further work is required to fully investigate the 
application of FW DTI to sporadic SVD, which is beyond the scope of this thesis.  
 
 
3.8.4 Cognition  
The cognitive profile of sporadic SVD has been extensively researched and 
consistently seen as a deficit in EF and PS, with little change in memory (Lawrence et 
al., 2013, McPherson and Cummings, 1996, Zhou and Jia, 2009). The cognitive 
profile is similar in CADASIL. However, they have also been seen to have additional 
memory problems (Charlton et al., 2006b). We did not see a significant deficit in EF 
in any of our groups (Table 3.5). However, we did see a significant deficit in PS in 
both the sporadic SVD group and the CADASIL group, and a deficit in LTM in the 
CADASIL group. 
 
Brain volume, and in particular GM volume, has previously been associated with EF 
in sporadic SVD patients (Nitkunan et al., 2011, Lawrence et al., 2013). In our study, 
GM volume was only significantly associated with EF in the CADASIL group, and 
not in the sporadic SVD or control groups (Table 3.8). There were no association 
between brain volume and EF for any of the groups. Studies have also found brain 
volume and GM volume to be associated with PS (Lawrence et al., 2013, Croall et al., 
2017). We found no association of brain volume or GM volume with PS across any of 
the groups (Table 3.8).  However, we did find an association between GM volume 
and GC for both the sporadic SVD and CADASIL groups (Table 3.6). This highlights 
the important role of GM atrophy in in the cognitive deficits seen in SVD, which is in 
agreement with previous work (Lambert et al., 2015, Smith et al., 2015).   
 
Interestingly, WML was not significantly correlated with cognition in our results 
(Tables 3.6-3.10). This is not an unexpected finding, as there is discrepancy in the 
literature with some studies that have found an association with cognition (Yamawaki 
et al., 2015, Croall et al., 2017) and some studies have not (Lawrence et al., 2013). 
Our results, and other non-significant results in the literature, do have a general trend 
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for higher WML volume and lower cognition scores, so it is likely that there is a small 
association that cannot be detected without large sample sizes.   
 
Lacune count and volume were not associated with any of the cognitive indices in our 
data (Table 3.6-10). In the literature, lacune count is continually a highly significant 
predictor for a range of cognitive tests in SVD patients (Arboix, 2011, Smith et al., 
2015, Croall et al., 2017, Blanco-Rojas et al., 2013, Vermeer et al., 2003). It is likely 
that again the small sample sizes make it difficult to detect this significance in our 
data.  
 
CMB count was not associated with any cognitive indices (Tables 3.6-10). There are 
some discrepancies in the literature as to whether CMB are associated with cognition; 
some studies have found there is no association (Lawrence et al., 2013, Smith et al., 
2015), whereas others have found an association with cognitive decline (Patel et al., 
2013, Akoudad et al., 2016, Zhang et al., 2018). Therefore, it is not unexpected that 
we did not find this association. 
 
DTI parameters have repeatedly been shown to correlate with cognition, more 
specifically EF and PS (Lawrence et al., 2013, Croall et al., 2017, D'Souza et al., 
2018). FA median in the NAWM was associated with GC (Table 3.6), EF (Table 3.7) 
and PS (Table 3.8) in the CADASIL group. FA median in the NAWM was associated 
with GC in the sporadic SVD group (Table 3.10).  
 
The FW technique has been recently applied to a sporadic SVD population and found 
that FW itself was highly correlated with PS (Duering et al., 2018).  We found a 
similar result in our data, where the FW value itself was associated with GC (Table 
3.6) and PS (Table 3.8) in the NAWM of the sporadic SVD group. FW corrected FA 
median values showed a similar pattern to uncorrected FA values, showing a 
significant association with GC (Table 3.6), EF (Table 3.7) and PS (Table 3.8) the 
CADASIL group. FW corrected values seemed to have a higher significance value in 
comparison to the uncorrected values, suggesting they may be a ‘cleaner’ way of 
extracting the measurement. However, they did not show any additional associations 
with cognition that had not already been seen with the uncorrected FA and MD 
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values. As the application for this technique to an SVD population is limited, more 







3.9 Summary of Findings 
 
This chapter has addressed the following areas:  
• Age was similar between the sporadic SVD and control groups, but was 
significantly lower in CADASIL compared to control 
• Sporadic SVD and CADASIL patients showed a significantly higher load of 
the conventional MRI markers of WMLs, lacunes and CMBs compared to 
control 
• Sporadic SVD and CADASIL participants showed significant differences in 
FA and MD compared to control, as both uncorrected and FW corrected 
values 
• Sporadic SVD and CADASIL participants showed significantly higher FW 
compared to control 
• Sporadic SVD and CADASIL participants showed deficits in PS, whilst 
CADASIL participants also showed a deficit in LTM 
• GM volume was associated with GC in the sporadic SVD group and EF and 
GC in the CADASIL group 
• Both uncorrected and FW corrected FA median values in the NAWM showed 
a correlation with GC in the sporadic SVD group and with EF, PS and GC in 
the CADASIL group  
 
This chapter has provided an overview of the demographics and explored the 
prevalence of the conventional MRI markers, DTI markers and cognitive scores in our 
sporadic SVD and CADASIL populations. We have also explored the relationship 
between the various MRI and DTI markers with cognition. Our end-points can now 
be used for the next stage of this project, to determine their association with BBB 






Chapter 4: BBB permeability – Group differences 




4.1.1 Aims of the Chapter 
The previous chapter described the conventional MRI and DTI markers collected 
from our control, sporadic SVD and CADASIL groups and investigated them with 
cognition. This chapter explores BBB permeability in our participants and looks at the 
following specific questions:  
• Is there a difference in BBB permeability between sporadic SVD and control 
groups? Does this difference occur globally or focally?  
• Is there a difference in BBB permeability between CADASIL and control 
groups? Does this difference occur globally or focally?  
• Is there a difference in BBB permeability in the NAWM and WML? Is this 
pattern the same across all groups? 
• Is there a spatial pattern of increased BBB permeability in close proximity to 
WMLs?  
• Is BBB permeability associated with conventional MRI markers, DTI markers 
and cognition? 
 
The main hypothesis of this chapter is:  
• BBB permeability will be significantly higher in the sporadic SVD and 
CADASIL patients compared to our healthy controls.  
 
Exploratory outcomes beyond the main hypotheses are:  
• Investigate if BBB permeability is different in the NAWM compared to WML 
• Investigate if BBB permeability is increased in close proximity to WMLs  
• Investigate if there is a relationship between BBB permeability and 





4.1.2 BBB permeability in SVD 
As discussed in Chapter One, BBB permeability is thought to be involved in SVD. 
Many studies have shown an increase in BBB permeability in SVD patients compared 
to controls (Wardlaw et al., 2003, Wardlaw et al., 2009, Topakian et al., 2010, Huisa 
et al., 2015, Zhang et al., 2017, Wardlaw et al., 2017). Additionally, cross-sectional 
studies have looked at the association between BBB permeability and WML volume. 
The majority of studies have found an association with WML volume (Topakian et 
al., 2010, Zhang et al., 2019, Li et al., 2017c, Wardlaw et al., 2017), but this 
relationship has not been found in all studies (Huisa et al., 2015). A limited number of 
studies have also looked at the relationship between cognitive function and BBB 
permeability cross-sectionally and have found an association with cognitive deficits 
(Hanyu et al., 2002, Zhang et al., 2019).  
 
Based on all of this evidence, it is widely accepted that BBB permeability is in some 
way involved in SVD. However, the challenge is determining if BBB permeability is 
an initial causal part of SVD pathogenesis or if it is simply a consequence of the 
disease. It is also possible that increased permeability is a mixture of the two, where it 
is triggered as a consequential process but does then exacerbate the disease further. If 
increased BBB permeability can be shown to be pathological in SVD, it would be a 
possible target for therapeutics.  
 
A small number of follow-up studies have looked at whether baseline BBB 
permeability can predict future damage. Follow-up studies are the only way to 
determine for definite if increased permeability is a causal mechanism in SVD. Huisa 
et al. found that only 11% of voxels that showed high permeability at baseline 
progressed to WML at follow-up (Huisa et al., 2015). However, looking from a 
cognitive point of view, Wardlaw et al. found that high BBB permeability at baseline 
led to worsened functional outcome 3 years on (Wardlaw et al., 2013b).  
 
More recent studies have tried to further our understanding of the pathogenesis by 
looking at BBB permeability in brain regions where WMLs tend to grow, namely the 
rim around the existing WML. This region has been described as the ‘penumbra’ of 
the WMLs, after DTI changes were shown to occur in this area (Maillard et al., 2011). 
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Penumbras have long been investigated in acute stroke. The concept of the penumbra 
in ischaemic stroke is that this region is tissue that has been affected by the ischaemia 
but is salvageable if the cause of the ischaemia can be removed in time (Paciaroni et 
al., 2009). It is unknown if a penumbra exists around WMLs, but if it could be 
identified then this could be an area to target with therapeutics to prevent WML 
growth. Studies investigating BBB permeability in this penumbra region have yielded 
conflicting results, with Wardlaw et al. finding that permeability increased in a linear 
fashion to be lowest in the NAWM, steadily increasing to peak permeability in the 
WML (Wardlaw et al., 2017); whilst Huisa et al. found that permeability in the WML 
penumbra was higher than in the WML, but equivalent to the permeability in the rest 
of the NAWM (Huisa et al., 2015).  
 
Previous studies are consistent that there is increased BBB permeability in SVD. 
However, longitudinal studies have so far provided conflicting results for a role of 
BBB permeability in the pathogenesis and the penumbra evidence is mixed and 
inconclusive. Further cross-sectional and follow-up studies that compare BBB 
permeability with a range of imaging and clinical outcomes are required to help 
unravel the role for BBB permeability in SVD.   
 
 
4.1.3 DCE-MRI for BBB permeability 
In recent years, there has been an increased use of DCE-MRI to assess BBB 
permeability. However, there has been variability in the approaches and the findings 
in the literature. The main challenge in SVD is that the permeability changes are 
subtle and therefore require sensitive techniques to be able to detect this change above 
the noise (Wardlaw et al., 2017). Further, BBB permeability has also been seen to 
increase with normal ageing (Erdő et al., 2017), and therefore this factors in 
additional difficulties for picking it up as pathological process. In contrast, the BBB 
permeability changes in acute stroke are much more pronounced and easier to detect 
(Yang and Rosenberg, 2011). However, it is widely agreed that DCE-MRI is the most 
evolved and promising technique for obtaining accurate BBB permeability values in 




In DCE-MRI, gadolinium is injected and the leakage of the gadolinium through the 
vessel wall is detected through a T1 shortening effect on the tissue protons (Taheri et 
al., 2011b).  
 
The evolution of the DCE-MRI technique can be seen in the literature. Early studies 
simply looked at the change in the T1 signal. One study took patients with a 
CSF/albumin ratio indicative of increased BBB permeability and investigated MR 
signal changes in the WML, but found no significant changes (Bronge and Wahlund, 
2000). However, another study using a similar technique found there was an increased 
permeability in the WML of patients compared to age matched controls (Hanyu et al., 
2002). The inconclusive nature of these studies is likely due to the limited sensitivity 
of the technique they were using, which is not appropriate for detecting subtle 
permeability changes.  
 
The technique then progressed to use a mixed model of signal enhancement to 
quantify the amount of gadolinium. Comparing lacunar vs. cortical stroke with this 
technique showed an increase in the lacunar stroke patients in the CSF (Wardlaw et 
al., 2008) and the WM (Wardlaw et al., 2009).  
 
The area under the signal enhancement curve was the next progression of this 
technique, where mean signal intensity change was taken for 30 minutes post-
injection and plotted against time. Permeability was seen to be increased in the 
NAWM with this technique in SVD patients compared to control (Topakian et al., 
2010). 
 
An improvement to the technique allowed researchers to use fast T1 mapping to 
measure more subtle BBB leakage, thought to be important in SVD (Hanyu et al., 
2002). The new technique used only a quarter of the standard gadolinium dose, which 
was found to have both adequate washout from the blood and change in the MRI 
signal intensity over 25 minutes (Taheri et al., 2011b). Taheri et al. also found that 
this dose causes faster 1/T1 changes than at higher concentrations, providing a more 
sensitive measure. Pharmacokinetic modelling could then be used to separate the 
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vascular and extravascular components and allow for quantitative estimates of the 
BBB leakage rate. 
 
The introduction of Patlak modelling was then apparent as the pharmacokinetic model 
of choice for many studies.  Recent studies have further justified its application for 
monitoring low-level leakage in diseases such as SVD (Heye et al., 2016). The 
progression of the technique to this point meant that permeability could now be 
mapped to individual voxels and be studied in individual patients rather than in 
groups. Permeability in the WM was shown to be higher in patients compared to 
controls (Taheri et al., 2011a, Huisa et al., 2015). Later studies replicated this data, 
finding increased leakage in the NAWM, WM and GM in SVD patients compared to 
controls (Zhang et al., 2017). 
 
 
4.1.4 Global vs. Focal BBB permeability 
SVD is a heterogeneous disease with large clinical variation between patients. SVD 
contains many points of focal damage, due to individual WMLs and lacunar infarcts, 
which damage specific areas of the brain (Ter Telgte et al., 2018). However, this focal 
damage can then lead to downstream global changes in brain networks and structure, 
plus triggering many inflammatory cascades that will have downstream effects in 
other brain regions. There has been evidence from wider ischaemic stroke research 
suggesting that focal damage can lead to permeability changes in remote regions, 
which does have clinical implications (Liu et al., 2018a). Therefore, its important that 
both global and focal permeability are taken into consideration, as they may have 
distinct roles in the pathogenesis.  
 
This combination of focal and global effects may underlie the heterogeneity seen in 
SVD and explain why quantification of focal WMLs and the lacunes does not 
perfectly correlate with symptoms (Gouw et al., 2011). The recent advances in DCE-
MRI techniques mean it is now possible to generate permeability values for every 
voxel in the brain, allowing various measurements to be taken. Therefore, 
permeability can be looked at from both a global and a focal perspective to 





There were 19 controls, 19 sporadic SVD and 19 CADASIL participants who 
received BBB permeability imaging and so were included in this chapter. 
Methodology was described in Chapter Two.  
 
 
4.2.1 Defining BBB permeability Values 
Global mean permeability was defined as the mean permeability of all voxels in the 
ROI. Hotspot mean permeability was defined as the mean permeability of all voxels 
above the ‘normal’ threshold in the ROI, calculated from our control subjects and 
defined as any voxel above 6.5 x 10-4 L/g min. Global and hotspot mean permeability 
were expressed as L/g min. The hotspot permeability volume was expressed as a 
percentage (%) of the voxels that showed permeability values above the threshold 
within the given ROI.  
 
Penumbra values were defined as a 3mm rim around the WMLs. Global means, 




4.2.2 Statistical Analysis 
Group differences between BBB permeability values for sporadic SVD and control 
and CADASIL and control were analysed using the ANCOVA test and were 
controlled for age and sex. Pairs of comparisons were adjusted using Bonferroni. If 
there was a significant difference seen, an ANCOVA controlling for the 
cardiovascular risk factors of hypertension, hyperlipidaemia, type 2 diabetes and 
smoking was performed to see if the significance was still present. None of the BBB 
permeability parameters were normally distributed so were all transformed to meet 
normality assumptions of parametric statistical tests. The global permeability 
measures of WM, NAWM and WML were all transformed with cube root. The mean 
hotspot permeability measures of WM, NAWM and WML were log transformed; 
WM and NAWM with base:10 constant:10-6 and WML with base:10 constant:10-3. 
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Hotspot permeability volume measure for WM, NAWM and WML were all 
transformed with cube root.  
 
Comparisons between the BBB permeability values of the NAWM and WML were 
performed using Wilcoxon signed rank tests for paired non-parametric data. These 
tests were performed on the raw untransformed values. P values were corrected for 
multiple comparisons using FDR.  
 
Group differences in the penumbra permeability values between sporadic SVD and 
control and CADASIL and control were analysed using ANCOVA tests and were 
controlled for age and sex. Pairs of comparisons were adjusted using Bonferroni. If 
there was a significant difference seen, a further ANCOVA controlling for the 
cardiovascular risk factors was performed to see if the significance was still present. 
All penumbra values were transformed with a cube root to meet normality 
assumptions.  
 
Comparisons between permeability values for the NAWM and WML and the 
penumbra permeability values were carried out using the Wilcoxon signed rank tests 
for paired non-parametric data. These tests were performed on the raw untransformed 
values. P values were corrected for multiple comparisons using FDR. 
 
Multivariate linear models were used to investigate the association between 
permeability parameters (independent) and imaging markers (dependent), controlled 
for age and sex. If the imaging parameter was a volumetric measure, then ICV was 
also used as a control. When significant associations were seen, a further linear model 
controlling for the cardiovascular risk factors was performed to see if the significance 
was still present. Permeability parameters were transformed in the same way detailed 
earlier to meet normality assumptions. Imaging markers were transformed if required, 
with the same transforms as described in Chapter Three. P values were adjusted for 
multiple comparisons with FDR.  
 
Multivariate linear models were also used to investigate if permeability parameters 
(independent) were significantly associated with cognitive indices (dependent). These 
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analyses were controlled for age, sex and premorbid IQ. Permeability parameters 
were transformed in the same way as detailed earlier to meet normality assumptions. 






4.3.1 Group Differences 
Permeability values in the WM, NAWM and WML were compared between the 
sporadic SVD and control groups and the CADASIL and control groups. Example 
images showing regions of significant permeability in a representative image from 
each of the groups is shown in Figure 4.1.  
 
Mean global permeability was compared between groups in Figure 4.2. In the WM, 
the global permeability was significantly higher in sporadic SVD group compared to 
control, when controlled for age and sex (p<0.001 (p=0.001 when adjusted for 
multiple comparisons)). The significance was still present when controlled for 
cardiovascular risk factors (p=0.001). In the NAWM, a similar pattern was seen, 
where global permeability was significantly higher in the sporadic SVD group 
compared to control when controlled for age and sex (p<0.001 (p<0.001 when 
adjusted for multiple comparisons)) and cardiovascular risk factors (p<0.001). 
Finally, global permeability in the WML was compared between groups, with a 
significantly higher global permeability seen in the sporadic SVD group compared to 
control when controlled for age and sex (p<0.001 (p<0.001 when adjusted for 
multiple comparisons)) and cardiovascular risk factors (p<0.001). In the CADASIL 
group, the pattern was quite different, with no significant difference from the control 
group seen in the mean global permeability of the whole WM, NAWM or WML.  
 
The mean permeability of the hotspots was compared between groups in Figure 4.3. 
In the WM and NAWM, the mean permeability of the hotspots was not significantly 
different between sporadic SVD and control group. In the WML, the mean 
permeability of the hotspots was significantly higher in the sporadic SVD group 
compared to control when controlled for age and sex (p=0.004 (p=0.009 when 
adjusted for multiple comparisons)) and cardiovascular risk factors (p=0.004). The 
CADASIL group had no significant difference from control for the mean value of the 




Finally, the volume of the permeability hotspots was compared between groups, as 
shown in Figure 4.4. In the WM, the volume of the permeability hotspots was 
significantly higher in sporadic SVD compared to control when controlled for age and 
sex (p=0.004 (p=0.010 when adjusted for multiple comparisons)) and cardiovascular 
risk factors (p=0.007). In the NAWM, the same pattern was seen where the volume of 
permeability hotspots was also significantly higher in the sporadic SVD group 
compared to control when controlled for age and sex (p=0.003 (p=0.007 when 
adjusted for multiple comparisons)) and cardiovascular risk factors (p=0.006). The 
WML also followed the same pattern, with an increased volume of permeability 
hotspot in the sporadic SVD group compared to control when controlled for age and 
sex (p=0.002 (p=0.004 when adjusted for multiple comparisons)) and cardiovascular 
risk factors (p=0.002). The CADASIL group was not significantly different from 







Figure 4.1: Example images of BBB permeability hotspots (blue) overlayed onto T2 







Figure 4.2: Mean global permeability (L/g min) of the WM, NAWM and WML. 
Group comparisons were controlled for age and sex.  
A) Permeability in the WM was significantly higher in the sporadic SVD group 
compared to control (p=0.001). There was no significant difference between the 
CADASIL group and control (p=0.443).  
B) Permeability in the NAWM was significantly higher in the sporadic SVD group 
compared to control (p<0.001). There was no difference between CADASIL and 
control (p=0.344).  
C) Permeability in the WML was significantly higher in sporadic SVD compared to 
control (p<0.001). There was no significant difference between CADASIL and 






Figure 4.3: Mean hotspot permeability (L/g min) of the WM, NAWM and WML. 
Group comparisons were controlled for age and sex.   
A) There was no significant difference in the hotspot mean permeability in the WM of 
the sporadic SVD group compared to control (p=0.104) or the CADASIL group 
compared to control (p=0.794).  
B) There was no significant difference in the hotspot mean permeability in the 
NAWM of the sporadic SVD group compared to control (p=0.074) or CADASIL 
group compared to control (p=1.000).  
C) Hotspot mean permeability in the WML of the sporadic SVD group was 
significantly higher than control (p=0.009). There was no significant difference 






Figure 4.4: Hotspot permeability volume (%) of the WM, NAWM and WML. All 
analyses were controlled for age and sex.  
A) Hotspot permeability volume of the WM was significantly higher in the sporadic 
SVD group compared to control (p=0.010). There was no significant difference 
between CADASIL and control (p=1.000).   
B) Hotspot permeability volume of the NAWM was significantly higher in the 
sporadic SVD compared to control (p=0.007). There was no significant difference 
between CADASIL and control (p=0.869).   
C) Hotspot permeability volume of the WML was significantly higher in sporadic 
SVD compared to control (p=0.004). There was no significant difference between 





4.3.2 NAWM vs. WML 
The permeability values in the NAWM and WML were compared within the 
individual groups, to see if there was a significant difference between them (Table 
4.1).  
 
In the control group, the NAWM values were consistently significantly higher than 
the WML values for the global permeability mean value (p=0.008), hotspot 
permeability mean value (p=0.008) and hotspot permeability volume (p=0.024).  
 
In the sporadic SVD group, NAWM values were significantly higher than the WML 
values for the global permeability mean (p=0.024) and hotspot permeability mean 
(p=<0.001), but no different for the hotspot permeability volumes.  
 
In the CADASIL group, the NAWM values were significantly higher than the WML 
values for the global permeability mean (p=0.008), hotspot permeability mean 





Group Imaging parameter NAWM WML P 
value 
Median IQR Median IQR 
Control Global permeability 
mean (x103, L/g min) 0.046 0.071 0.009 0.062 0.008 
Control Hotspot permeability 
mean (x103, L/g min) 1.977 1.183 1.033 1.943 0.008 
Control Hotspot permeability 












volume (%) 10.660 14.480 9.314 10.518 0.709 
CADASIL Global permeability 
mean (x103, L/g min) 0.046 0.136 0.026 0.103 0.008 
CADASIL Hotspot permeability 
mean (x103, L/g min) 2.009 1.541 1.562 1.468 0.022 
CADASIL Hotspot permeability 
volume (%) 2.088 7.429 1.393 5.027 0.016 
 
Table 4.1: Pairwise comparisons of BBB permeability in the NAWM and WML. 





4.3.3 WML Penumbra  
BBB permeability values from the penumbra were calculated and compared between 
the sporadic SVD and control groups and the CADASIL and control groups.  
 
Values of global BBB permeability within the penumbra are shown and compared in 
Figure 4.5. The global permeability of the sporadic SVD group was significantly 
higher than control when controlled for age and sex (p=0.003 (p=0.006 when adjusted 
for multiple comparisons)) and controlled for cardiovascular risk factors (p=0.003). In 
the CADASIL group, the global BBB permeability values were not significantly 
different from control. 
 
Mean values of the BBB permeability hotspots from the penumbra were compared in 
Figure 4.6. The mean value of the permeability hotspots was significantly higher in 
the sporadic SVD group compared to control when controlled for age and sex 
(p=0.002 (p=0.004 when adjusted for multiple comparisons)) and cardiovascular risk 
factors (p=0.003). In the CADASIL group, the mean values of the BBB permeability 
hotspots were not significantly different from control. 
 
Finally, the volumes of the BBB permeability hotspots within the penumbras were 
compared, shown in Figure 4.7. In the sporadic SVD group, the volume of 
permeability hotspots in the penumbra was significantly larger than control when 
adjusted for age and sex (p=0.009 (p=0.018 when adjusted for multiple comparisons)) 
and cardiovascular risk factors (p=0.011). In the CADASIL group, there was no 
significant difference from control for the volume of the BBB permeability hotspots 






Figure 4.5: Global mean BBB permeability (L/g min) in the penumbra was compared 
between groups when controlled for age and sex. The penumbra mean was 
significantly higher in SVD compared to control (p=0.006). CADASIL was no 
different from control (p=0.263).   
 
Figure 4.6: The mean value of the BBB permeability hotspots (L/g min) in the 
penumbra were compared between the groups, controlling for age and sex. The mean 
of the hotspots was significantly higher in the sporadic SVD group compared to 




Figure 4.7: The volume of the BBB permeability hotspots (%) in the penumbra were 
compared between the groups, controlling for age and sex. The volume of the 
hotspots was significantly higher in sporadic SVD compared to control (p=0.018). 
There was no difference between CADASIL and control (p=0.947).  
 
 
Penumbra values were then compared with corresponding NAWM and WML values, 
to see if they were significantly different in permeability to these regions, shown in 
Table 4.2. 
 
Within the control group, penumbra values were similar to all corresponding NAWM 
and WML values except for the hotspot permeability in the WML. The mean value of 
the permeability hotspots in the penumbra was significantly higher than in the WML 
(p=0.003).  
 
In the sporadic SVD group, the penumbra values were similar to the corresponding 
NAWM and WML for the global permeability mean and the volume of the 
permeability hotspots. However, when comparing to the mean value of the 
permeability hotspots, the penumbra values were significantly lower than the NAWM 




Within the CADASIL group, the penumbra values were similar to the NAWM values, 
but significantly higher than the WML values. The global permeability mean of the 
penumbra was significantly higher than in the WML (p=0.003). The hotspot mean of 
the penumbra was also significantly higher than the WML (p=0.010) and the hotspot 










Median IQR Median IQR 
Control NAWM mean (x103, L/g min) 0.046 0.071 0.045 0.054 0.984 
WML mean (x103, L/g min) 0.009 0.062 0.045 0.054 0.118 
NAWM hotspot mean (x103, L/g min) 1.977 1.183 1.664 1.548 0.204 
WML hotspot mean (x103, L/g min) 1.033 1.943 1.664 1.548 0.003 
NAWM hotspot volume (%) 2.074 2.314 1.885 1.810 0.984 
WML hotspot volume (%) 0.543 3.661 1.885 1.810 0.118 
Sporadic 
SVD 
NAWM mean (x103, L/g min) 0.295 0.620 0.286 0.534 0.488 
WML mean (x103, L/g min) 0.161 0.361 0.286 0.534 0.204 
NAWM hotspot mean (x103, L/g min) 3.397 3.036 2.783 3.007 0.025 
WML hotspot mean (x103, L/g min) 2.376 2.624 2.783 3.007 0.002 
NAWM hotspot volume (%) 10.660 14.480 10.699 12.054 0.984 
WML hotspot volume (%) 9.314 10.518 10.699 12.054 0.488 
CADASIL NAWM mean (x103, L/g min) 0.046 0.136 0.055 0.163 0.488 
WML mean (x103, L/g min) 0.026 0.103 0.055 0.163 0.003 
NAWM hotspot mean (x103, L/g min) 2.009 1.541 2.187 1.764 0.649 
WML hotspot mean (x103, L/g min) 1.562 1.468 2.187 1.764 0.010 
NAWM hotspot volume (%) 2.088 7.429 2.585 9.167 0.508 
WML hotspot volume (%) 1.393 5.027 2.585 9.167 0.004 
 
Table 4.2: Pairwise comparisons for the individual groups for the global mean 
permeability values, hotspot mean permeability values and hotspot permeability 






Associations between BBB permeability parameters and WML volume are shown in 
Table 4.3. There was a significant association between the mean value of the 
permeability hotspots in the WML of the control group and total WML volume when 
controlled for age, sex and ICV (β =0.718, p<0.001 (p=0.009 when adjusted for 
multiple comparisons). This significance was still present when additionally 
controlled for the cardiovascular risk factors (β =0.677, p=0.013). There were no 
other significant associations seen between the BBB permeability parameters and 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM 0.334 0.545 0.241 0.570 -0.438 0.104 
WML 0.581 0.063 -0.077 0.768 -0.089 0.753 
Hotspot 
mean 
NAWM 0.271 0.570 0.184 0.640 -0.250 0.570 
WML 0.718 0.009 0.159 0.640 0.101 0.753 
Hotspot 
volume 
NAWM 0.341 0.545 0.154 0.640 -0.195 0.614 
WML 0.594 0.063 -0.176 0.640 -0.049 0.813 
 
Table 4.3: Associations between BBB permeability and WML volume when adjusted 
for age, sex and ICV. Table shows standardised β coefficients and p values. 
Significant p values are shown in bold. 
 
 
4.3.5 Lacunar Infarcts  
Lacunar infarcts were measured as lacune volume and as lacune count. Lacune 
volume was compared with the measures of BBB permeability in the different groups 
(Table 4.4) and none of the parameters were significantly associated with lacune 
volume. Similarly, lacune count was compared with the various measures of BBB 
permeability in the different groups (Table 4.5) and also showed that lacune count 








Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM 0.006 0.978 0.213 0.978 -0.336 0.575 
WML 0.009 0.978 0.138 0.978 -0.448 0.281 
Hotspot 
mean 
NAWM 0.010 0.978 0.094 0.978 0.096 0.978 
WML 0.044 0.978 0.280 0.978 -0.121 0.978 
Hotspot 
volume 
NAWM 0.007 0.978 0.181 0.978 -0.389 0.407 
WML 0.000 0.998 0.060 0.978 -0.490 0.276 
 
Table 4.4: Associations between BBB permeability and lacune volume when adjusted 
for age, sex and ICV. Table shows standardised β coefficients and p values. 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.007 0.962 0.307 0.694 -0.396 0.290 
WML -0.002 0.976 0.199 0.797 -0.534 0.062 
Hotspot 
mean 
NAWM 0.027 0.897 -0.031 0.962 0.131 0.845 
WML 0.051 0.784 0.282 0.709 -0.202 0.784 
Hotspot 
volume 
NAWM -0.010 0.962 0.352 0.668 -0.465 0.140 
WML -0.012 0.962 0.173 0.845 -0.564 0.060 
 
Table 4.5: Associations between BBB permeability and lacune count when adjusted 
for age and sex. Table shows standardised β coefficients and p values. Significant p 




The associations between CMB count with BBB permeability parameters for the 









Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.045 0.587 0.281 0.420 -0.211 0.420 
WML -0.061 0.420 0.402 0.420 -0.256 0.420 
Hotspot 
mean 
NAWM 0.018 0.808 -0.127 0.737 0.020 0.902 
WML -0.077 0.420 0.318 0.420 -0.298 0.420 
Hotspot 
volume 
NAWM -0.027 0.737 0.326 0.420 -0.244 0.420 
WML -0.072 0.420 0.399 0.420 -0.244 0.420 
 
Table 4.6: Associations between BBB permeability and CMB count when adjusted 
for age and sex. Table shows standardised β coefficients and p values. Significant p 
values are shown in bold. 
 
 
4.3.7 Brain Volume 
The associations between the BBB permeability parameters and brain volume are 
shown in Table 4.7; there were no significant associations seen. The associations 
between BBB permeability parameters and GM volume are then shown in Table 4.8; 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.021 0.980 -0.019 0.980 0.270 0.980 
WML 0.046 0.980 0.010 0.980 0.369 0.903 
Hotspot 
mean 
NAWM -0.012 0.980 0.063 0.980 -0.073 0.980 
WML 0.040 0.980 0.004 0.980 0.121 0.980 
Hotspot 
volume 
NAWM -0.052 0.980 -0.059 0.980 0.239 0.980 
WML -0.059 0.980 -0.008 0.980 0.309 0.954 
 
Table 4.7: Associations between BBB permeability and brain volume when adjusted 
for age, sex and ICV. Table shows standardised β coefficients and p values. 








Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.123 0.799 -0.222 0.710 0.580 0.078 
WML 0.028 0.891 -0.071 0.799 0.517 0.109 
Hotspot 
mean 
NAWM -0.068 0.799 0.140 0.799 0.176 0.799 
WML -0.065 0.799 -0.226 0.710 0.204 0.799 
Hotspot 
volume 
NAWM -0.095 0.799 -0.286 0.640 0.452 0.152 
WML -0.099 0.799 -0.077 0.799 0.448 0.152 
 
Table 4.8: Associations between BBB permeability and GM volume when adjusted 
for age, sex and ICV. Table shows standardised β coefficients and p values. 




The association between FA median and the BBB permeability parameters are shown 
for the NAWM in Table 4.9 and for the WML in Table 4.10. A higher FA median in 
the NAWM was associated with global permeability of the NAWM in the CADASIL 
group when adjusted for age and sex (β=0.543, p=0.002 (p=0.031 when adjusted for 
multiple comparisons)). When adjusted for all of the cardiovascular risk factors, the 
association was still significant (β=0515, p=0.019). No other parameters were 

















Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.067 0.865 -0.506 0.233 0.543 0.031 
WML -0.104 0.821 -0.218 0.671 0.326 0.304 
Hotspot 
mean 
NAWM -0.299 0.349 -0.037 0.898 0.316 0.304 
WML -0.288 0.349 -0.360 0.349 0.154 0.671 
Hotspot 
volume 
NAWM -0.049 0.875 -0.528 0.233 0.392 0.233 
WML -0.077 0.865 -0.181 0.730 0.297 0.304 
 
Table 4.9: Associations between BBB permeability and FA NAWM median when 
adjusted for age and sex. Table shows standardised β coefficients and p values. 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.058 0.828 -0.101 0.828 -0.311 0.828 
WML -0.209 0.828 -0.107 0.828 -0.080 0.828 
Hotspot 
mean 
NAWM -0.424 0.828 0.263 0.828 0.091 0.828 
WML -0.227 0.828 -0.236 0.828 -0.241 0.828 
Hotspot 
volume 
NAWM -0.137 0.828 -0.160 0.828 -0.282 0.828 
WML -0.128 0.828 -0.080 0.828 -0.056 0.828 
 
Table 4.10: Associations between BBB permeability and FA WML median when 
adjusted for age and sex. Table shows standardised β coefficients and p values. 




Associations between MD peak height and BBB permeability parameters are shown 
for NAWM in Table 4.11 and WML in Table 4.12. There were no associations 
between any of the BBB permeability parameters and the MD peak height in the 
NAWM for any of the groups. However, there was a significant negative association 
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between the global mean value of BBB permeability in the WML and MD peak 
height in the WML in the control group when adjusted for age and sex (β=-0.675, 
p=0.003 (p=0.027 when adjusted for multiple comparisons)). The significance was 
still present after adjusting for cardiovascular risk factors (β=-0.583, p=0.021). 
Similarly, there was significant negative association between the mean value of the 
BBB permeability hotspots in the WML and MD peak height in the WML in the 
control group when adjusted for age and sex (β=-0.830, p<0.001 (p=0.001 when 
adjusting for multiple comparisons)). The significance was still present after adjusting 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.196 0.855 0.225 0.855 0.194 0.855 
WML -0.118 0.942 0.236 0.855 0.069 0.942 
Hotspot 
mean 
NAWM -0.109 0.942 0.386 0.855 0.277 0.855 
WML -0.042 0.984 0.000 0.999 -0.013 0.999 
Hotspot 
volume 
NAWM -0.175 0.855 0.116 0.942 0.071 0.942 
WML -0.070 0.942 0.201 0.914 0.027 0.999 
 
Table 4.11: Associations between BBB permeability and MD NAWM peak height 
when adjusted for age and sex. Table shows standardised β coefficients and p values. 

















Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.420 0.324 0.220 0.626 0.020 0.940 
WML -0.675 0.027 0.315 0.443 -0.056 0.877 
Hotspot 
mean 
NAWM -0.405 0.324 0.305 0.456 0.114 0.790 
WML -0.830 0.001 0.207 0.626 -0.149 0.790 
Hotspot 
volume 
NAWM -0.418 0.324 0.107 0.790 -0.157 0.790 
WML -0.639 0.060 0.270 0.539 -0.098 0.790 
 
Table 4.12: Associations between BBB permeability and MD WML peak height 
when adjusted for age and sex. Table shows standardised β coefficients and p values. 




Associations between FW median and BBB permeability parameters are shown for 
NAWM in Table 4.13 and WML in Table 4.14. There was no association between 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM 0.097 0.782 0.333 0.782 -0.238 0.782 
WML 0.189 0.782 0.165 0.782 -0.088 0.782 
Hotspot 
mean 
NAWM 0.122 0.782 0.012 0.963 -0.261 0.782 
WML 0.238 0.782 0.278 0.782 -0.077 0.782 
Hotspot 
volume 
NAWM 0.048 0.867 0.380 0.782 -0.144 0.782 
WML 0.148 0.782 0.149 0.782 -0.072 0.782 
 
Table 4.13: Associations between BBB permeability and FW NAWM median when 
adjusted for age and sex. Table shows standardised β coefficients and p values. 








Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM 0.078 0.899 -0.159 0.860 -0.197 0.769 
WML 0.293 0.703 -0.283 0.703 0.020 0.931 
Hotspot 
mean 
NAWM 0.346 0.633 -0.413 0.633 -0.420 0.578 
WML 0.368 0.633 -0.149 0.860 0.164 0.790 
Hotspot 
volume 
NAWM 0.117 0.899 -0.024 0.931 0.068 0.899 
WML 0.440 0.633 -0.237 0.769 0.052 0.899 
 
Table 4.14: Associations between BBB permeability and FW WML median when 
adjusted for age and sex. Table shows standardised β coefficients and p values. 
Significant p values are shown in bold. 
 
 
4.3.11 FW adjusted FA 
Associations between FW adjusted FA median and BBB permeability parameters are 
shown for NAWM in Table 4.15 and WML in Table 4.16. There was a significant 
negative association between the volume of the BBB permeability hotspots in the 
NAWM and the FW adjusted FA median in the NAWM in the sporadic SVD group 
(β=-0.672, p=0.005 (p=0.045 when adjusted for multiple comparisons)). This 
association was still present after adjusting for cardiovascular risk factors (β=-0.671, 
p=0.012). In the CADASIL group, there was a significant positive association 
between the global mean value of BBB permeability of the NAWM and the FW 
adjusted FA median in the NAWM  (β=0.614, p<0.001 (p=0.009 when adjusted for 
multiple comparisons)). This association was still present after adjusting for 
cardiovascular risk factors (β=0.593, p=0.008). There were no significant associations 
between any of the other permeability parameters with the FW adjusted FA values in 












Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.005 0.981 -0.522 0.126 0.614 0.009 
WML -0.098 0.775 -0.474 0.135 0.376 0.135 
Hotspot 
mean 
NAWM -0.198 0.525 0.168 0.706 0.377 0.135 
WML -0.286 0.291 -0.469 0.135 0.172 0.583 
Hotspot 
volume 
NAWM 0.039 0.919 -0.672 0.045 0.447 0.125 
WML -0.035 0.919 -0.563 0.126 0.347 0.146 
 
Table 4.15: Associations between BBB permeability and FW adjusted FA NAWM 
median when adjusted for age and sex. Table shows standardised β coefficients and p 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.206 0.695 -0.228 0.695 -0.490 0.467 
WML -0.190 0.695 -0.273 0.695 -0.064 0.855 
Hotspot 
mean 
NAWM -0.576 0.217 0.198 0.695 -0.098 0.806 
WML -0.145 0.737 -0.344 0.695 -0.180 0.695 
Hotspot 
volume 
NAWM -0.352 0.695 -0.257 0.695 -0.285 0.695 
WML -0.112 0.806 -0.227 0.695 0.004 0.989 
 
Table 4.16: Associations between BBB permeability and FW adjusted WML median 
when adjusted for age and sex. Table shows standardised β coefficients and p values. 
Significant p values are shown in bold. 
 
 
4.3.12 FW adjusted MD 
Associations between FW adjusted MD peak height and BBB permeability 
parameters are shown for NAWM in Table 4.17 and WML in Table 4.18. There was 
no association between any of the BBB permeability parameters and the FW adjusted 
MD peak height values in the NAWM. There was a significant negative association 
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between the mean value of the BBB permeability hotspots in the WML and the FW 
adjusted MD peak height in the WML in the control group (β=-0.725, p=0.001 
(p=0.017 when adjusted for multiple comparisons)). This association was still present 
after adjusting for cardiovascular risk factors (β=-0.665, p=0.019). There were no 
significant associations between any of the other permeability parameters with the 






Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM 0.192 0.427 0.273 0.427 -0.334 0.360 
WML 0.307 0.353 0.507 0.353 -0.299 0.360 
Hotspot 
mean 
NAWM 0.100 0.660 0.077 0.821 0.000 0.999 
WML 0.329 0.353 0.310 0.425 -0.160 0.584 
Hotspot 
volume 
NAWM 0.116 0.631 0.275 0.427 -0.277 0.397 
WML 0.281 0.360 0.497 0.353 -0.242 0.425 
 
Table 4.17: Associations between BBB permeability and FW adjusted MD NAWM 
peak height when adjusted for age and sex. Table shows standardised β coefficients 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.311 0.680 -0.120 0.859 0.358 0.680 
WML -0.582 0.103 -0.111 0.859 -0.046 0.861 
Hotspot 
mean 
NAWM -0.253 0.680 -0.304 0.680 0.061 0.861 
WML -0.725 0.017 -0.083 0.859 -0.252 0.680 
Hotspot 
volume 
NAWM -0.289 0.680 -0.114 0.859 0.078 0.859 
WML -0.566 0.145 -0.139 0.859 -0.097 0.859 
 
Table 4.18: Associations between BBB permeability and FW adjusted MD WML 
peak height when adjusted for age and sex. Table shows standardised β coefficients 




The association between BBB permeability parameters and GC can be seen in Table 
4.19. The associations between BBB permeability parameters and the various 
cognitive domains of EF, PS, WoM and LTM can be found in Tables 4.20, 4.21, 4.22 
and 4.23 respectively. There was no association between any of the BBB permeability 






Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.169 0.551 -0.149 0.561 0.586 0.118 
WML -0.275 0.328 0.037 0.945 0.459 0.278 
Hotspot 
mean 
NAWM -0.227 0.441 0.006 0.977 0.325 0.440 
WML -0.149 0.561 -0.064 0.891 0.417 0.288 
Hotspot 
volume 
NAWM -0.211 0.441 -0.237 0.441 0.473 0.278 
WML -0.160 0.551 -0.012 0.977 0.410 0.288 
 
Table 4.19: Associations between BBB permeability and GC when adjusted for age, 
sex and premorbid IQ.  Table shows standardised β coefficients and p values. 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.244 0.463 -0.229 0.463 0.669 0.066 
WML -0.276 0.421 -0.124 0.684 0.561 0.101 
Hotspot 
mean 
NAWM -0.132 0.684 -0.036 0.863 0.046 0.863 
WML -0.187 0.587 -0.051 0.863 0.583 0.101 
Hotspot 
volume 
NAWM -0.230 0.463 -0.357 0.227 0.569 0.101 
WML -0.105 0.684 -0.205 0.463 0.452 0.227 
 
Table 4.20: Associations between BBB permeability and EF when adjusted for age, 
sex and premorbid IQ.  Table shows standardised β coefficients and p values. 








Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.244 0.463 -0.229 0.463 0.669 0.066 
WML -0.276 0.421 -0.124 0.683 0.561 0.134 
Hotspot 
mean 
NAWM -0.142 0.683 -0.036 0.853 0.092 0.774 
WML -0.204 0.511 -0.087 0.737 0.536 0.136 
Hotspot 
volume 
NAWM -0.230 0.463 -0.357 0.227 0.569 0.134 
WML -0.105 0.684 -0.205 0.463 0.452 0.227 
 
Table 4.21: Associations between BBB permeability and PS when adjusted for age, 
sex and premorbid IQ.  Table shows standardised β coefficients and p values. 







Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM 0.029 0.950 -0.127 0.937 0.306 0.937 
WML -0.153 0.937 -0.035 0.937 0.041 0.946 
Hotspot 
mean 
NAWM -0.198 0.937 -0.057 0.937 0.230 0.937 
WML -0.191 0.937 -0.097 0.937 0.152 0.937 
Hotspot 
volume 
NAWM -0.006 0.977 -0.136 0.937 0.081 0.937 
WML -0.072 0.937 -0.042 0.937 -0.068 0.937 
 
Table 4.22: Associations between BBB permeability and WoM when adjusted for 
age, sex and premorbid IQ.  Table shows standardised β coefficients and p values. 













Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global mean NAWM -0.069 0.936 -0.129 0.936 0.088 0.936 
WML -0.181 0.936 0.211 0.936 0.060 0.936 
Hotspot  
mean 
NAWM -0.141 0.936 -0.197 0.936 0.175 0.936 
WML -0.017 0.936 0.042 0.936 0.041 0.936 
Hotspot 
volume 
NAWM -0.104 0.936 -0.135 0.936 0.019 0.936 
WML -0.142 0.936 0.216 0.936 0.069 0.936 
 
Table 4.23: Associations between BBB permeability and LTM when adjusted for age, 
sex and premorbid IQ.  Table shows standardised β coefficients and p values. 








This chapter has shown that there seems to be both a global and focal increase in BBB 
permeability in the sporadic SVD group compared to control. There does not seem to 
be increased permeability in the CADASIL group compared to control. Permeability 
was higher in the NAWM compared to the WML, with no significant increase in 
permeability seen in the WML penumbra. The volume of the BBB permeability 
hotspots in the NAWM of the sporadic SVD group was associated with FW corrected 
FA values in the NAWM, suggesting a higher volume of highly permeable tissue is 
associated with decreased WM integrity of the tissue.    
 
 
4.4.1 Group Differences in Sporadic SVD vs. Control 
Global permeability of the whole WM, NAWM and WML were all significantly 
higher in sporadic SVD compared to control (Figure 4.2), suggesting that there is a 
global increase in BBB permeability throughout the WM in SVD.   
 
In the literature, many studies have compared global BBB permeability between 
sporadic SVD and controls, and have shown permeability to be significantly higher in 
the sporadic SVD group (Wardlaw et al., 2009, Topakian et al., 2010, Huisa et al., 
2015, Taheri et al., 2011a). Therefore, our data is consistent with the literature, 
suggesting a global increase in permeability in sporadic SVD compared to control. 
 
Hotspots were then created by filtering out all voxels that had a permeability value 
below a ‘normal threshold’ determined from our control group, to allow focal regions 
of high permeability to be identified. The mean value of permeability within these 
regions was calculated, as well as the volume of the regions. This analysis method 
filters out the ‘noise’ from normal fluctuations in permeability, and in theory should 
therefore only represent the pathological permeability. The mean value of the 
permeability hotspots in the WM and NAWM showed no significant difference 
between sporadic SVD and control, although there was a trend for the values to be 
higher (Figure 4.3). However, there was a significantly higher mean value in the 
permeability hotspots of sporadic SVD compared to control in the WML. The volume 
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of the permeability hotspots was consistently shown to be higher in the sporadic SVD 
group compared to the control group in the WM, NAWM and WML (Figure 4.4).  
 
Previous studies have used a similar hotspot analysis to us, by establishing a threshold 
by which voxels must pass to class as having significant BBB permeability. A 
significant increase in the hotspot mean of sporadic SVD compared to control has 
been seen in the WM (Huisa et al., 2015, Taheri et al., 2011a), although not in all 
studies (Zhang et al., 2017). Zhang et al. found a significantly increased volume of 
hotspot BBB permeability leakage in sporadic SVD compared to control in the 
NAWM and WML (Zhang et al., 2017). 
 
An explanation to the discrepancies shown in the literature is probably due to the 
methods used to establish the hotspot threshold. Huisa et al. used a previously 
established threshold that had given the maximum accuracy of correctly predicting 
control and patients (Huisa et al., 2015). Zhang et al. took positively skewed 
histograms of permeability and removed the ‘normal distribution’ part of the 
histogram to leave only the positively skewed values, suggested to be the high 
permeability values (Zhang et al., 2017). Taheri et al. used the same method as our 
study, taking the voxels with a value greater than the 95th centile of the permeability 
distribution from the NAWM of the control population (Taheri et al., 2011a). 
Interestingly, the control permeability value from the Taheri et al. paper is around half 
of the value from our study (3 x 10-4 L/g min compared to 6.5 x 10-4 L/g min). This 
may be due to the use of elderly controls in our study, who naturally have higher 
levels of BBB permeability.  
 
Our result and the results of previous studies would suggest that the choice of hotspot 
threshold can impact on the hotspot parameters. It would suggest that if a higher 
threshold is used then this is less likely to show a significant difference in the mean 
value of the hotspots, but potentially more likely to show a significant difference in 
the volume of the hotspots. Therefore, this must be carefully considered when 




Overall, our results our consistent with the literature, showing that there is increased 
BBB permeability in sporadic SVD, with a significant increase in global permeability 
and hotspot volume throughout the NAWM and WML, compared to control.  
 
 
4.4.2 Group Differences in CADASIL vs. Control 
In CADASIL, the involvement of BBB permeability in the mechanism is less clear. 
The CADASIL group showed no significant difference in BBB permeability from the 
control group for any of the parameters (Figures 4.2-4).  
 
There were two severe outliers in the CADASIL group for the mean value of the BBB 
permeability hotspots in the WM and NAWM, which can be seen in Figure 4.3. There 
was no obvious reason to exclude these outliers and therefore they were left in for the 
analysis. However, we did rerun the analysis without these outliers to see if they were 
skewing the results. This analysis can be found in Appendix A; the analysis shows no 
difference in the pattern of the results to when the outliers are left in. Removing the 
outliers still shows no significant difference in the mean value of the BBB 
permeability hotspots between the CADASIL and control groups in the WM (Figure 
A.1) or the NAWM (Figure A.2). 
 
The CADASIL literature on BBB permeability is limited. In an early study, Dichgans 
et al. found elevated protein content and an elevated CSF/serum albumin ratio in 
CADASIL patients, suggesting there is an increased permeability of the BBB 
(Dichgans et al., 1999). Other studies of CADASIL patients have shown changes in 
pericytes (Dziewulska and Lewandowska, 2012) and an increase in circulating 
biomarkers of endothelial cell dysfunction (Pescini et al., 2017, Rufa et al., 2008), 
also suggesting an increase in BBB permeability. However, when BBB permeability 
was measured in CADASIL mice models, an increased permeability was not seen 
(Cognat et al., 2014, Joutel et al., 2010). 
 
The literature is conflicting, but would suggest that there is a role for increased BBB 
permeability in CADASIL patients. One explanation for the lack of difference seen in 
our study could be that our CADASIL participants were significantly younger than 
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controls (Table 3.1). BBB permeability is known to increase with age (Mooradian and 
McCuskey, 1992, Farrall, 2009, Goodall et al., 2018), and therefore this could be 
influencing the results. The analyses were controlled for age, but the relationship may 
be more complicated than the analyses account for, with potentially a step effect 
rather than a linear effect. Age-matched controls should be used in future studies to 
see if there is still no group difference seen.  
 
Looking closely at the graphs, it seems that CADASIL has a wide range of 
permeability values, with some values closer to the levels seen in sporadic SVD, 
whilst others are more similar to control (Figures 4.2-4). Potentially, this could be due 
to the fact that our CADASIL participants had a wide range of disease severity, with 
some patients in an early stage where they may have no symptoms, whilst others are 
late stage having experienced major symptoms such as stroke.     
 
The unclear nature of the role of BBB permeability in CADASIL and the high spread 
of values seen, led us to investigate permeability within the CADASIL group 
specifically (Appendix B). We compared the permeability between patients who were 
over 55, had a stroke history and had migraine history. The results showed that there 
was a significant difference between the global mean permeability of the NAWM in 
patients who had a stroke compared to those who had not (Table B.4). Interestingly, 
BBB permeability was higher in patients who had not experienced a stroke, 
suggesting that maybe BBB permeability has a role in CADASIL pre-stroke. It is 
important to note that this data uses very low group numbers and therefore it is 
impossible to fully explore the role of BBB permeability in CADASIL without a 
larger sample size and broader range of clinical symptoms.  
 
Our data does not show an obvious role for BBB permeability in CADASIL. 
However, it suggests that BBB permeability could be worth investigating further in 
the CADASIL population. Future studies should compare CADASIL BBB 
permeability with age matched controls, to see if this is influencing the lack of 
association seen in our study. Additionally, they should investigate permeability in 
various stages of CADASIL disease, to see if the role of permeability is dependent on 
the disease time-course.  
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4.4.3 NAWM vs. WML 
We performed pairwise comparisons on the permeability values in the NAWM and 
WML, to see if there was a significant difference (Table 4.1). In the control and 
CADASIL participants, the permeability in the NAWM was consistently significantly 
higher than in the WML for the three measures of permeability (global mean, hotspot 
mean and hotspot volume). In the sporadic SVD group, permeability in the NAWM 
was significantly higher than in the WML for the global mean and hotspot mean, 
however the volume of hotspot permeability was not significantly different between 
the NAWM and WML.  
 
The difference in permeability in the NAWM and WML has been explored previously 
in the literature, with little consensus. Huisa et al. reported similar results to ours, 
where there is significantly more permeability in the NAWM compared to the WML 
(Huisa et al., 2015). However, other studies have shown the opposite, with 
significantly higher permeability in the WML compared to NAWM (Wardlaw et al., 
2017, Heye et al., 2016). Other studies have reported no significant difference 
between NAWM and WML permeability (Bronge and Wahlund, 2000). Some studies 
have reported values for NAWM and WML permeability in the text without 
performing statistical comparisons between the two; Zhang et al. reported NAWM 
permeability as higher (Zhang et al., 2017), whilst others report WML permeability as 
higher (Hanyu et al., 2002, Li et al., 2018b).  
 
The discrepancies in the literature are confusing and make it difficult to interpret the 
data. The likely source for the discrepancies is due to differing imaging techniques, 
analysis and normalisation methods. A recent paper by Thrippleton et al. has 
attempted to bring together a consensus with recommendations for usage of DCE-
MRI technique for BBB leakage in SVD to try to reduce some of this discrepancy in 
the data and allow studies to be more easily interpreted and compared with one 
another (Thrippleton et al., 2019).  
 
The pattern of permeability in the NAWM and WML is important to establish, as this 
would help to provide evidence for or against the pathogenic role of BBB 
permeability in SVD. If the consensus were that permeability is more evident in the 
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WML then this would suggest it is more of a secondary process to damage. However, 
if the consensus were that there is higher BBB permeability in the NAWM, as shown 
in our study, this would suggest that permeability could be involved in the formation 
of WML from previously NAWM and is therefore pathogenic.   
 
 
4.4.4 WML Penumbra 
There is a growing interest in the SVD field in the penumbra of the WML (Maillard et 
al., 2011). Studies have shown that approximately 80% of new WML voxels represent 
extensions of existing WML (Maillard et al., 2012). DTI studies have suggested that 
there is disrupted WM integrity beyond the area of the WMLs and within the NAWM 
(Lee et al., 2009), and that these changes are associated with increased WML growth 
at follow-up (de Groot et al., 2013). This body of research has led to the hypothesis 
that there may be changes in BBB permeability in the penumbra of the WMLs, which 
pre-empts WML growth.  
 
We took a 3mm penumbra of the WML and measured the BBB permeability in this 
region. We then compared between the groups to see if there were differences 
between our patients and controls (Figures 4.5-7). We found that the penumbra 
followed a similar pattern to the rest of the WM, where the permeability was 
significantly increased in the sporadic SVD group compared to control. The 
CADASIL group was not significantly different from control. We repeated the 
analysis removing the outliers in the CADASIL group and found the results to follow 
the same pattern (Figure A.3).  
 
We then went on to compare the penumbra permeability values to the NAWM and 
WML permeability values within the individual groups (Table 4.2). In the control 
group, the mean value of the hotspots in the penumbra were significantly higher than 
the mean value of the hotspots in the WML, but similar to the NAWM. Penumbra 
values were similar to the global mean and volume of the hotspots in the NAWM and 
WML. In the sporadic SVD group, the mean value of the hotspots in the penumbra 
was significantly higher than the mean value of the hotspots in the WML, but 
significantly lower than the NAWM. Again, penumbra values were similar to the 
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global mean and volume of the hotspots in the NAWM and WML. In the CADASIL 
group, penumbra values were significantly higher than WML values, but were similar 
to NAWM values for the global mean, hotspot mean and hotspot volume. The results 
are slightly confusing, but the overall pattern suggests that the penumbra permeability 
values are similar to the NAWM, but higher than the WML.   
 
We repeated this penumbra analysis with a 6mm penumbra, and found that this 
yielded the same pattern of results. The results of the 6mm penumbra can be found in 
Appendix C. The 6mm penumbra contained the same outliers in the CADASIL group 
as the 3mm penumbra, therefore the analysis was also repeated without these outliers 
(Figure A.4) and found to have the same pattern of results.  
 
Only two previous studies have investigated the penumbra of the WML, which is 
probably due to the fact that the techniques have only become sophisticated enough to 
do so quite recently. Huisa et al. created a 4mm rim around the WMLs (of which 
2mm was WML and 2mm was the adjoining NAWM and investigated the 
permeability in this area. They found that 51% of the total permeability voxels were 
located in the 4mm rim, 9% in the core of the WML and 49% in the NAWM (Huisa et 
al., 2015). These results were similar the results from our study, suggesting that the 
penumbra does have higher permeability compared to the WML, but not compared to 
the rest of the NAWM.  
 
Wardlaw et al. reported a very different pattern of permeability, where there was 
higher permeability in the WML compared to the NAWM (Wardlaw et al., 2017). 
They found an interesting observation that the permeability increased with proximity 
to the WML, suggesting that there may be some permeability changes in the 
penumbra of the WMLs.  
 
More studies with higher numbers are required which investigate the penumbra of the 
WML to validate the findings. Ideally, these further studies would use a consensus 
protocol so that results of future studies can be directly compared to try to minimise 




4.4.5 Association with WML Volume 
WML volume was found to be significantly associated with mean permeability of the 
hotspots in the WML of the control group (Table 4.3). There was also a trend, which 
did not reach significance once corrected for multiple comparisons, for WML volume 
to be associated with both the global permeability mean and volume of the 
permeability hotspots in the WMLs of the control group. This association was not 
seen in the sporadic SVD or CADASIL groups.  
 
The association of WML volume with WML permeability in the control group, but 
not the sporadic SVD or CADASIL groups, is an interesting finding. One explanation 
could be that BBB permeability is important for WML progression at early stages of 
the disease. Our healthy control group was comprised of an elderly population, where 
most of them had some degree of WML on their MRI scan, and therefore they could 
be seen as a very early-stage pre-symptomatic SVD population. Our SVD group, on 
the other hand, is quite a severe population, with inclusion criteria of confluent WML 
and lacunar stroke. Our CADASIL group is also a severe population, with the highest 
mean WML volume of all of the groups in this study (Table 3.2). Therefore, if BBB 
permeability is involved in WML growth, it could be that this is only detectable in 
early stages of the disease, whereas in later stages of the disease, when there are many 
pathological processes occurring, there is too much noise to see the association. This 
explanation could be supported by the current literature, where studies using a lacunar 
stroke population (with no inclusion criteria for WML volume) (Wardlaw et al., 2017, 
Topakian et al., 2010, Zhang et al., 2017) and non-SVD populations (Li et al., 2018b) 
showed a correlation between WML volume and BBB leakage, whereas a study using 
a more severe SVD population, defined by both WML volume and lacunar stroke, did 
not show this association (Huisa et al., 2015).  
 
Unfortunately, our study has relatively small group sizes, which makes it difficult to 
examine these associations within the groups. To fully understand the role of BBB 
permeability in WML growth, larger longitudinal studies that map the WML 
progression from early to late stage SVD are required to see if the participants with 




4.4.6 Associations with Lacunes, CMBs and Brain Volume 
The control and sporadic SVD groups were not significantly associated with any other 
imaging markers of lacune number or volume, CMB number, brain volume or GM 
volume (Tables 4.4-.8). Lacune and CMB number were shown to be significantly 
associated with BBB leakage in one recent study of SVD patients (Li et al., 2018b). 
However, this association could be mediated by the fact that patients with higher 
WML volume are likely to have a more severe phenotype, and therefore have higher 
numbers of lacunes and CMBs. An ordinal SVD score, which combines the presence 
of lacunes, WMLs, CMBs and perivascular spaces was also found to be significantly 
associated with BBB permeability (Li et al., 2018b). To the best of my knowledge, an 
association between BBB permeability and brain volume or GM volume has never 
previously been reported in the literature.  
 
The lack of association between permeability and these parameters would suggest that 
BBB permeability is not directly involved in the pathological mechanisms of lacune 
formation, CMB formation or GM atrophy. However, we cannot rule out a causal 
relationship, where BBB permeability may influence the subsequent development of 
lacune formation, CMB formation or atrophy. Longitudinal studies are required to 
fully understand this.   
 
 
4.4.7 Associations with FA in the sporadic SVD group  
In the SVD group, a higher volume of permeability hotspots in the NAWM was 
associated with a lower FA in the NAWM, after adjustment for FW (Table 4.15). 
Interestingly, this association was not significant before the FW adjustment (Table 
4.9).  
 
Reductions in FA manifest in the histogram as a lower median and peak location, and 
a increased peak height due to the increased frequency of lower FA values. In turn, 
this causes a greater rightward tail of the distribution (more positive skew) and more 
pronounced peak (greater kurtosis) (Zeestraten et al., 2016). Median has been used 
widely in the literature as the most useful FA histogram parameter, with a decrease in 
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FA median corresponding to damage to the WM ultrastructure and a more severe 
disease phenotype (Brookes et al., 2014, Croall et al., 2017).  
 
In the sporadic SVD group, our results suggest that a higher volume of high 
permeability voxels in the NAWM are associated with a reduction in NAWM FA, 
indicating a reduction in the directionality of diffusion tensor and therefore suggesting 
a disruption of the WM fibres. The fact that the association is only present after FW 
correction, would suggest that the association is specific to changes in the WM fibres 
themselves.  
 
An association between BBB permeability and FA in the NAWM in SVD has not 
previously been reported in the literature. However, an association between NAWM 
FA and WML growth has been shown, where NAWM regions with lower FA were 
shown to be more likely to progress to WML (de Groot et al., 2013). Therefore, this 
association could suggest that an increased volume of BBB permeability in the 
NAWM could be involved in disruption of the WM fibres in the NAWM, which may 
progress to WML in the future. This would need to be explored by following up the 
patients over time to see if brain regions with high BBB permeability and/or low FA 
at baseline progress to WMLs at follow-up.  
 
 
4.4.8 Associations with FA in the CADASIL group   
Higher global permeability in the NAWM was associated with a higher FA median in 
the NAWM in the CADASIL group (Table 4.9). After FW correction, the same 
pattern was seen with a stronger association (Table 4.15). The association seen 
between BBB permeability and FA in the CADASIL group is opposite to that seen in 
the sporadic SVD group. The association suggests that CADASIL patients with 
higher overall NAWM permeability had a higher FA and therefore more intact WM 
axonal fibres in the NAWM.  
 
As this is the first time this technique has been applied to CADASIL patients, there is 
no existing literature to compare our results to. Looking at the CADASIL subgroup 
analysis of Appendix B, global mean permeability of the NAWM was significantly 
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higher in CADASIL patients with no history of stroke (Table B.4). Further, non-
stroke CADASIL patients also had a higher FA NAWM median (Table B.3). 
Therefore, stroke history could be mediating the effect that we are seeing, where BBB 
permeability is higher in CADASIL before the first stroke occurs, which happens to 
coincide with a lower severity disease phenotype shown by the higher FA NAWM 
median. Interestingly, this association was not seen for older vs. younger patients, or 
for patients with a history of migraine compared to those without (Table B.2 and B.6).  
 
Further studies are needed with higher sample sizes to investigate the role of BBB 
permeability in CADASIL. If BBB permeability is important in the pre-stroke stages 
of the CADASIL disease process, then it could be a process to target with 
therapeutics, to slow down the disease progression before the severe symptoms occur.  
 
 
4.4.9 Associations with MD in the Control group 
A lower MD peak height in the WML was associated with a higher global and hotspot 
mean of BBB permeability of the WML in the control group (Table 4.12). Hotspot 
BBB mean was still associated after FW adjustment (Table 4.18).  
 
MD peak height has previously been shown to be the most sensitive MD histogram 
parameter for detecting SVD severity and progression (Zeestraten et al., 2016) and 
therefore has been the most widely used in studies (Lawrence et al., 2013, Croall et 
al., 2017). MD histogram distributions represent ultrastructural WM damage that 
manifests as increases in diffusivity; this means that pathological tissue results in a 
higher median and peak location but a lower peak height, as higher diffusivity values 
are identified with greater frequency (Zeestraten et al., 2016). Increases in diffusivity 
values causes the rightward tail of the distribution to become broader, increasing the 
positive skew. Therefore a negative association between MD peak height and BBB 
permeability suggests that there is higher WML BBB permeability in the control 
participants with increased ultrastructural damage in the WML. The same association 
was present when using the FW corrected MD peak height values (Table 4.18). This 
is important as the FW correction reduces the effect of oedema caused by BBB 
permeability and vacuolization within myelin sheaths. This allows MD to represent 
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microstructural tissue damage, such as axonal degeneration and loss of WM fibre 
organisation, more specifically.  This association was not seen for the sporadic SVD 
or CADASIL groups.  
 
Once again, if we take our control group as an early stage pre-clinical asymptomatic 
SVD group with mild WMLs, then this would provide further evidence that BBB 
permeability of the WML may have a role early on, contributing to the 
microstructural tissue damage. MD has been investigated in studies of BBB 
permeability but the parameters have not been directly compared to one another 
(Munoz Maniega et al., 2017). Therefore, we cannot compare our results to the 
literature. Further studies are needed to investigate the role of BBB permeability in 
early stage SVD, and whether it is a pathological process that is occurring in the 
WML to disrupt the WM fibres and lead to WML growth.   
 
 
4.4.10 Associations with Cognition  
None of the BBB permeability parameters were significantly associated with any of 
cognitive parameters across any of the groups (Tables 4.19-23).  
 
Cognition has only been investigated in relation to BBB permeability in a small 
number of studies. An early study by Hanyu et al. used the MMSE and found that 
there was a significant correlation between worsened MMSE score and increased 
BBB permeability (Hanyu et al., 2002). A later study by Zhang et al. used more 
intensive cognitive testing and found that a higher leakage rate in the NAWM was 
associated with lower EF and PS scores in healthy controls, but not in SVD patients 
(Zhang et al., 2019). Wardlaw et al. looked at functional outcome using the Oxford 
Handicap Score, 3 years after quantifying BBB permeability, and found that higher 
basal ganglia BBB permeability at baseline was associated with poorer functional 
outcome (Wardlaw et al., 2013b).  
 
More studies with higher participant numbers and more comprehensive testing are 
required to see if cognition is associated with BBB permeability in sporadic SVD and 
control patients. Further, testing cognitive change across time is likely a more 
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interesting end-point to explore, as if BBB permeability is pathological then it would 
be expected to associated with decreasing cognition over time, even if there is no 




DCE-MRI techniques are the most established and widely agreed method for imaging 
BBB permeability in human subjects. However, the technique is not without 
limitations.  
 
The largest limitation in terms of data interpretation lies in the variety of ways that the 
data can be analysed. Differing methods here have led to discrepancies in results and 
have limited the progression of the field. A recent paper has suggested 
recommendations about how to use and analyse DCE-MRI for BBB permeability in 
SVD to try to reduce these discrepancies (Thrippleton et al., 2019).  
 
The nature of DCE-MRI means the method is reliant on an intravenous injection of 
gadolinium. This limits the subjects that can take part in the study, as some cannot 
have gadolinium due to kidney failure. It also means that every participant must 
endure the invasive implanting of the venous line for the injection, which can be a 
deterrent and lead to problems with recruitment. Further, the scan time for DCE-MRI 
is long and many participants struggle to tolerate this, further limiting those who are 
willing to take part.   
 
An emerging option for imaging BBB permeability, which could reduce some of 
these limitations, is arterial spin labelling based methods. Multicompartmental 
modelling of the arterial spin labeling signal provides a potential route to measuring 
BBB permeability to water, with a new method for estimating global water BBB 
permeability recently proposed (Lin et al., 2018). Currently, sensitivity limitations 
mean the technique does not have the capability of DCE-MRI but hopefully in 
coming years, increasing technological advances will improve the methodology and 




4.5 Summary of Findings 
 
Returning to the aims of this chapter, the following areas have been addressed:  
 
1. Global BBB permeability was significantly higher in sporadic SVD compared 
to control, in the whole WM, NAWM and WML 
2. The volume of the BBB permeability hotspots was significantly higher in 
sporadic SVD compared to control, in the whole WM, NAWM and WML  
3. BBB permeability in the CADASIL group was not significantly different from 
controls for any of the parameters or regions 
4. BBB permeability was higher in the NAWM compared to the WML 
5. The permeability in the penumbra of the WML had similar permeability to the 
NAWM, but was significantly higher than the WML permeability 
6. BBB permeability in the WMLs of the control group was associated with 
increased WML volume and decreased MD peak height in the WML, 
suggesting higher permeability is associated with microstructural tissue 
damage 
7. BBB permeability in the NAWM of the SVD group was associated with 
decreased FA median of the tissue, suggesting a higher permeability is 
associated with disruption of WM fibre organisation 
8. BBB permeability in the NAWM of the CADASIL group was associated with 
increased FA median of the tissue, suggesting a higher permeability is 
associated with increased WM fibre integrity 
9. BBB permeability was not associated with any of the cognitive parameters in 
any of the groups 
 
This chapter has investigated BBB permeability between the groups and in 
comparison to the other end-points collected in the study. The next chapter will 
investigate PK binding, as a representation of microglia activation, and the 




Chapter 5: PK binding – Group Differences and 




5.1.1 Aims of the Chapter 
The previous chapter explored differences in BBB permeability measures between the 
patient and control groups. Chapter Four also looked at the relationship of BBB 
permeability with conventional MRI markers and cognition. This chapter looks at PK 
binding as a measure of microglia activation to answer similar questions:  
• Is there a difference in PK binding between sporadic SVD and control groups? 
Does this difference occur globally or focally?  
• Is there a difference in PK binding between CADASIL and control groups? 
Does this difference occur globally or focally?  
• Is there a difference in PK binding in the NAWM and WML? Is this pattern 
the same across all groups? 
• Is there a spatial pattern of increased PK binding in close proximity to WMLs?  
• Is PK binding associated with conventional MRI markers, DTI markers and 
cognition? 
 
The main hypothesis of this chapter is:  
• PK binding will be significantly higher in the sporadic SVD and CADASIL 
patients compared to our healthy controls.  
 
Exploratory outcomes beyond the main hypotheses are:  
• Investigate if PK binding is different in the NAWM compared to WML 
• Investigate if PK binding is increased in close proximity to WMLs  
• Investigate if there is a relationship between PK binding and conventional 






5.1.2 Neuroinflammation in SVD 
Inflammation is vital for survival, defending the body from invaders by eliminating 
the injurious agent and removing the damaged tissue components so that the body can 
begin to heal. However, many chronic diseases have shown a detrimental role for 
inflammation, where the immune system recognises a normal component of the body 
as foreign and attacks it. Further, chronic inflammation can lead to the generation of 
oxidative stress and production of free radical molecules that are damaging. A 
pathogenic role for inflammation has been suggested in SVD (Low et al., 2019, Fu 
and Yan, 2018).   
 
Many of the studies investigating inflammation in SVD to date, have focused on 
inflammatory biomarkers from the blood (Low et al., 2019). As discussed in Chapter 
One, SVD etiology primarily occurs in the brain, and therefore microglia and 
astrocytes are the cells responsible for the immune response. Typically, microglia are 
activated first, initiating morphological changes and expression and release of pro-
inflammatory mediators and other signaling molecules (Russo and McGavern, 2015). 
Therefore, measures of blood biomarkers are far from optimal for exploring the role 
of neuroinflammation in SVD.  
 
There has been some post-mortem work that has investigated the presence of 
microglia in SVD. However, the results have been conflicting. Early studies 
suggested that higher levels of microglia were present in the WML of SVD patients 
(Tomimoto et al., 1996, Young et al., 2008). Later studies then showed that there is 
also increased microglia in the NAWM (Simpson et al., 2007b, Forsberg et al., 2018). 
In CADASIL, only one post-mortem study has investigated microglia and found there 
was no change compared to control (Brennan-Krohn et al., 2010). Post-mortem 
studies tend to be of a severe late-stage disease phenotype, and may not represent the 
pathology occurring earlier on. Microglia activation is likely to be a dynamic process, 
which may have varying roles throughout the SVD pathology, which may mean that 
post-mortem studies are not as relevant to early and mid-stage disease.  
 
Techniques to image neuroinflammation have surged over the past 15 years, as 
accurate imaging of neuroinflammation can be used for diagnosis and monitoring, as 
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well as guide the development of novel treatments for a range of diseases (Albrecht et 
al., 2016). PET is by far the most commonly used technique for imaging 
neuroinflammation, with a growing range of tracers continually being developed to 
allow for new and improved targeting.  
 
PET inflammation studies have the potential to answer many questions on the 
pathogenesis of SVD. PET can be used to investigate neuroinflammation both cross-
sectionally, in comparison to a control group, and longitudinally, to investigate the 
effect of baseline neuroinflammation on disease progression. PET methods can be 
used to understand global changes in neuroinflammation, but also more focal changes 
by investigating where the inflammatory regions are on a voxel-by-voxel basis. They 
can be used to investigate whether neuroinflammation is more prevalent in WML or 
NAWM and whether the penumbra of the WMLs is important, in the same way that 
DCE-MRI explored BBB permeability in Chapter Four.  
 
 
5.1.3 TSPO PET imaging 
PET methods that target neuroinflammation primarily focus on TSPO, a five 
transmembrane domain protein situated in the outer mitochondrial membrane. In the 
healthy CNS, TSPO is constitutively expressed by multiple cell types, including glia 
and neurons, at low levels (Cosenza-Nashat et al., 2009). However, during 
neuroinflammation, TSPO is upregulated predominantly, if not exclusively, in glia 
cells (Chen and Guilarte, 2008). The specific cell expressing TSPO is a point of 
controversy for TSPO imaging, as technically it could be both microglia and 
astrocytes. It is impossible to know the relative contribution of microglia and 
astrocytes to TSPO and it is probably dependent on many factors, including the 
disease being investigated and the time-course of inflammation in that disease. This is 
something to consider when comparing TSPO expression across studies, as it may not 
be measuring the same composition of cells. Despite this, many studies reference the 





PK is the most widely used TSPO imaging agent. However, PK has low brain 
penetrance and high nonspecific binding, which limits signal to background ratio 
(SBR) and the ability of the tracer to detect subtle PET signals related to glial 
activation (Venneti et al., 2006). Second generation TSPO ligands have been 
generated, including [C11]PBR28, [F18]DPA-714, [F18]FEPPA, [C11]DAA1106, 
[F18]PBR06, and [F18]PBR111. These ligands possess much higher signal-to-
background ratio (SBR) than PK and have been used to image glial activation in a 
number of pathologies including psychiatric disorders (van der Doef et al., 2015), 
amyotrophic lateral sclerosis (Zurcher et al., 2015) and chronic pain (Loggia et al., 
2015).  
 
Unfortunately, all second-generation TSPO ligands are confounded by the existence 
of two binding sites: one with high affinity and one with low affinity (Owen et al., 
2010). Individual subjects have differential expression of the binding sites, making it 
difficult to compare TSPO binding of second-generation ligands between individuals. 
For example, among people of European ancestry, ~50% express only high affinity 
sites, ~10% express only low affinity sites and ~40% express equal numbers of high 
and low affinity sites (Kreisl et al., 2013). This makes impossible to know if a group 
difference is due to pathological differences or simply a difference in binding sites. 
However, recent advances in genetics have identified a single nucleotide 
polymorphism in the TSPO gene (Ala147Thr) (Owen et al., 2012), which fully 
predicts the binding site, so now this can be added into the recruitment strategy to 
match subjects by genotype for this imaging (Mizrahi et al., 2012). However, this 
would require genotyping of subjects prior to recruitment, which is expensive and 
time consuming, and adds an extra layer of complexity into often already complex 
studies. Therefore, PK is currently still the best option for TSPO imaging.  
 
 
5.1.4 PET Analysis 
PET analysis requires an estimation of specific binding of the ligand to the molecule 
of interest. The gold standard for PET is kinetic modelling with arterial sampling, 
with a plasma AIF and correction for plasma free fraction (Gunn et al., 2001). This is 
an invasive procedure that is uncomfortable for the patients. Additionally, this method 
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has substantial variability with TSPO. This is thought to be due to high PK binding to 
the plasma protein α1-acid glycoprotein, which is up regulated in inflammatory states 
(Lockhart et al., 2003). This is expected to be the same for the second-generation 
ligands but has not been directly investigated. Therefore, outcome estimation of 
specific binding is difficult using arterial sampling with TSPO ligands and other 
methods have been developed.  
 
Alternative methods include SRTM and the use of semi-quantitative measures (Scott 
et al., 2017). These methods have been validated and shown to provide accurate 
values (Logan et al., 1996, Lammertsma and Hume, 1996). SRTM involves taking a 
brain region as the reference region, from which the other region values are derived. 
Technically, the reference tissue should be a region where there is no specific binding 
of the ligand. However, for many ligands, including PK, a true reference tissue does 
not exist in the brain. Therefore, a ‘pseudo-reference region’ can be used, which 
contains low levels of TSPO and is thought to have consistent TSPO binding across 
participants. Lyoo et al. used the cerebellum as an anatomically defined pseudo-
reference region; comparing the use of this reference region to arterial sampling 
methods, they found the cerebellum pseudo-reference region to provide more accurate 
results (Lyoo et al., 2015). Data-driven techniques have now been adopted that can 
identify voxels across the brain with TACs mirroring those of controls, as an 
automatic way of extracting a reference tissue input function (Turkheimer et al., 
2007). The technique uses supervised cluster analysis the TAC of each voxel as a sum 
of the kinetics of 4 predefined tissues (normal GM and WM and the 2 sources of 
specific binding, activated microglia and vasculature) obtained from control subjects. 
The reference kinetic can then be obtained by averaging the whole brain, whilst each 
pixel TAC is weighted by its normal index of the reference region of the GM or WM.  
 
The SRTM technique means that an arterial line does not need to be placed in the 
patient, minimising patient discomfort. Further, this method helps to correct for the 
within-subject signal differences caused by the TSPO genotype of the individual 
patient (Coughlin et al., 2014). However, it is important that the methods are fully 
validated in the individual study population and that the reference region is carefully 





5.1.5 Global vs. Focal Inflammation 
As discussed in Chapter Four, SVD is a heterogeneous disease with many points of 
focal damage in the brain due to individual WMLs and lacunar infarcts. However, this 
then leads to many downstream global changes to networks and structure (Ter Telgte 
et al., 2018). Inflammation after acute stroke has been well-documented as a primarily 
focal event leading to secondary global changes (Shi et al., 2019). Primary focal 
inflammation occurs immediately after stroke onset in the region of the lesion and is 
often irreversible. Cells affected by the injury trigger a cascade of secondary events 
including BBB damage, excitotoxicity, oxidative stress, microvascular failure and 
mitochondrial disturbance, all of which promote secondary brain injury (Fu et al., 
2015). The contribution of global vs. focal inflammation to SVD is debated in the 
literature, but it is important to differentiate between the processes as they are 
probably representative of very different inflammatory cascades (Kawabori and 
Yenari, 2015).  
 
Global inflammatory measures can be calculated from PET imaging, by taking the 
mean binding for an ROI, such as NAWM and WML. Focal inflammation is slightly 
more difficult, as PET imaging techniques are notorious for having low spatial 
resolution and therefore making it difficult to assess changes in small ROIs. However, 
with this technique we can identify hotspots, which are voxels above the ‘normal’ 
threshold, determined from a control group of patients. The location of these hotspots 
may be important, but also the volume of them will give a representative estimation of 






There were 17 controls, 16 sporadic SVD and 14 CADASIL who received PK PET 
imaging and so were included in this chapter. Methodology was described in Chapter 
Two.  
 
5.2.1 Defining PK binding Values 
Global mean PK binding was defined as the mean PK binding of all voxels in the 
ROI. Hotspot mean PK binding was defined as the mean PK binding of all voxels 
above the ‘normal’ threshold, calculated from our control subjects in the same way as 
for the permeability data, and defined as voxel that was above 0.135 (ratio of the 
reference region, no units). The hotspot PK binding volume was expressed as a 
percentage (%) of the voxels that showed PK binding values above the threshold 
within the given ROI.  
 
Penumbra values were defined as a 3mm rim around the WMLs. Global means, 




5.2.2 Statistical Analysis 
All group differences were analysed using an ANCOVA test, comparing between 
sporadic SVD and control groups, and between CADASIL and control groups. All 
analyses were controlled for age and sex. Pairs of comparisons were adjusted using 
Bonferroni. If there was a significant difference seen, additional controlling for 
cardiovascular risk factors of hypertension, hyperlipidaemia, type 2 diabetes and 
smoking was performed to determine if results remained significant. Some of the PK 
binding parameters were not normally distributed so they were transformed to meet 
normality assumptions. The global PK binding measures of WM, NAWM and WML 
were log transformed (base:10 constant:10-1). The mean hotspot PK binding measures 
of WM and NAWM met normality assumptions, however WML did not so was 
transformed by squaring. The hotspot volume of WM and NAWM did not meet 
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normality so they were log transformed (base:10). Hotspot volume of WML also did 
not meet normality so was log transformed (base:10 constant:10-1).  
 
Comparisons between the PK binding values of the NAWM and WML were 
performed using Wilcoxon signed rank tests for paired non-parametric data. These 
tests were performed on the raw untransformed values. P values were corrected for 
multiple comparisons using FDR.  
 
PK binding values in the penumbra were also analysed using ANCOVAs, comparing 
between sporadic SVD and control groups, and CADASIL and control groups. Pairs 
of comparisons were adjusted using Bonferroni. If there was a significant difference 
seen, then a further ANCOVA controlling for the cardiovascular risk factors was 
performed, to see if the significance was still present. Global mean PK binding values 
for the penumbra met normality assumptions. Hotspot mean PK binding values for the 
penumbra did not meet normality assumptions so were log transformed (base:10). 
Hotspot PK binding volumes for the penumbra also did not meet normality 
assumptions so were log transformed (base:10).   
 
Comparisons between PK binding values for the various brain regions and the 
corresponding penumbra value were carried out using the Wilcoxon signed rank tests 
for paired non-parametric data. These tests were performed on the raw untransformed 
values. P values were corrected for multiple comparisons using FDR. 
 
Multivariate linear models were then used to investigate the association between PK 
binding parameters (independent) and imaging markers (dependent), controlled for 
age and sex. If the imaging parameter was a volumetric measure, then ICV was also 
used as a control. For significant associations, a further linear model with the 
cardiovascular risk factors was also used to see if the significance was still present. If 
required, PK binding parameters were transformed in the same way as detailed 
earlier, to meet normality assumptions. Imaging markers were also transformed if 
required, using the same transforms as described in Chapter Three. P values were 




Multivariate linear models were also used to investigate if PK binding parameters 
(independent) were significantly associated with cognitive indices (dependent). These 
analyses were controlled for age, sex and premorbid IQ. For any of the PK binding 
parameters that do not fit normality assumptions, the same transforms as detailed 






5.3.1 Group Differences 
PK binding values in the WM, NAWM and WML were calculated for each individual 
patient and comparisons were made between the sporadic SVD and control groups, 
and between the CADASIL and control groups. Representative images from each of 
the groups showing hotspots of significant PK binding are shown in Figure 5.1.  
 
Global PK binding for each group is shown in Figure 5.2. There was no significant 
difference in the global PK binding between the sporadic SVD and control group or 
the CADASIL control group in the WM, NAWM or the WML.  
 
The mean values of the PK binding hotspots are shown for the different groups in 
Figure 5.3. In the WM, there was a significantly higher mean in the PK binding 
hotspots in the sporadic SVD group compared to control when controlled for age and 
sex (p<0.001 (p<0.001 when adjusted for multiple comparisons)) and cardiovascular 
risk factors (p<0.001). The mean PK binding hotspot values in the WM were also 
significantly higher in CADASIL compared to control when controlled for age and 
sex (p=0.007 (p=0.015 when adjusted for multiple comparisons)) and cardiovascular 
risk factors (p=0.006). In the NAWM, the mean binding hotspot value was 
significantly higher in sporadic SVD compared to control when controlling for age 
and sex (p<0.001 (p<0.001 when adjusted for multiple comparisons)) and 
cardiovascular risk factors (p<0.001). However, the mean binding hotspot value in the 
NAWM was not significantly different in CADASIL compared to control. In the 
WML, the mean binding hotspot value was significantly higher in the sporadic SVD 
group compared to control when controlling for age and sex (p<0.001 (p<0.001 when 
adjusted for multiple comparisons)) and cardiovascular risk factors (p<0.001). 
Similarly, the mean binding hotspot value in the WML was significantly higher in 
CADASIL compared to control, when controlling for both age and sex (p<0.001 





The volumes of the PK binding hotspots were compared between groups in Figure 
5.4. In the WM, the volume of the hotspots was not significantly different between 
sporadic SVD and control or between CADASIL and control. However, in the 
NAWM the volume of the PK binding hotspots was significantly higher in the 
sporadic SVD compared to control when controlled for age and sex (p=0.001 
(p=0.003 when adjusted for multiple comparisons)) and cardiovascular risk factors 
(p=0.001). There was no significant difference in the volume of the NAWM hotspots 
in the CADASIL group compared to control. In the WML, the volume of the hotspots 
in the sporadic SVD group was significantly higher than control when controlled for 
age and sex (p=0.002 (p=0.003 when adjusted for multiple comparisons)) and 
cardiovascular risk factors (p=0.002). This was mirrored in the CADASIL group, 
where the volume of the hotspots in the WML was significantly higher than control 
when controlled for age and sex (p<0.001 (p<0.001 when adjusted for multiple 





Figure 5.1: Example images of PK binding hotspots (red) overlayed onto T2 FLAIR 







Figure 5.2: Mean global PK binding in the WM, NAWM and WML controlled for 
age and sex.  
A) Global mean PK binding in the WM was not significantly different between 
sporadic SVD and control (p=1.000) or CADASIL and control (p=0.566).   
B) Global mean PK binding in the NAWM was not significantly different between 
sporadic SVD and control (p=0.571) or CADASIL and control (p=0.615).   
C) Global mean PK binding in the WML was not significantly different between 







Figure 5.3: Hotspot mean PK binding in the WM, NAWM and WML, controlled for 
age and sex.  
A) Hotspot mean PK binding in the WM was significantly higher in the sporadic SVD 
group compared to control (p<0.001) and in the CADASIL group compared to control 
(p=0.015).  
B) Hotspot mean PK binding in the NAWM was significantly higher in the sporadic 
SVD group compared to control (p<0.001). However, it was not significantly 
different in the CADASIL group compared to control (p=0.117).  
C) Hotspot volume of PK binding in the WML was significantly higher in the 
sporadic SVD group compared to control (p<0.001) and in the CADASIL group 






Figure 5.4: Hotspot volume of PK binding (%) in the WM, NAWM and WML.  
A) Hotspot volume of PK binding in the WM was not significantly different between 
sporadic SVD and control (p=0.123) or CADASIL and control (p=1.000).  
B) Hotspot volume of PK binding in the NAWM was significantly higher in sporadic 
SVD compared to control (p=0.003). However, it was not significantly different in 
CADASIL compared to control (p=0.073).  
C) Hotspot volume of PK binding in the WML was significantly higher in the 
sporadic SVD group compared to control (p=0.003) and in the CADASIL group 





5.3.2 NAWM vs. WML 
Pairwise comparisons between the NAWM PK binding values and corresponding 
WML values are shown in Table 5.1.  
 
In the control group, there was no significant difference in the global PK binding 
mean between the NAWM and WML. However, there was a significantly higher 
mean of the PK binding hotspots in NAWM compared to WML (p<0.001) and 
significantly higher volume of the PK binding hotspots in NAWM compared to WML 
(p<0.001).  
 
In the sporadic SVD, there was significantly higher PK binding in the NAWM 
compared to WML when investigating global binding mean (p=0.003), hotspot 
binding mean (p=0.007) and hotspot binding volume (p=0.003).  
 
In the CADASIL group, there was no significant difference in the global PK binding 
mean between the NAWM and WML. However, there was a significantly higher 
mean of the PK binding hotspots in the NAWM compared to WML (p=0.021) and 







Group Imaging parameter NAWM WML P 
value 
Median IQR Median IQR 
Control Global PK binding 
mean 0.030 0.021 0.036 0.158 0.900 
Control Hotspot PK binding 
mean 0.174 0.017 0.000 0.146 <0.001 
Control Hotspot PK binding 
volume (%) 3.761 4.085 0.000 0.671 <0.001 
Sporadic 
SVD 
Global PK binding 
mean 0.054 0.033 -0.003 0.045 0.003 
Sporadic 
SVD 
Hotspot PK binding 
mean 0.204 0.028 0.182 0.044 0.007 
Sporadic 
SVD 
Hotspot PK binding 
volume (%) 9.442 7.199 0.858 3.341 0.003 
CADASIL Global PK binding 
mean 0.052 0.045 0.013 0.044 0.134 
CADASIL Hotspot PK binding 
mean 0.196 0.030 0.180 0.023 0.021 
CADASIL Hotspot PK binding 
volume (%) 6.805 10.004 1.327 2.665 0.007 
 
Table 5.1: Comparisons of PK binding in the NAWM and WML. Significant p values 





5.3.3 WML Penumbra 
PK binding values from the penumbras were calculated and compared between the 
sporadic SVD and control groups, and between the CADASIL and control groups. 
Global mean binding values were compared, as well as the mean and volume of the 
PK binding hotspots.  
 
Global mean PK binding in the penumbra was compared between the groups in 
Figure 5.5. The global mean PK binding in the penumbra was not significantly 
different between sporadic SVD and control groups or the CADASIL and control 
groups.   
 
Mean values of the PK binding hotspots in the penumbra were then compared 
between groups in Figure 5.6. There was no significant difference in the mean binding 
values of the hotspots in the penumbra of the sporadic SVD group compared to 
control. However, the mean values of the PK binding hotspots were significantly 
higher in the CADASIL penumbra compared to control when controlling for age and 
sex (p=0.003 (p=0.007 when adjusted for multiple comparisons)) and cardiovascular 
risk factors (p=0.005).  
 
The volumes of the PK binding hotspots were compared in the penumbras in Figure 
5.7. There was no significant difference in the volume of the PK binding hotspots in 
the penumbra between the sporadic SVD and control groups or the CADASIL and 





Figure 5.5: Global mean PK binding of the penumbra regions were compared between 
groups when controlled for age and sex. Global mean binding values were no 
different in sporadic SVD and control groups (p=0.248).  There was also no 
difference between CADASIL and control (p=0.100).  
 
Figure 5.6: Mean values of the PK binding hotspots in the penumbras were compared 
between the groups, controlling for age and sex. Hotspot mean binding values were 
not significantly higher in sporadic SVD compared to control (p=0.060). However, 





Figure 5.7: Volumes of the PK binding hotspots in the penumbras (%) were compared 
between the groups. Hotspot volumes were not significantly different between 
sporadic SVD and control (p=0.762). There was also no difference between 
CADASIL and control (p=0.352).   
 
 
Penumbra values were compared with corresponding NAWM and WML values in 
Table 5.2. In the control group, penumbra values were significantly lower than global 
mean PK binding values in the NAWM (p<0.001) and WML (p<0.001). Mean values 
of the PK binding hotspots were significantly lower in the penumbra in comparison to 
the NAWM (p<0.001), but significantly higher than the WML (p=0.001). The same 
pattern was present for the volume of the PK binding hotspots, with penumbra values 
significantly lower than NAWM (p=0.001), but higher than WML (p<0.001).  
 
In the sporadic SVD group, the global mean binding of the penumbra was 
significantly lower than NAWM (p<0.001) and WML (p<0.001). The mean values of 
the PK binding hotspots within the penumbra were significantly lower than in the 
NAWM (p=0.004), but no different from the WML. The volume of the PK binding 
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hotspots in the penumbra was significantly lower than the NAWM (p=0.011), but 
significantly higher than the WML (p=0.042).  
 
In the CADASIL group, penumbra values were significantly lower than both NAWM 
(p<0.001) and WML (p<0.001) values for global mean PK binding. They were similar 
to NAWM and WML for mean values of the PK binding hotspots. The volume of the 
PK binding hotspots in the penumbra was significantly lower than the NAWM 






Group PK binding 
measurement 
Mean PK binding  Mean Penumbra  P value 
Median IQR Median IQR 
Control NAWM mean  0.030 0.021 -0.054 0.041 <0.001 
WML mean  0.036 0.158 -0.054 0.041 <0.001 
NAWM hotspot mean 0.174 0.017 0.166 0.013 <0.001 
WML hotspot mean 0.000 0.146 0.166 0.013 0.001 
NAWM volume (%) 3.761 4.085 2.501 2.213 0.001 
WML volume (%) 0.000 0.671 2.501 2.213 <0.001 
Sporadic 
SVD 
NAWM mean  0.054 0.033 -0.090 0.066 <0.001 
WML mean  -0.003 0.045 -0.090 0.066 <0.001 
NAWM hotspot mean 0.204 0.028 0.179 0.025 0.004 
WML hotspot mean 0.182 0.044 0.179 0.025 0.348 
NAWM volume (%) 9.442 7.199 3.212 5.930 0.011 
WML volume (%) 0.858 3.341 3.212 5.930 0.042 
CADASIL NAWM mean  0.052 0.045 -0.084 0.034 <0.001 
WML mean  0.013 0.044 -0.084 0.034 <0.001 
NAWM hotspot mean 0.196 0.030 0.185 0.019 0.117 
WML hotspot mean 0.180 0.023 0.185 0.019 0.205 
NAWM volume (%) 6.805 10.004 2.754 5.076 0.001 
WML volume (%) 1.327 2.665 2.754 5.076 0.028 
 
Table 5.2: Pairwise comparisons for the individual groups for the global mean PK 
binding values, hotspot mean PK binding values and hotspot PK binding volume with 




Associations between the PK binding parameters and WML volume are shown in 
Table 5.3. In the control group, the volume of the PK binding hotspots in the NAWM 
was significantly associated with the volume of the WMLs when controlled for age 
and sex (β=0.835, p=0.002 (p=0.035 when adjusted for multiple comparisons)). When 
the analysis was rerun accounting for all of the cardiovascular risk factors, the 
significance was still present (β=0.838, p=0.017). All other PK binding parameters 
were not significant. In the sporadic SVD and CADASIL groups, none of the PK 
binding parameters were significantly associated with WML volume.   
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM 0.385 0.478 0.236 0.640 0.281 0.485 
WML -0.199 0.640 -0.083 0.837 0.215 0.640 
Hotspot 
mean 
NAWM 0.650 0.074 0.203 0.640 0.155 0.640 
WML 0.580 0.074 -0.157 0.772 -0.064 0.838 
Hotspot 
volume 
NAWM 0.835 0.035 0.537 0.215 0.266 0.478 
WML 0.503 0.154 -0.218 0.640 0.090 0.820 
 
Table 5.3: Associations between PK binding and WML volume when adjusted for 
age, sex and ICV. Table shows standardised β coefficients and p values. Significant p 
values are shown in bold. 
 
 
5.3.5 Lacunar Infarcts 
Lacunar infarcts were measured as lacune volume and as lacune count. Lacune 
volume was compared with the measures of PK binding in the different groups (Table 
5.4), but none of the parameters were found to be significantly associated with lacune 
volume. Similarly, lacune count was compared with the various measures of PK 






PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.078 0.728 -0.195 0.756 0.271 0.756 
WML -0.122 0.728 -0.513 0.728 -0.179 0.756 
Hotspot 
mean 
NAWM 0.076 0.728 -0.113 0.760 0.345 0.728 
WML -0.032 0.760 -0.108 0.760 0.274 0.756 
Hotspot 
volume 
NAWM 0.074 0.756 -0.109 0.760 0.348 0.728 
WML -0.056 0.756 -0.435 0.728 0.198 0.756 
 
Table 5.4: Associations between PK binding and lacune volume when adjusted for 
age, sex and ICV. Table shows standardised β coefficients and p values. Significant p 
values are shown in bold. 
 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.049 0.716 -0.122 0.803 0.262 0.716 
WML -0.133 0.607 -0.519 0.607 -0.213 0.716 
Hotspot 
mean 
NAWM 0.084 0.607 0.009 0.978 0.329 0.607 
WML -0.036 0.758 0.012 0.978 0.314 0.716 
Hotspot 
volume 
NAWM 0.093 0.607 0.044 0.978 0.386 0.607 
WML -0.050 0.716 -0.396 0.607 0.275 0.716 
 
Table 5.5: Associations between PK binding and lacune count when adjusted for age 
and sex. Table shows standardised β coefficients and p values. Significant p values 




The association between CMB count for the different group with PK binding 
parameters is shown in Table 5.6. There were no significant associations seen with 




PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.027 0.745 -0.176 0.704 0.354 0.388 
WML -0.053 0.704 -0.499 0.381 -0.151 0.704 
Hotspot 
mean 
NAWM -0.055 0.704 -0.424 0.388 -0.124 0.704 
WML -0.047 0.704 -0.519 0.381 0.624 0.381 
Hotspot 
volume 
NAWM -0.042 0.704 -0.488 0.381 -0.025 0.922 
WML -0.054 0.704 -0.795 0.064 0.412 0.425 
 
Table 5.6: Associations between PK binding and CMB count when adjusted for age 
and sex. Table shows standardised β coefficients and p values. Significant p values 
are shown in bold. 
 
 
5.3.7 Brain Volume 
The association between the PK binding parameters and brain volume are shown in 
Table 5.7. There were no associations with any of the parameters in any of the groups. 
The association between PK binding parameters and GM volume are then shown in 
Table 5.8. Similar to brain volume, there were no significant associations seen.  
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.071 0.855 0.263 0.416 -0.329 0.724 
WML 0.010 0.985 0.412 0.156 0.319 0.724 
Hotspot 
mean 
NAWM -0.112 0.731 0.021 0.985 -0.586 0.416 
WML -0.093 0.734 0.059 0.920 -0.385 0.724 
Hotspot 
volume 
NAWM 0.004 0.985 0.138 0.724 -0.492 0.416 
WML -0.213 0.416 0.256 0.455 -0.441 0.724 
 
Table 5.7: Associations between PK binding and brain volume when adjusted for age, 
sex and ICV. Table shows standardised β coefficients and p values. Significant p 




PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.085 0.775 -0.091 0.775 -0.542 0.274 
WML -0.112 0.775 0.430 0.230 0.457 0.358 
Hotspot 
mean 
NAWM -0.305 0.358 -0.460 0.230 -0.611 0.230 
WML -0.217 0.459 -0.271 0.459 -0.559 0.367 
Hotspot 
volume 
NAWM -0.119 0.775 -0.453 0.230 -0.537 0.230 
WML -0.341 0.285 0.047 0.862 -0.672 0.230 
 
Table 5.8: Associations between PK binding and GM volume when adjusted for age, 
sex and ICV. Table shows standardised β coefficients and p values. Significant p 




The associations between FA median and the PK binding parameters are shown for 
the NAWM in Table 5.9 and for the WML in Table 5.10. There were no associations 
between any of the PK binding parameters and FA in any of the groups.  
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.118 0.677 0.007 0.979 -0.461 0.227 
WML 0.204 0.443 0.284 0.443 0.518 0.227 
Hotspot 
mean 
NAWM -0.289 0.405 -0.336 0.405 -0.253 0.434 
WML -0.317 0.405 0.283 0.443 -0.706 0.227 
Hotspot 
volume 
NAWM -0.397 0.405 -0.339 0.405 -0.340 0.405 
WML -0.288 0.405 0.390 0.405 -0.602 0.227 
 
Table 5.9: Associations between PK and FA NAWM median when adjusted for age 
and sex. Table shows standardised β coefficients and p values. Significant p values 





PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM 0.035 0.949 -0.280 0.949 0.156 0.949 
WML -0.428 0.949 0.176 0.949 0.311 0.949 
Hotspot 
mean 
NAWM -0.021 0.949 0.032 0.949 -0.374 0.949 
WML -0.082 0.949 -0.022 0.949 0.133 0.949 
Hotspot 
volume 
NAWM -0.053 0.949 0.093 0.949 -0.094 0.949 
WML -0.032 0.949 0.093 0.949 -0.074 0.949 
 
Table 5.10: Associations between PK binding and FA WML median when adjusted 
for age and sex. Table shows standardised β coefficients and p values. Significant p 




Associations between MD peak height and PK binding parameters are shown for 
NAWM in Table 5.11 and WML in Table 5.12. There were no associations between 
any of the PK binding parameters and the MD peak height in the NAWM in any of 
the groups. There was a significant negative association between PK binding hotspot 
volume in the NAWM and MD peak height in the WML in the control group when 
controlled for age and sex (β=-0.864, p=0.003 (p=0.043 when adjusted for multiple 
comparisons)). The significance was still present after adjusting for cardiovascular 













PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.298 0.580 0.036 0.898 -0.200 0.694 
WML -0.179 0.694 0.242 0.694 0.540 0.580 
Hotspot 
mean 
NAWM -0.035 0.898 0.133 0.857 -0.183 0.694 
WML -0.255 0.694 0.099 0.866 -0.529 0.580 
Hotspot 
volume 
NAWM -0.244 0.694 0.107 0.866 -0.156 0.732 
WML -0.230 0.694 0.288 0.694 -0.451 0.580 
 
Table 5.11: Associations between PK binding and MD NAWM peak height when 
adjusted for age and sex. Table shows standardised β coefficients and p values. 
Significant p values are shown in bold. 
 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.434 0.307 0.172 0.631 0.389 0.386 
WML 0.241 0.562 0.531 0.133 -0.208 0.664 
Hotspot 
mean 
NAWM -0.665 0.100 0.495 0.157 -0.297 0.536 
WML -0.590 0.102 0.271 0.547 -0.137 0.792 
Hotspot 
volume 
NAWM -0.864 0.043 0.151 0.665 0.055 0.859 
WML -0.511 0.186 0.656 0.092 0.428 0.433 
 
Table 5.12: Associations between PK binding and MD WML peak height when 
adjusted for age and sex.  Table shows standardised β coefficients and p values. 




Associations between FW median and PK binding parameters are shown for the 
NAWM in Table 5.13 and WML in Table 5.14. There were no associations seen 




PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM 0.292 0.808 -0.156 0.808 0.050 0.814 
WML -0.129 0.808 -0.198 0.808 -0.415 0.570 
Hotspot 
mean 
NAWM -0.076 0.809 -0.116 0.808 0.163 0.808 
WML 0.226 0.808 -0.307 0.808 0.499 0.570 
Hotspot 
volume 
NAWM 0.262 0.808 -0.155 0.808 0.086 0.808 
WML 0.182 0.808 -0.421 0.808 0.248 0.808 
 
Table 5.13: Associations between PK binding and FW NAWM median when adjusted 
for age and sex. Table shows standardised β coefficients and p values. Significant p 
values are shown in bold. 
 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.020 0.986 0.182 0.910 0.049 0.986 
WML -0.129 0.910 -0.518 0.910 -0.103 0.910 
Hotspot 
mean 
NAWM -0.015 0.986 -0.005 0.986 0.290 0.910 
WML 0.150 0.910 0.316 0.910 0.212 0.910 
Hotspot 
volume 
NAWM 0.164 0.910 0.123 0.910 0.240 0.910 
WML 0.182 0.910 -0.223 0.910 0.149 0.910 
 
Table 5.14: Associations between PK binding and FW WML median when adjusted 
for age and sex. Table shows standardised β coefficients and p values. Significant p 
values are shown in bold. 
 
 
5.3.11 FW adjusted FA 
Associations between FW adjusted FA median and PK binding parameters are shown 
for NAWM in Table 5.15 and WML in Table 5.16. There was no association between 
any of the PK binding parameters and either of the FW adjusted FA median values for 
any of the groups. 
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PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.079 0.832 -0.148 0.754 -0.527 0.206 
WML 0.267 0.394 -0.074 0.833 0.543 0.257 
Hotspot 
mean 
NAWM -0.221 0.490 -0.422 0.394 -0.253 0.490 
WML -0.253 0.441 -0.087 0.833 -0.746 0.206 
Hotspot 
volume 
NAWM -0.349 0.394 -0.450 0.394 -0.382 0.394 
WML -0.206 0.490 -0.164 0.754 -0.634 0.206 
 
Table 5.15: Associations between PK binding and FW adjusted FA NAWM median 
when adjusted for age and sex. Table shows standardised β coefficients and p values. 
Significant p values are shown in bold. 
 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.028 0.923 -0.364 0.923 0.054 0.923 
WML -0.596 0.359 -0.233 0.923 0.331 0.923 
Hotspot 
mean 
NAWM -0.059 0.923 -0.163 0.923 -0.254 0.923 
WML -0.160 0.923 0.058 0.923 0.473 0.923 
Hotspot 
volume 
NAWM 0.046 0.923 -0.111 0.923 -0.056 0.923 
WML -0.080 0.923 -0.195 0.923 -0.123 0.923 
 
Table 5.16: Associations between PK binding and FW adjusted WML median when 
adjusted for age and sex. Table shows standardised β coefficients and p values. 
Significant p values are shown in bold. 
 
 
5.3.12 FW adjusted MD  
Associations between FW adjusted MD peak height and PK binding parameters are 
shown for NAWM in Table 5.17 and WML in Table 5.18. There was no association 
between any of the PK binding parameters and the FW adjusted MD peak height 
values in the NAWM. There was a significant negative association between PK 
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binding hotspot volume in the NAWM and FW adjusted MD peak height in the WML 
in the control group  (β=-0.930, p=0.005 (p=0.006 when adjusted for multiple 
comparisons)). This significance was still present after adjusting for cardiovascular 
risk factors (β=-0.880, p=0.004). 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM 0.013 0.997 -0.030 0.997 0.384 0.706 
WML 0.040 0.997 0.276 0.852 -0.201 0.964 
Hotspot 
mean 
NAWM 0.265 0.768 0.295 0.852 0.158 0.964 
WML 0.012 0.997 0.480 0.706 0.011 0.997 
Hotspot 
volume 
NAWM 0.001 0.997 0.174 0.964 0.492 0.706 
WML -0.002 0.997 0.548 0.706 0.389 0.768 
 
Table 5.17: Associations between PK binding and FW adjusted MD NAWM peak 
height when adjusted for age and sex. Table shows standardised β coefficients and p 
values. Significant p values are shown in bold. 
 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.456 0.279 0.324 0.430 -0.024 0.937 
WML 0.302 0.434 -0.210 0.559 -0.485 0.296 
Hotspot 
mean 
NAWM -0.676 0.098 0.476 0.279 -0.239 0.503 
WML -0.579 0.122 0.634 0.180 0.039 0.937 
Hotspot 
volume 
NAWM -0.930 0.006 0.336 0.434 -0.256 0.496 
WML -0.515 0.180 0.283 0.496 0.430 0.430 
 
Table 5.18: Associations between PK binding and FW adjusted MD WML peak 
height when adjusted for age and sex. Table shows standardised β coefficients and p 






The association between PK binding parameters and GC can be seen in Table 4.19. 
The associations between PK binding parameters and the various cognitive domains 
of EF, PS, WoM and LTM can be found in Tables 5.20, 5.21, 5.22 and 5.23 
respectively. There was no association between any of the PK binding parameters in 
any of the groups with cognition. 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.082 0.901 0.098 0.901 -0.457 0.531 
WML -0.185 0.789 0.149 0.901 0.598 0.342 
Hotspot 
mean 
NAWM -0.033 0.977 -0.107 0.901 0.016 0.977 
WML -0.050 0.926 0.073 0.926 -0.899 0.075 
Hotspot 
volume 
NAWM -0.103 0.901 0.008 0.977 -0.272 0.901 
WML 0.095 0.901 0.136 0.901 -0.780 0.194 
 
Table 5.19: Associations between PK binding and GC when adjusted for age, sex and 
premorbid IQ. Table shows standardised β coefficients and p values. Significant p 
values are shown in bold. 
 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.212 0.742 0.093 0.742 -0.415 0.742 
WML 0.144 0.742 -0.085 0.766 0.350 0.742 
Hotspot 
mean 
NAWM -0.141 0.742 -0.052 0.861 -0.262 0.742 
WML -0.108 0.742 0.116 0.742 -0.989 0.083 
Hotspot 
volume 
NAWM -0.271 0.742 0.139 0.742 -0.364 0.742 
WML 0.093 0.742 -0.020 0.921 -0.684 0.732 
 
Table 5.20: Associations between PK binding and EF when adjusted for age, sex and 
premorbid IQ.  Table shows standardised β coefficients and p values. Significant p 
values are shown in bold. 
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PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM 0.235 0.752 0.102 0.863 -0.298 0.752 
WML -0.438 0.607 0.231 0.752 0.786 0.100 
Hotspot 
mean 
NAWM 0.088 0.863 0.005 0.989 0.161 0.787 
WML -0.288 0.752 0.291 0.752 -0.834 0.101 
Hotspot 
volume 
NAWM 0.206 0.752 0.267 0.752 -0.070 0.863 
WML -0.229 0.752 0.286 0.752 -0.575 0.607 
 
Table 5.21: Associations between PK binding and PS when adjusted for age, sex and 
premorbid IQ.  Table shows standardised β coefficients and p values. Significant p 
values are shown in bold. 
 
 
PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.006 0.982 0.154 0.616 -0.434 0.531 
WML -0.064 0.982 0.130 0.747 0.044 0.982 
Hotspot 
mean 
NAWM -0.026 0.982 -0.230 0.616 0.018 0.982 
WML 0.180 0.747 -0.108 0.833 -0.366 0.616 
Hotspot 
volume 
NAWM 0.028 0.982 -0.240 0.616 -0.327 0.616 
WML 0.334 0.531 0.055 0.982 -0.654 0.342 
 
Table 5.22: Associations between PK binding and WoM when adjusted for age, sex 
and premorbid IQ.  Table shows standardised β coefficients and p values. Significant 










PK value Brain 
region 
Control Sporadic SVD CADASIL 
β P value β P value β P value 
Global 
mean 
NAWM -0.112 0.896 -0.060 0.896 -0.482 0.280 
WML -0.308 0.499 0.279 0.514 0.464 0.325 
Hotspot 
mean 
NAWM 0.027 0.917 -0.088 0.896 0.198 0.788 
WML -0.050 0.896 -0.117 0.896 -0.373 0.499 
Hotspot 
volume 
NAWM 0.028 0.917 -0.240 0.499 -0.327 0.499 
WML 0.334 0.325 0.055 0.896 -0.654 0.280 
 
Table 5.23: Associations between PK binding and LTM when adjusted for age, sex 
and premorbid IQ.  Table shows standardised β coefficients and p values. Significant 


















Taking PK binding as a marker of microglia activation, this chapter has shown that 
there are increased regions of hotspot microglia activation in the NAWM and WML 
of the sporadic SVD group compared to control. There were also increased hotspots 
of microglia activation in the WML of the CADASIL group compared to control. 
However, there was not a significant increase in global microglia activation in 
sporadic SVD or CADASIL compared to control. Microglia activation was higher in 
the NAWM compared to the WML, with no significant increase in microglia 
activation seen in the WML penumbra. 
 
 
5.4.1 Global Group Differences  
Global PK binding was not significantly different between the sporadic SVD and 
control groups or the CADASIL and control groups in the whole WM, NAWM or 
WML (Figure 5.2).  
 
The main reason behind this result is likely the analysis techniques that used in this 
study. As described in Chapter Two, we used the SRTM approach to quantify BPND in 
the WM (Lammertsma and Hume, 1996), and then weighted each pixel TAC to its 
‘normal’ WM index. The GM was originally used as the reference region but was 
found to be unreliable in this cohort. However, it is questionable as to whether there is 
any ‘normal’ tissue in the WM of the SVD populations, and therefore this is probably 
why we cannot detect a global change here, even if there is one. As PK imaging has 
not previously been performed in an SVD population, we cannot compare this with 
previous studies.  
 
PK imaging for microglia activation has been performed in other neurological 
disorders. Multiple sclerosis (MS) PK studies have a fairly consistent method, using 
the SRTM to quantify BPND in the GM as the reference region (Airas et al., 2018). 
These studies have shown mixed results, where some showed that global binding in 
the NAWM was increased compared to control (Politis et al., 2012, Rissanen et al., 
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2014, Giannetti et al., 2015, Rissanen et al., 2018) whilst others have found no 
significant group difference (Debruyne et al., 2003).  
 
PK imaging has also been used in Alzheimer’s disease, where results have been 
inconsistent. The SRTM approach is the method of choice in Alzheimer’s disease 
(Gunn et al., 1997). Early studies found there was increased PK tracer uptake in 
Alzheimer’s patients compared to controls (Cagnin et al., 2001, Edison et al., 2008, 
Yokokura et al., 2011). However, later studies have not seen this significant group 
difference (Schuitemaker et al., 2013). 
 
Ischaemic stroke studies have also used PK to investigate the role of microglia after 
an acute infarct. In ischaemic stroke, there are more options for the reference region, 
as stroke causes a focal infarct and therefore non-infarcted tissue can be used as a 
reference region. Most studies take the cerebellum as the reference region. There was 
found to be no increase in PK binding in acute stroke patients compared to controls 
within the first 72 hours but there was a significant difference at 1 week, which is still 
evident at 30 days, although it has declined (Price et al., 2006, Gerhard et al., 2005). 
The evidence from acute stroke suggests that microglia activation is a very dynamic 
process that can change dramatically over the course of a few days.  
 
Taking all of this work together, it is obvious that the analysis technique for different 
studies is dependent on the individual pathology of the disease. Further, the mixed 
results seen in MS, Alzheimer’s disease and ischaemic stroke, suggest that even when 
a consistent analysis technique is used, studies can still show differing results. Using 
the WM as the reference region in SVD has shown no global group difference in PK 
binding. As further PET techniques are developed, there may be a better way of 
analysing this data, which reveals a group difference. Alternatively, the dynamic 
nature of microglia activation could mean that a global difference can only be 
detected during certain stages of the disease pathogenesis. Longitudinal studies that 
track microglia activation over time would be needed to establish this. On the other 
hand, it could be that there truly is no global difference in microglia activation in 




5.4.2 Focal Group Differences 
Hotspots were created, which investigated the voxels above a threshold, established 
from the normal control group. The mean and volume of these hotspots was 
calculated and compared between groups.  
 
In the sporadic SVD group, the mean and volume of hotspot PK binding were 
significantly higher than control in the NAWM and WML (Figure 5.3-4). The mean 
hotspot PK binding was also significantly higher in the whole WM of the sporadic 
SVD group compared to control. Interestingly, the volume of the PK binding hotspots 
in the WM was not significantly different from control. Investigating this further, it 
seems as though the standard deviation in the control group is increased in the WM 
compared to in the NAWM or WML separately. This is probably because the controls 
with the most extensive and highest binding in the NAWM also had the most 
extensive and highest binding the WML, and therefore when these regions are 
combined, this has lead to a large range of values across the group.   
 
In the CADASIL group, the mean and volume of the PK binding hotspots was 
significantly higher in the WML of the CADASIL group compared control (Figures 
5.3-4). The hotspot relationships seen in the WM and NAWM were slightly more 
complicated. In the WM, the mean, but not the volume, of the PK binding hotspots 
was significantly higher in the CADASIL group compared to control (Figure 5.3). 
The lack of association seen between the WM volumes is probably due to the same 
explanation as above, where the standard deviation of the control group was much 
higher in the WM. In the NAWM, neither the mean nor the volume of the PK binding 
hotspots was significantly different from control, even though there was a trend for 
them to be higher than the control group. The lack of association seen in the NAWM 
is probably due to the small group size of the CADASIL group; we had a particularly 
high failure rate of PET ligand production in the CADASIL group, meaning we were 
only able to get PK imaging in 14 participants, limiting the power of our results.  
 
The investigation of focal inflammatory hotspots has not been widely used in the 
literature. However, one study of Alzheimer’s disease did use a similar technique to 
look at clusters of hotspot voxels. They found there was a significantly higher volume 
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of hotspots in the occipital lobe in Alzheimer’s disease compared to healthy controls 
(Schuitemaker et al., 2013). Similarly to in our study, they did not find a significant 
difference with the conventional global analyses. The authors suggested that this is 
because microglial activation is a subtle phenomenon in Alzheimer’s. A focal analysis 
was also used in a cognitive healthy elderly population; similarly they were found to 
have a significantly higher volume of PK binding hotspots compared to a younger 
population (Kumar et al., 2012). 
 
There is significant overlap between Alzheimer’s disease and SVD, with many 
elderly patients having some degree of both pathologies (Liu et al., 2018b). Therefore, 
the similarities between our results and the Alzheimer’s and elderly cohorts suggest 
that there may be a focal role for microglia activation in the disease pathologies. 
Follow-up data is needed to determine whether these focal regions of inflammation 
are pathological by seeing if SVD-related pathology, such as WML growth, develops 
in these regions.  
 
 
5.4.4 NAWM vs. WML 
We found that the mean and volume of the PK binding hotspots were higher in the 
NAWM than in the WML for control, sporadic SVD and CADASIL groups (Table 
5.1). Global mean PK binding values were significantly higher in the NAWM 
compared to the WML in the sporadic SVD group, but there was no significant 
difference between NAWM and WML for control or CADASIL groups.  
 
This result is in contrast to post-mortem studies of SVD, where they have reported 
significantly higher markers of microglia in the WMLs compared to in the NAWM 
(Simpson et al., 2007b, McAleese et al., 2016). However, as discussed above, this 
may be because post mortem studies are measuring end-stage disease whereas our 
study is looking at earlier stages.  
 
PK studies of MS, however, have found a similar result to our study, where there was 
a higher level of PK binding in the NAWM compared to WML (Debruyne et al., 
2003). In MS, this has been suggested to represent ‘preactive lesions’, thought to be a 
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result of alterations in brain homeostasis leading to microglial activation in NAWM 
(van Horssen et al., 2012). Early studies elucidated that this damage does not 
necessarily indicate irreversible damage or impaired function of brain tissue and even 
suggested that it could be a protective response to the damage (Graumann et al., 2003, 
Heppner et al., 2005). However, more recent studies have shown that higher microglia 
activation in the NAWM was associated with a higher risk of developing MS at 2 
years, suggesting that this process is pathological (Giannetti et al., 2015).  Therefore, 
a similar process could be occurring in SVD, where the inflammation is spreading 
away from the WMLs and into the NAWM to represent regions that are undergoing 
pathological processes prior to progressing into WMLs.  
 
PK studies in acute stroke have investigated microglia activation both in and around 
the infarct and have reported various trends. Price et al. studied PK binding over time 
after acute stroke and suggested that the PK binding begins in the infarct and it is only 
during the later sub-acute phase that the peri-infarct zone shows increased uptake 
(Price et al., 2006). However, a later study by Gulyas et al. found no significant 
difference in PK binding in the ischaemic core compared to the peri-infarct area one 
month after acute stroke (Gulyas et al., 2012). PK binding has been shown to be 
increased in the contralateral hemisphere after the sub-acute phase, suggesting the 
neuroinflammation continues to extend out from the infarct (Gerhard et al., 2005, 
Pappata et al., 2000). Further, studies investigating specific fibre tracts found that 
there was PK binding seen in the WM tract if a lesion had occurred at some point on 
the tract, suggesting this may be a method by which the inflammation spreads 
(Radlinska et al., 2009).  
 
The acute infarcts seen in ischaemic stroke are different to the WMLs seen in SVD, as 
the WMLs are not caused by a single acute event, rather by chronic hypoxia. 
However, the WMLs of SVD still represent focal damage to the tissue and often occur 
within the WM tracts. Therefore, in SVD it is likely that a similar process of 
inflammation spreading along the WM tracts also occurs and this may be why we are 
seeing higher levels of microglial activation in the NAWM. The comparatively lower 
inflammation in the WML may be because the WMLs in SVD are usually not acute or 
recent. Therefore, the inflammatory processes that occur here may only be temporary 
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and as time goes on and the WML becomes inactive, the inflammatory processes may 
spread away from the insult and into the NAWM.  
 
Further studies that investigate changes in the PK binding in both the NAWM and 
WML over time are required to see whether a temporal relationship is occurring here 
and provide further insight into what is happening in the pathogensis of SVD.   
 
 
5.4.5 WML Penumbra 
We had hypothesised that the penumbra PK binding values would be significantly 
higher if microglia activation is involved in the pathogenesis of SVD, as these regions 
are the most likely place for new WMLs to form (Maillard et al., 2011).  
 
First, we investigated the PK binding in the penumbra between the sporadic SVD and 
control groups, and the CADASIL and control groups. The mean of the PK binding 
hotspots was significantly higher in the sporadic SVD penumbra compared to control 
(Figure 5.6). However, there was no significant difference between the groups for the 
volume of the hotspots or the global PK binding (Figure 5.5 and 5.7). There was no 
significant difference between CADASIL and control for any of the penumbra PK 
binding values. It was unclear as to whether the significant increase seen in the mean 
of the PK binding hotspots in the sporadic SVD group was because the penumbra had 
significantly higher microglia activation, or because the sporadic SVD brain was in a 
heightened inflammatory state more generally.   
 
Therefore, we then compared the penumbra PK binding values to the respective 
NAWM and WML values, within the individual groups. The global PK binding 
values showed a similar pattern across the different groups where the global PK 
binding in the penumbra was significantly lower than the global PK binding in the 
NAWM or the WML (Table 5.2). 
 
The mean values of the PK binding hotspots showed different trends in different 
groups. In the control group, the mean binding of the PK hotspot was significantly 
lower in the penumbra than in the NAWM values but significantly higher than in the 
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WML (Tables 5.2). In the sporadic SVD group, the mean binding of the PK hotspot 
was also significantly lower in the penumbra than in the NAWM, but was similar to 
the WML (Tables 5.2). In the CADASIL group, the penumbra values were similar to 
both the NAWM and WML (Tables 5.2).  
 
Finally, looking at the volume of the PK binding hotspots in the penumbra, there was 
a similar trend across all of the groups. The volume of the PK binding hotspots was 
significantly lower than in the NAWM, but significantly higher than the WML for all 
of the groups (Tables 5.2).  
 
We repeated this analysis with a 6mm penumbra, to see if that resulted in the same 
patterns as the 3mm penumbra. The patterns were similar across all analysis, and can 
be found in Appendix C.   
 
These results are slightly confusing, but suggest that in general, the penumbra of the 
WMLs have lower global PK binding than the NAWM or the WML. Whereas, the 
hotspot PK binding is lower than the NAWM but higher than the WML.   
 
Acute stroke studies have also investigated the penumbra around the infarct, where 
the importance of this region has been long established. A study of acute stroke found 
that on day 6 after acute infarct, there is a rim of increased PK binding around the 
infarct (Ramsay et al., 1992). However, this was not seen in all studies; a more recent 
study looking at patients in the sub-acute and early chronic stages after stroke found 
there was no significant increase in PK binding at these time-points, suggesting no 
significant increase in microglia activation in the penumbra region (Morris et al., 
2018). A study looking at the penumbra of intracerebral haemorrages 4-28 days after 
stroke also had confusing results, with some patients showing increased PK binding 
and others not (Abid et al., 2018). 
 
The results seen here are difficult to draw conclusions from. However, the lower 
global PK binding that was seen in the penumbra of all groups compared to the 
NAWM and WML suggests that there is less overall activated microglia in the WML 
penumbra. Taken together, the PK binding hotspot results suggests that the values 
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seen in the penumbra are generally higher than those in the WML, but lower than 
those in the NAWM. This may be due to partial volume effects, as resolution of PET 
imaging is poor and so a 3mm or 6mm penumbra may be too small to give accurate 
read-outs. A better option for exploring the penumbra of WMLs would probably be to 
look at post-mortem data, and to see if there are cells there that are positive for 
activated microglia. However, this still comes with limitations, as this would be 




5.4.6 Associations with WML Volume and MD  
The volume of the PK hotspots in the NAWM of the control group was associated 
with WML volume (Table 5.3). Further, the volume of the PK hotspots in the NAWM 
of the control group was significantly associated with a lower MD peak height in the 
WML. As discussed in Chapter Four, MD peak height is the most sensitive histogram 
parameter for SVD severity and progression, with a lower peak height representative 
of higher diffusivity and increased ultrastructural damage in the WM (Zeestraten et 
al., 2016). Therefore, this association suggests that a higher volume of inflammation 
in the NAWM is associated with increased WML volume and increased 
ultrastructural damage in the control subject WMLs. These associations were not 
evident in any of the other groups.  
 
The significant association in the control group, but not the sporadic SVD or 
CADASIL group, may be relevant if the control group can be seen as an 
asymptomatic ‘early SVD’ population, due to the fact that they are an elderly cohort. 
It could be that later down the line, the inflammatory mechanisms have become too 
complex due to the widespread damage, and therefore these associations become lost 
in the noise.  
 
As PK imaging has not been previously reported in relation to WML in an SVD or 
healthy elderly cohort, it is therefore difficult to put this finding into context. One 
study of MS patients found that there was a correlation between PK binding in the 
NAWM and WML volume (Giannetti et al., 2015) but, to the best of my knowledge, 
195 
 
there have been no other reports of this in the literature. Further, as this was the only 
significant association seen as a result of many analyses performed, this finding needs 
to be treated with caution and reproduced in a larger sample size to be confirmed.   
 
 
5.4.7 Associations with Lacunes, CMBs, Brain Volume and FA  
There was no association between PK binding and lacune volume (Table 5.4), lacune 
number (Table 5.5), CMB number (Table 5.6), brain volume (Table 5.7), GM volume 
(Table 5.8) or any of the FA parameters (Tables 5.9, 5.19, 5.15 and 5.16) in any of the 
groups. This would suggest that microglia activation is not involved in the underlying 
pathology leading to these imaging characteristics. Alternatively, it may be that there 
is a temporal relationship between microglia activation and these parameters (i.e. one 
predicts another) and a single time-point analysis, as we have done in this study, is not 
able to see this relationship. Longitudinal studies are required to investigate if there is 
a temporal relationship between microglia activation and these imaging parameters.  
 
 
5.4.8 Association with Cognition 
PK binding was not associated with GC in any of the groups (Table 5.19). Further, 
when investigating the individual cognitive indices, there was no correlation between 
cognition and EF (Table 5.20), PS (Table 5.21), WoM (Table 5.22) or LTM (Table 
5.23) in any of the groups.  
 
PK binding and cognition have been previously studied in Alzheimer’s disease and 
mild cognitive impairment, where there was also found to be no correlation with 
cognitive function (Schuitemaker et al., 2013, Okello et al., 2009). However, when 
analysing regions in more detail, one study did find an association between MMSE 
and PK binding in the posterior cingulate gyrus, parietal and frontal cortical regions 
(Edison et al., 2008), whilst another found an association between LTM and PK 
binding in the precuneus (Passamonti et al., 2018). Further, a recent study used PK 
PET and functional MRI to establish a relationship between increased PK binding and 
disruption of network function (Passamonti et al., 2019). Passamonti et al. showed 
that, in Alzheimer’s disease, patients with a higher association between these two 
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parameters had decreased cognitive function. This suggests that microglia activation 
may be mediating cognition through decreased functional connectivity of networks.  
 
Our results suggests that there is no direct association between cognition and 
microglia activation cross-sectionally. However, there could be a longitudinal 
association where microglia activation is causative of underlying damage, leading to a 
greater decline in cognition over time. Follow-up studies are needed to see if baseline 




The use of PK imaging to provide in vivo quantification and localisation of 
neuroinflammation in patient populations offers great scope of application, to further 
our understanding of the role of microglia activation across many diseases. A key 
limitation of this study is the lack of previous studies investigating PK imaging in 
SVD, as this has meant we could not compare our results to previous literature and 
have no repeat scanning, so do not know how reproducible these values are.  
 
PK imaging itself is not without limitations, the key ones being low brain 
bioavailability and poor signal-to-noise due to high nonspecific binding (Largeau et 
al., 2017). Further, the short half-life of carbon-11 means that the tracer must be 
produced just before required. This brings a certain amount of unpredictability into 
the study, as the tracers can fail last minute or not pass quality control. 
 
Another important limitation of PK is that it is non-specific for activated microglia, as 
TSPO is expressed by multiple types of immune cells including astrocytes (Lavisse et 
al., 2012). It is impossible to differentiate between these cell types during the PK 
imaging. So, although many studies reference ‘activated microglia’ when discussing 
PK results, really the results may also be representative of other cell types.  
 
Further, inflammation itself is a very dynamic process and PK imaging only supplies 
us with a snapshot of this process. Repeat scanning is necessary to track the dynamics 




In addition to these, there are other limitations that are general to PET imaging, that 
must be kept in mind when designing a study and interpreting the results. To quantify 
the data, a reference region is required to be able to calculate the ligand binding 
relative to the reference region (Alam et al., 2017). In states of disease, there often is 
no brain region free from pathology, and therefore it can be difficult to find an 
appropriate reference region for this purpose. Therefore, techniques vary between 
studies (Airas et al., 2015) and this needs to be kept in mind when evaluating and 
comparing the literature.  
 
PET imaging also has notoriously poor spatial resolution, which makes it difficult to 
image small brain regions and leads to issues with partial volume. With improving 
technology, the spatial resolution of PET should continue to improve. However, due 
to the fundamental physics of PET cameras, the spatial resolution will always be 
limited (Moses, 2011).  
 
Other general PET limitations include cost and patient willingness to participate. The 
cost of PET tracers and scanner time is high, and means that studies often end up with 
a relatively low sample size that can make results difficult to interpret. Finally, the 
reality that PET involves a radioactive injection that leads to an increased risk of 
cancer makes it imperfect for use in research studies and can make it difficult to 




5.5 Summary of Findings 
 
Returning to the aims of this chapter, the following areas have been addressed:  
 
1. Global PK binding was not significantly different in the sporadic SVD or 
CADASIL groups compared to control in the WM, NAWM or WML 
2. The mean of the PK binding hotspots was significantly higher in the WM, 
NAWM and WML of the sporadic SVD patients compared to control; the 
volume of the PK binding hotspots was also significantly higher in the 
NAWM and WML of the sporadic SVD group compared to control 
3. The mean of the PK binding hotspots was significantly higher in CADASIL 
group compared to control in the WM and WML; the volume of the PK 
binding hotspots was significantly higher in the WML 
4. Global PK binding in the penumbra was lower than in the NAWM or WML 
across all of the groups 
5. Hotspot PK binding in the penumbra was generally lower than NAWM but 
higher than in the WML across the groups 
6. PK binding volume in the NAWM of the control group was associated with 
increased WML volume and decreased MD peak height in the WML, 
suggesting increased WML severity is associated with increased volume of 
microglia activation elsewhere 
7. PK binding was not associated with any of the cognitive parameters in any of 
the groups 
 
This chapter has investigated PK binding between the groups and in comparison to 
the other end-points collected in the study. The next chapter will investigate the 




Chapter 6: Relationship between BBB permeability 




6.1.1 Aims of the Chapter 
The previous chapters explored BBB permeability and PK binding separately, by 
comparing them between the patient and control groups, and also exploring the 
relationship with imaging and cognitive markers. This chapter now looks at the 
relationship between BBB permeability and PK binding and investigates the 
following specific questions:  
• Is there a correlation between BBB permeability and PK binding in the 
control, sporadic SVD and CADASIL groups?  
• Is there a significant difference in the spatial distribution of BBB permeability 
and PK binding between groups?  
• Is there an association between the spatial overlap of BBB permeability and 
PK binding in individual groups?  
 
The main hypotheses of this chapter are:  
• BBB permeability and PK binding will be significantly correlated in the 
sporadic SVD, CADASIL and healthy control groups 
• There will be a significant spatial overlap between regions of increased BBB 




6.1.2 Hypothesised Mechanism of BBB Permeability and Inflammation 
The evidence for the presence of increased BBB permeability and PK binding in SVD 
were outlined in Chapters 4 and 5. However, we have not yet investigated the 
relationship between BBB permeability and PK binding. The hypothesised cascade of 
events linking BBB permeability and inflammation to SVD pathophysiology can be 




The full hypothesised mechanism underlying the pathogenesis of SVD can be found 
in Chapter One. However, briefly, underlying pathology of the small vessels is 
thought to trigger an inflammatory response through up-regulation of HIF-1α 
(Rosenberg, 2018). HIF-1α then leads to a recruitment of macrophages and activation 
of microglia. These cells release proteases and free radicals in the process of 
remodelling the damaged vessels. These free radicals and proteases then break down 
the fibrotic basal lamina, disrupt tight junction proteins to lead to increase in BBB 
permeability, and attack myelinated fibres.  
 
 
6.1.3 Evidence for BBB Permeability and Inflammation in the Pathogenesis of SVD 
Animal studies of SVD, where SHR/SP rats undergo unilateral carotid artery 
occlusion and are fed a low protein high salt diet to induce WMLs and cognitive 
deficits, have investigated the link between BBB permeability and inflammation in 
more detail (Jalal et al., 2012, Kaiser et al., 2014).  
 
The WMLs in these rats contain reactive astrocytes and activated microglia (Jalal et 
al., 2012). Additionally, these rats are seen to have increased BBB permeability and 
decreased tight junction proteins in the vascular endothelial cells (Yang et al., 2018). 
Taking this further, co-labelling of MMP-9 and immunoglobulin G found they were 
localised to similar regions, suggesting MMP-9 may be associated with BBB 
disruption (Jalal et al., 2015).  
 
Jalal et al. found that treatment with minocycline, an anti-inflammatory agent with 
many actions including MMP-9 inhibition, led to significantly reduced WML size and 
improved cognition (Jalal et al., 2015). Minocycline almost entirely blocked BBB 
leakage and enhanced the protein levels of the tight junctions, facilitating repair 
(Yang et al., 2018). Interestingly, more recent studies have used MMP-9 specific 
drugs and found that they do not have this ability of minocycline (Raz et al., 2018). 
Therefore, it has now been suggested that the beneficial action of minocycline may 
not be through MMP-9 specifically, but through a broader effect on inflammation 
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involving suppression of microglia (Giuliani et al., 2005) or through multiple MMPs 
(Jin et al., 2013, Machado et al., 2006).  
 
These animal studies provide evidence for BBB permeability and inflammation in the 
pathogenesis of SVD, resulting in damage to the WM that leads to WML formation 
and cognitive deficits. They suggest that broader inflammatory mechanisms need to 
be examined, to understand the protective effects of minocycline that have been seen 





There were 16 controls, 15 sporadic SVD and 13 CADASIL who received both BBB 
permeability and PK PET imaging and so were included in this chapter. Most of the 
methodology was described in Chapter 2.  
 
 
6.2.1 Voxel-based Analysis 
Binary maps were created of voxels of significant BBB permeability and PK binding 
by thresholding the data, as described previously to generate the hotspot maps. To 
create the overlap maps, these binary maps were then added to produce maps of 
overlap voxels, voxels with just BBB permeability, voxels with just PK binding and 
voxels with neither BBB permeability nor PK binding. The total number of voxels in 
the WM, NAWM and WML were then extracted.  
 
 
6.2.2 Statistical Analysis 
Spearman’s rank correlation test was used to test all of the correlations between BBB 
permeability and respective PK binding values. P values were adjusted for multiple 
comparisons using FDR.  
 
Chi squared tests were then used to assess the homogeneity of the permeability and 
PK binding on a voxel-by-voxel basis for all regions of all groups. The test of 
homogeneity investigates the distributions, to see if the frequency of overlap voxels, 
permeability voxels, PK binding voxels and voxels with neither permeability nor PK 
binding follows a similar distribution across the groups.  
 
Chi squared tests were then again used to assess the independence of BBB 
permeability and PK binding on a voxel-by-voxel basis for all regions for all groups, 
except for the WML of the control group. The WML of the control group had an 
expected frequency of <5 in one of the cells, and therefore did not meet the 






6.3.1 Correlation between BBB Permeability and PK binding 
Correlation matrices of BBB permeability and PK binding associations can be seen in 
Tables 6.1-3. Table 6.1 shows the associations in the WM, Table 6.2 shows 
associations in the NAWM and Table 6.3 shows associations in the WML. There 








Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.43 0.07 0.22 
Hotspot mean 0.41 0.22 0.27 





Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.3 0.24 -0.01 
Hotspot mean 0.28 0.57 0.28 





Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.25 -0.37 -0.19 
Hotspot mean 0.52 -0.12 0.29 
Hotspot volume 0.04 -0.27 -0.27 
*p<0.05, **p<0.01, ***p<0.001 
 
Table 6.1: Correlation matrices of Spearman’s Rho values for associations between 
BBB permeability and PK binding parameters in the WM. 1) Control. 2) Sporadic 






Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.36 0.08 0.18 
Hotspot mean 0.36 0.19 0.25 
Hotspot volume 0.39 0 0.1 
 
B 
Sporadic SVD PK 
Global mean Hotspot mean Hotspot volume 
BBB 
Global mean -0.05 0.25 -0.18 
Hotspot mean -0.3 0.39 0.15 





Global mean Hotspot mean Hotspot volume 
BBB 
Global mean -0.41 -0.13 -0.24 
Hotspot mean 0.11 0.02 0.14 
Hotspot volume -0.38 0.03 -0.19 
*p<0.05, **p<0.01, ***p<0.001 
Table 6.2: Correlation matrices of Spearman’s Rho values for associations between 
BBB permeability and PK binding parameters in the NAWM. 1) Control. 2) Sporadic 








Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.18 0.32 0.24 
Hotspot mean 0.06 0.33 0.29 





Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.28 -0.52 -0.52 
Hotspot mean 0.4 -0.33 -0.4 





Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.59 -0.6 -0.58 
Hotspot mean 0.25 -0.64 -0.41 
Hotspot volume 0.46 -0.44 -0.41 
*p<0.05, **p<0.01, ***p<0.001 
Table 6.3: Correlation matrices of Spearman’s Rho values for associations between 
BBB permeability and PK binding parameters in the WML. 1) Control. 2) Sporadic 





6.3.2 Distribution of BBB permeability PK binding Voxels 
Example images of the regions of increased BBB permeability and PK binding are 
shown in Figure 6.2. 
 
The distribution of the voxels are shown as percentages for each of the groups for the 
WM (Figure 6.3), NAWM (Figure 6.4) and WML (Figure 6.5). Tests of homogeneity 
showed a significant difference in the distribution of the voxels between the groups in 






Figure 6.2: Example images of permeability (blue) and PK hotspots (red) overlayed 







Figure 6.3: Distributions of the voxels in the WM for each group, displayed as a 
percentage. The control group was made up of 0.14% overlap, 2.61% BBB, 4.54% 
PK binding and 92.59% neither. The sporadic SVD group was made up of 0.46% 
overlap, 9.83% BBB, 5.98% PK binding and 83.3% neither. The CADASIL group 
was made up of 0.19% overlap, 6.47% BBB, 5.05% PK binding and 88.12% neither. 





Figure 6.4: Distributions of the voxels in the NAWM for each group, displayed as a 
percentage. The control group was made up of 0.14% overlap, 2.66% BBB, 4.71% 
PK binding and 92.35% neither. The sporadic SVD group was made up of 0.71% 
overlap, 11.31% BBB, 8.34% PK binding and 78.87% neither. The CADASIL group 
was made up of 0.27% overlap, 6.93% BBB, 7.77% PK binding and 84.76% neither. 






Figure 6.5: Distributions of the voxels in the WML for each group, displayed as a 
percentage. The control group was made up of 0.01% overlap, 1.83% BBB, 0.61% 
PK binding and 97.53% neither. The sporadic SVD group was made up of 0.31% 
overlap, 9.59% BBB, 2.22% PK binding and 87.93% neither. The CADASIL group 
was made up of 0.07% overlap, 3.40% BBB, 2.15% PK binding and 94.31% neither. 





6.3.3 Overlap Analysis of BBB permeability and PK binding Voxels 
Tests of independence were used within the groups, to see if there was a significantly 
different distribution of voxels compared to chance.  
 
In the control group, there was no significant difference from chance for the 
distribution of the voxels in the WM, NAWM or the WML (Table 6.4).  
 
In the sporadic SVD group, the number of voxels with both significantly high 
permeability and inflammation was significantly lower than expected by chance in the 
WM (p<0.001), NAWM (p<0.001) and WML (p<0.001) (Table 6.5).  
 
In the CADASIL group, the number of voxels with both significantly high 
permeability and inflammation was significantly lower than expected by chance in the 
WM (p<0.001) and NAWM (p<0.001) (Table 6.6). However, there was no significant 




 Inflammation No inflammation Total 
Permeability 908 (858) 16400 (16450) 17308 
No permeability 28562 (28612) 548812 (548762) 577374 
Total 29470 565212 594682 
 
B 
 Inflammation No inflammation Total 
Permeability 904 (861) 15976 (16019) 16880 
No permeability 28194 (28237) 525415 (525372) 553609 
Total 29098 541391 570489 
 
C 
 Inflammation No inflammation Total 
Permeability 4 (4) 424 (424) 428 
No permeability 198 (198) 19467 (19467) 19665 
Total 202 19891 20093 
 
Table 6.4: Contingency tables of observed (expected) values for the number of voxels 
with significant permeability and PK binding in the control group. A) WM (p=0.074). 






 Inflammation No inflammation Total 
Permeability 4191 (5454) 62007 (60744) 66198 
No permeability 45966 (44703) 496583 (497846) 542549 
Total 50157 558590 608747 
 
B 
 Inflammation No inflammation Total 
Permeability 4019 (5845) 51315 (49489) 55334 
No permeability 38252 (36426) 306556 (308382) 344808 
Total 42271 357871 400142 
 
C 
 Inflammation No inflammation Total 
Permeability 256 (335) 10608 (10529) 10864 
No permeability 4883 (4804) 151019 (151098) 155902 
Total 5139 161627 166766 
 
Table 6.5: Contingency tables of observed (expected) values for the number of voxels 
with significant permeability and PK binding in the sporadic SVD group. A) WM 






 Inflammation No inflammation Total 
Permeability 1052 (2188) 32828 (31692) 33880 
No permeability 35060 (33924) 490291 (491427) 525351 
Total 36112 523119 559231 
 
B 
 Inflammation No inflammation Total 
Permeability 931 (2321) 24727 (23337) 25658 
No permeability 28861 (27471) 274888 (276278) 303749 
Total 29792 299615 329407 
 
C 
 Inflammation No inflammation Total 
Permeability 215 (234) 8007 (7988) 8222 
No permeability 6905 (6886) 235518 (235537) 242423 
Total 7120 243525 250645 
 
Table 6.6: Contingency tables of observed (expected) values for the number of voxels 
with significant permeability and PK binding in the CADASIL group. A) WM 







This chapter has shown that there is no relationship between the amount of BBB 
permeability and PK binding present. There was no significant spatial overlap in 
regions of significant BBB permeability and PK binding in the control group. 
However, in the sporadic SVD and CADASIL groups, the spatial locations of BBB 
permeability and PK binding are significantly distinct from one another in the whole 
WM and NAWM.   
 
 
6.4.1 Correlating BBB permeability and PK binding 
Associations between the BBB permeability and PK binding values were performed 
and displayed for the WM (Table 6.1), NAWM (Table 6.2) and WML (Table 6.3). 
There were no associations seen between any of the parameters in any of the groups.  
 
Correlations were also explored between the BBB permeability and PK binding 
values for all of the groups combined, shown in Appendix D. This did find one 
significant correlation between the global PK binding and the mean value of the BBB 
permeability hotspots in the WM (Table D.1). However, no other correlations were 
seen and so it is likely that this was simply due to chance.  
 
The lack of correlations was surprising, as we expected that patients with more severe 
disease would have increased PK binding and BBB permeability, which would mean 
the two parameters would correlate with one another. However, it seems the 
relationship is not as linear as expected.  
 
It is difficult to put these findings into context of the literature, as PK binding for 
microglia activation and DCE-MRI for BBB permeability have not before been 
reported in an SVD population. Studies have investigated biomarkers of BBB 
permeability and inflammation SVD. However, only a very limited number have 
correlated these outcomes together, as most correlate instead with disease progression 
(Cipollini et al., 2019). Staszewski et al. used ICAM-1, a marker of endothelial 
inflammation, which could be considered a surrogate marker of BBB permeability; 
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they found a correlation with the inflammatory marker PF4, but not IL-1, TNF-α, IL6 
or CRP (Staszewski et al., 2019). This study therefore also suggests that the cross-
sectional relationship between BBB permeability and inflammation may not be linear. 
However, this study used blood biomarkers rather than neuroinflammatory markers 
and therefore only has limited similarities to our study.  
 
PK binding and DCE-MRI has been investigated in acute intracerebral haemorrhage, 
where again, there was not a clear relationship between PK binding and permeability 
(Abid et al., 2018). Abid et al. found a consistent increased BBB permeability around 
the haematoma, but microglia activation only present in this region in some of the 
patients. This suggests that microglia activation is a dynamic process, which may 
have fast-moving timescales after stroke.  
 
Larger studies in this area that investigate both the temporal and spatial overlap 
between inflammation and BBB permeability are needed to help understand the 
underlying pathophysiology of SVD. The latest developments in PET/MR technology 
have now made it possible to visualise these two processes in the same patients, and 
these techniques now need to be utilised for longitudinal follow-up of patients to 




6.4.2 BBB permeability and PK binding Distributions 
There was a significant difference in the spatial distributions of the voxels across the 
different groups in the WM (Figure 6.3), NAWM (Figure 6.4) and WML (Figure 6.5).  
 
The distribution of voxels followed a similar pattern to that seen in Chapters 4 and 5, 
where sporadic SVD and CADASIL had a higher volume of BBB permeability and 
PK binding, compared to control. Therefore, there were a higher number of voxels 
with significant BBB permeability and PK binding in the sporadic SVD and 
CADASIL groups, compared to control. This then means that we would expect to see 
a higher number of overlap voxels in the sporadic SVD and CADASIL groups 
compared to control, just by chance. Therefore, just because the relative number of 
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overlap voxels is higher in sporadic SVD and CADASIL groups, it does not mean that 
we can conclude that there is a spatial relationship between BBB permeability and PK 
binding in disease. A test that explores the spatial independence of BBB permeability 
and PK binding voxels from one another within each group is required to see if the 
amount of overlap voxels is significantly different from chance.  
 
 
6.4.3 Spatial Analysis of BBB permeability and PK binding 
Within each group, we analysed the distribution of overlap voxels, just BBB 
permeability voxels, just PK binding voxels and voxels with neither PK binding nor 
permeability, to see if the number of overlap voxels was equivalent to that expected 
by chance. In the control group, we found that there was no significant overlap, and 
therefore the spatial distribution of BBB permeability and PK binding was no 
different to chance in the WM, NAWM and WML (Table 6.4). However, in the 
sporadic SVD group, we found that there was significantly less overlap then you 
would expect by chance in the WM, NAWM and WML (Table 6.5). This finding was 
mirrored by the CADASIL group in the WM and NAWM, although the WML was 
not significantly different from chance (Table 6.6).  
 
This finding is very interesting and unexpected, and suggests that the two processes 
are spatially distinct from one another. As the data here is cross-sectional, it could be 
that the activated microglia and increased BBB permeability occur at distinct stages 
of the pathological process, and so when taking a cross-sectional snapshot, you only 
see one of the pathologies, as it evolves through the mechanistic pathway over time. 
Both BBB permeability and microglia activation are both thought to be highly 
dynamic processes, although the detailed timescale of these dynamics has not been 
investigated (Shi and Wardlaw, 2016). Further follow-up scans are required to 
determine the timescale of voxels and whether they can transition from an 
inflammatory to permeability state, and vice versa, and whether permeability or 
inflammatory voxels eventually become WML.   
 
Another explanation could be that, due to the anatomy of the brain, microglia 
activation does not occur near regions of BBB permeability, so even though they were 
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involved in the same pathological cascade, they could communicate through 
signalling proteins but remain spatially distinct from one another. Post-mortem 
studies have looked at investigating these pathologies together. A recent study 
showed that vascular bagging, where the space between the vessel wall and external 
collagenous membrane of small vessels becomes widened due to BBB leakage, and 
activated microglia were both present throughout the WMLs and in the neighbouring 
WM areas (Forsberg et al., 2018). Microglia were found to be particularly 
concentrated around damaged vessels, whilst vascular bagging was found more 
generally throughout the brain, with Forsberg et al. hypothesising it developed in the 
frontoparietal and temporal WM primarily. As increasingly high resolution imaging 
techniques develop, it should become more accessible to image these pathologies in 
vivo and localise them both anatomically and functionally.  
 
The final option could be that the two pathologies are unrelated in SVD. This would 
contradict the previous animal studies, but may be the case if a pathological 




The largest technical limitation of this study was the resolution of the images, which 
had a voxel size of 2.0 x 2.0 x 3 mm. At this resolution, we cannot measure these 
processes on a cellular level, and so are incorporating thousands of cells into every 
voxel, making it a crude measurement of the underlying processes. The cross-
sectional nature of this study also limits the interpretation of the data, as we cannot 
know if these proposed pathological processes are causative of one another, or of 
damage to the WM.  
 
As imaging techniques and technology improve, higher resolution scans will likely 
become available that will be able to investigate this process in more detail. High-
resolution longitudinal imaging studies are needed to monitor the dynamics of 
microglia activation and BBB permeability in SVD, and the progression to WML and 
clinical symptoms, to understand if these mechanisms are involved in the pathological 
processes underlying the disease. 
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6.5 Summary of Findings 
 
Returning to the aims of this chapter, the following areas have been addressed: 
 
1. The amount of BBB permeability and PK binding were not significantly 
correlated  
2. The distribution of voxels was significantly different between groups, with a 
higher proportion of BBB permeability and PK binding voxels in the sporadic 
SVD and CADASIL groups compared to control 
3. In the control group, the number of overlap voxels (with both significant 
permeability and PK binding) was no different to chance 
4. In the sporadic SVD and CADASIL groups, the number of overlap voxels was 
significantly lower than chance would suggest in the WM and NAWM; in the 
sporadic SVD, this pattern also exists in the WML 
 
This chapter has explored the relationship between BBB permeability and PK 
binding, and the spatial overlap between the two. The next chapter will investigate 





Chapter 7: Blood Biomarkers in SVD and their 




7.1.1 Aims of the Chapter 
The previous chapters have explored BBB permeability and PK binding separately in 
relation to imaging markers and cognitive markers, and also in relation to one another. 
This chapter will investigate various serum biomarkers and explore differences 
between groups and the relationship between the biomarkers and BBB permeability 
and PK binding. The biomarkers studied in this chapter fall into the categories of 
inflammatory markers, MMPs and endothelial cell activation markers. This chapter 
will address the following specific questions:  
• Are blood biomarkers increased in SVD patients compared to controls?  
• Are blood biomarkers increased in CADASIL patients compared to controls?  
• Are blood biomarkers associated with increased permeability, quantified from 
DCE-MRI?  
• Are blood biomarkers associated with increased microglia activation, 
quantified from PET PK binding?  
 
Exploratory hypotheses in this chapter are:  
• Biomarkers will be increased in sporadic SVD patients and CADASIL 
patients compared to controls  
• MMPs and markers of endothelial cell activation will be associated with 
increased BBB permeability 
• Markers of inflammation will be associated with increased PK binding  
 
 
7.1.2 Blood Biomarkers 
Blood biomarkers provide simple measures that can be used in research as clinical 
trial end-points and in the clinic for diagnosis and tracking of disease progression 
(Kamtchum-Tatuene and Jickling, 2019), whilst also helping to further understand the 
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pathogenesis of a disease. Biomarker techniques tend to use labelled antibodies to tag 
the protein of interest and give a readout, which can then be quantified (Nimse et al., 
2016). In the field of neurology, the relevance of blood biomarkers is debatable, as 
blood biomarkers are a reflection of systemic processes and may not be representative 
of what is happening in the CNS (Polivka et al., 2016).  
 
There is a complex mechanistic pathway involved in the underlying pathology of 
SVD, which has not been fully characterised. There has been shown to be an 
inflammatory response involving microglia, neurons, astrocytes and endothelial cell 
release of pro-inflammatory markers (Rosenberg, 2018). This triggers inflammatory 
cascades both within the brain and within the vessel walls, leading to a breakdown in 
BBB integrity, which increases its permeability. Therefore, markers of this cascade 
may be present systemically.  
 
The pathogenesis is easiest to be explored in animal models, where pathways and 
processes can be easily manipulated and measured (Chesselet and Carmichael, 2012). 
Much of the current literature has focused on ischaemic events to investigate 
neuroinflammation (Kawabori and Yenari, 2015). The literature tends to focus on 
either focal ischaemia, such as the result of a stroke, or global ischaemia, such as the 
result of a heart attack (Traystman, 2003). There is also literature on 
neurodegenerative disorders, such as Alzheimer’s disease and MS (Chen et al., 2016). 
Focal acute mechanisms are relevant to SVD pathology as SVD is associated with 
lacunar stroke from acute blockage of the small vessels. However, the mechanisms 
are likely to be more complex in SVD, as SVD is also associated with chronic 
hypoxia due to small vessel damage, which may be more related to the global 
ischaemic and neurodegenerative mechanisms. This introduction will review the key 
neuroinflammatory mechanisms from the literature that have the most relevance to 




During acute ischaemia, cells become hyperactive or die, resulting in a release of 
glutamate and excitotoxicity (Terasaki et al., 2014). Excitotoxicity in chronic 
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ischaemia, such as SVD, has not been studied as widely as acute ischaemia. However, 
evidence suggests that chronic ischaemia also leads to an increase in glutamate, and 
that even a 10% increase in glutamate is enough to activate pathological cascades 
(Lewerenz and Maher, 2015)  
 
ROS are released from the brain and immune cells in response to excitotoxicity, 
leading to oxidative stress. An inflammatory response is also triggered both centrally 
and peripherally; microglial activation in the brain triggers various inflammatory 
cascades, opening the BBB and allowing activated blood-borne immune cells, such as 
neutrophils and T-cells, to infiltrate.  
 
Pro-inflammatory cytokines TNF-α, interleukin 1 (IL-1) and interleukin 6 (IL-6) are 
all released by activated cells including neurons, astrocytes, microglia and endothelial 
cells (Yang and Rosenberg, 2015, Doll et al., 2014). This can also trigger a wider 
systemic inflammatory response throughout the body.  
 
TNF-α precursor is membrane bound and cleaved by TNF-α converting enzyme 
(TACE) to release the soluble form of TNF-α that can bind to TNFR1 or TNFR2 (Liu 
et al., 1996). Virtually all cell types and tissues express TNFR1, which has an 
intracellular death domain, in which the adaptor protein TNFR-associated death 
domain protein (TRADD) can interact and elicit signalling for cell death or cell 
survival through recruitment of other adaptor proteins such as caspase-8 and FAS 
(Pobezinskaya and Liu, 2012). TNFR2 is mostly linked to the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) mediated inflammatory pathway 
(Rothe et al., 1995). Activation of the NF-κB pathway is commonly used as an 
indicator of inflammation in ischaemic stroke studies (Majid, 2014). Therefore, TNF-
α can lead to cell death and inflammation, depending on which receptor it is bound to 
and which cascades are activated.  
 
IL-1 exists as a family of 11 members, but IL-1α and IL-1β are the most important in 
the context of stroke (Sobowale et al., 2016). Both IL-1α and IL-1β are created as 
precursor proteins, which undergo cleavage into their active forms. IL-1α has some 
biological activity in its precursor state, whereas IL-1β is biologically inactive until it 
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is cleaved by caspase-1 (Thornberry et al., 1992). Both IL-1α and IL-1β produce their 
biological effects through binding to IL-1R1 which associates with the IL-1R1 
accessory protein (IL-1RAcP) and initiates intracellular signalling (Korherr et al., 
1997). IL-1 can also potentiate inflammation by activating microglia, increasing 
leukocyte infiltration and increasing breakdown of the BBB.  
 
Another important member of the IL-1 family in the context of stroke is IL-18. IL-18 
is a pro-inflammatory cytokine acting in both acquired and innate immunity and 
playing a crucial role in the inflammatory cascade (Yuen et al., 2007). IL-18 is also 
related to the atherosclerotic plaque propagation and instability. IL-18 acts as a 
modifier for the immune response through inducing cytokine gene expression and T 
helper cell differentiation, activating natural killer cells (Sedimbi et al., 2013).  
 
IL-6 is an interleukin that can have both pro-inflammatory and anti-inflammatory 
effects (Rothaug et al., 2016). IL-6 induces the hepatic acute phase response and is 
involved in lymphocyte and monocyte differentiation. IL-6 is an activator of the Janus 
Kinase (JAK)/signal transducer and activator of transcription (STAT) signalling 
pathway, which has many effects including increasing astrogliosis and angiogenesis 
for tissue remodelling and recovery after ischaemia (Erta et al., 2012). Other IL-6 
mechanisms include inhibiting TNF-α, inducing apoptosis in neutrophils and 
recruiting monocytes and T-cells (Marz et al., 1996).  
 
CHI3L1, also known as YKL-40, is a plasma protein produced by various cell-types 
including macrophages, vascular smooth muscle cells and some types of cancer cells 
(Kazakova and Sarafian, 2009, Renkema et al., 1998, Schultz and Johansen, 2010, 
Shao, 2013). The precise function of CHI3L1 is not fully understood, but it is thought 
to be involved in tissue remodelling during inflammation and in the angiogenic 
processes mediating infiltration, differentiation and maturation of macrophages and is 
therefore considered a marker of inflammation (Shao, 2013, Rathcke and Vestergaard, 
2009, Rehli et al., 2003, Rehli et al., 1997). It was originally thought to only be 
associated with macrophages, but recent studies suggest it is abundant in astrocytes 
and microglial cells also, making it a key player in neuroinflammation (Bonneh-




Inflammation in the CNS and vasculature can trigger a global inflammatory response 
seen by generic markers of inflammation. CRP is a biomarker of systemic 
inflammation, secreted by hepatocytes in response to cytokines, such as IL-6, IL1 and 
TNF-α (Chandra et al., 2014). CRP is not disease specific but is a sensitive marker 





Microglia, macrophages, infiltrating neutrophils, TNF-α and IL-1β are all involved in 
the transcription of MMPs. MMPs are a family of 26 extracellular and intracellular 
matrix-degrading enzymes that are important in development, tumour growth, brain 
development and injury (Rosenberg, 2016). In recent years, MMPs have become a 
point of interest for ischaemic stroke, after studies revealed that they have an 
important role in acute ischaemia (Yang and Rosenberg, 2015). Interest in MMPs in 
neurodegenerative disorders has also increased recently, with a role for them 
established in Alzheimer’s disease, Parkinson’s disease, ALS, Huntington’s disease 
and MS (Brkic et al., 2015).   
 
Extracellular matrix is the primary site of MMP action, but they are also involved in 
releasing molecules from the cell surface, cell signalling and cell death (Yong, 2005). 
MMPs act at several sites in the neurovascular unit, regulating the permeability of the 
BBB. Their major site of action is on the proteins in the basal lamina and the tight 
junction proteins, but studies indicate they can also act intracellularly (Yang et al., 
2007, Yang et al., 2010). Tissue inhibitors of metalloproteinases (TIMPs) are 
endogenous inhibitors of MMPs and, to date, four of them have been identified (Brew 
and Nagase, 2010). Once MMPs are activated, they are generally rapidly inactivated 
by a series of mechanisms that mainly involve the four TIMPs (Yang and Rosenberg, 
2015). 
 
MMP-2 and MMP-14 are constitutive enzymes, present in latent forms under normal 
conditions, which are initially activated in hypoxic/ischaemic injury (Yong et al., 
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2001). MMP-2 and MMP-14 are present in brain cells, particularly in astrocytes 
where the foot processes are connected to the endothelial cells (Yang and Rosenberg, 
2015). The activation of the constitutive enzymes is strictly controlled in a spatially 
specific manner, close to the site of activation. The biological basis for this is that 
MMP-2 and MMP-14 are activated in a trimolecular complex with metalloproteinase 
inhibitor-2 (TIMP-2). MMP-14 is bound to the membrane and therefore the activated 
MMP-2 is also connected to the membrane so the activity of the enzyme is 
constrained to the region close to the activation site and prevents MMP-2 doing 
extensive damage. MMP-2 initiates disruption of the basal lamina proteins and 
opening of the tight junction proteins, increasing permeability of the BBB (Yang et 
al., 2007). If the hypoxic stress is short-lived and there is no further MMP activation, 
then this initial phase is reversible and there can be a restoration of the basal lamina 
integrity (Rosenberg, 2016).  
 
If hypoxia progresses, as it is thought to do in SVD, the inducible enzymes of MMP-3 
and MMP-9 are released and activated (Yang and Rosenberg, 2015). The inducible 
enzymes have a much wider spread effect and are not constrained to only act close to 
the site of action, so this can lead to more extensive tissue damage. Microglia, 
macrophages and infiltrating neutrophils are the primary sources of MMP-3 and 
MMP-9. Cytokines activate the transcription sites leading to the formation of latent 
forms of the inducible enzymes, and then nitrosylation and other free radicals lead to 
their activation. This leads to major irreversible damage to the cerebral vessels with 
vasogenic oedema. Matrix metalloproteinase-8 (MMP-8) and matrix 
metalloproteinase-13 (MMP-13) are also involved in injury cascades (Cuadrado et al., 
2009), with MMP-8 having a critical role in mediating microglial activation through 
modulation of TNF-α activity (Yang and Rosenberg, 2015). Both MMPs and 
cytokines may be expressed in the blood during an inflammatory response to injury 
and infection.  
 
 
7.1.5 Endothelial Cell Activation 
Endothelial cells make up a key component of the BBB, with particular importance 
given to their tight junctions. Markers of endothelial cell activation have been 
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measured and seen to increase in ischaemic stroke (Cherian et al., 2003), 
neurodegeneration (Maiuolo et al., 2018) and SVD specifically (Poggesi et al., 2016). 
Markers of endothelial cell activation are predominantly cellular adhesion molecules.  
 
Tight junctions are a key to the function of endothelial cells and the BBB. Tight 
junctions consist of three integral membrane proteins: claudin, occluding and 
junctional adhesion molecules (JAM), as well as several cytoplasmic accessory 
proteins including ZO-1, cingulin, CDH5, platelet endothelial cell adhesion molecule-
1 (PECAM-1), activated leukocyte cell adhesion molecule (ALCAM), ICAM-1 and 
vascular cell adhesion molecule 1 (VCAM-1) (Yu et al., 2015). These proteins are 
key to seal the cell-cell contacts of endothelial cells and therefore have an important 
role in BBB permeability (Luissint et al., 2012). 
 
During injury, one of the most important events is the adhesion of leukocytes to the 
endothelium, which precedes their emigration to the tissues and is central to the 
inflammatory process (Panés et al., 1999). The recruitment of leukocytes and platelets 
in the cerebral microvascular is widely regarded as a rate-limiting step in the 
inflammatory response associated with cerebral hypoxia/ischaemia (Yilmaz and 
Granger, 2008). In response to hypoxia/ischaemia (or other inflammatory insult), the 
cerebral endothelium expresses high levels of adhesion molecules to recruit large 
numbers of leukocytes. The interaction appears to be largely mediated by P-selectin 
expressed on endothelial cells, which engages with circulating cells (Ishikawa et al., 
2003). Firm adhesion is then mediated by an interaction between ITGB2 on 
leukocytes with ICAM-1 on cerebral endothelial cells (Liu and Kubes, 2003). Studies 
of acute ischaemia have shown that P-selectin upregulation occurs as early as 15 
minutes following ischaemic insult, with increased E-selectin expression occurring 
within 2 hours (Zhang et al., 1998). Additional adhesion molecules have also been 
shown to partake in the transmigrational process of leukocytes, including ALCAM 
(Cayrol et al., 2008). 
 
Platelet adhesion seems to occur through a leukocyte independent method, and a 
leukocyte-dependent method. Increased leukocyte adhesion is accompanied by the 
recruitment of platelets (Ishikawa et al., 2004), and the leukocyte-dependent methods 
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involves the binding of platelet-associated P-selectin to its ligand P-selectin 
glycoprotein ligand 1 (PSGL-1) on leukocytes, which in turn utilise endothelial cell P-
selectin to create a platform on which leukocytes can establish a firm adhesion with 
ICAM-1, independent of ITGB2 (Yilmaz and Granger, 2008). Platelet independent 
method involves the binding of glycoprotein receptors to various ligands expressed on 
the surface of endothelial cells such as vWF, ICAM-1 and P-selectin (Tailor et al., 
2005). vWF, released during endothelial cell activation can also bind to the 
glycoprotein receptors to bind platelets to the endothelium. 
 
Interestingly, the effect of P-selectin seems to differ in focal versus global cerebral 
ischaemia, and therefore the role that it would have in SVD is unclear. Blocking P-
selectin in either model reduces leukocyte-endothelium interaction. However, in focal 
iscahemia, knockout mice of P-selectin had reduced neurological deficits compared to 
control (Connolly et al., 1997), suggesting P-selectin has detrimental effects. 
However, in global cerebral ischaemia, blocking P-selectin reduced survival 
(Lehmberg et al., 2006), suggesting a protective role.  
 
 
7.1.6 Relation to SVD 
The hypothesised cascade thought to be occurring in SVD can be seen in Figure 7.1. 
The evidence for the involvement of these mechanisms in SVD has predominantly 
come from studies of ischaemic stroke and neurodegeneration. Therefore, the 
relevance of these mechanisms to SVD specifically is unclear. Animal models of 
SVD have hypothesised that these mechanisms are occurring (Jalal et al., 2012, 
Kaiser et al., 2014), but the number of studies that have investigated this in SVD is far 
fewer than for ischaemic stroke or neurodegeneration. It is important to see if these 
mechanisms are occurring in human SVD, to understand their role in the 






Figure 7.1: Hypothesised cascade occurring in SVD where the initial response of 
hypoxia leads to ROS activation, and the release of pro-inflammatory cytokines. 
These then activate microglia, MMPs and initiate a global inflammatory response. 








Serum samples were taken from 20 controls, 20 sporadic SVD and 20 CADASIL 
patients and were used for the group comparisons. A DCE-MRI scan was carried out 
in 19 controls, 19 sporadic SVD and 19 CADASIL patients and was used to compare 
the blood biomarkers with BBB permeability. PK PET was taken from 17 controls, 16 
sporadic SVD and 14 CADASIL patients and was used to compare the blood 
biomarkers with microglia activation.   
 




As discussed in Chapter Two, the sample analysis carried out by Olink Proteomics 
and the Core Biochemical Assay Laboratory at Addenbrooke’s Hospital, which 
together provided a total of 93 biomarker quantifications from our serum samples. To 
decide which were useful to investigate, we used hypothesis driven methods from the 
literature detailed in the introduction, to understand which biomarkers are likely be 
involved in SVD. The biomarkers we investigated are as follows: 
• Inflammation: TNF-R1, TNF-R2, FAS, IL1-RT1, IL-6Rα, IL-18BP, CRP 
and CHI3L1  
• MMPs: MMP-2, MMP-3, MMP-9 and TIMP-4 
• Endothelial cell activation: E-selectin, P-selectin, ITGB2, vWF, CDH5, 
JAM-A, PECAM-1 and ALCAM 
 
 
7.2.2 Statistical Analysis 
ANCOVA analyses were used to compare between sporadic SVD and control, and 
between CADASIL and control. ANCOVAs were performed between the sporadic 
SVD and control groups and the CADASIL and control groups, controlled for age and 
sex. Pairs of comparisons were adjusted using Bonferroni. If significance was seen 
then the analysis was then repeated controlling for the cardiovascular risk factors of 
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hypertension, hyperlipidaemia, type 2 diabetes and smoking, to see if the significance 
was still present. 
 
Most of the biomarkers met assumptions of normality. However, TIMP-4, vWF, CRP 
and CHI3L1 did not meet normality assumptions, and were therefore log transformed 
(base:10) prior to analysis.  
 
Multivariate linear models were used to investigate the associations between 
individual biomarkers (independent) and BBB permeability or PK binding parameters 
(dependent), controlled for sex and age. When significant associations were seen, a 
further linear model controlling for the cardiovascular risk factors was performed to 
see if the significance was still present. Biomarkers were transformed in the same way 
as detailed above and BBB permeability and PK binding parameters were transformed 
in the same way as detailed in Chapters Four and Five respectively. They were 









Mean values and group comparisons for each of the inflammatory markers are shown 
in Table 7.1. TNFR1 was significantly higher in sporadic SVD compared to control 
when controlled for age and sex (p=0.002 (p=0.003 when adjusted for multiple 
comparisons)) and cardiovascular risk factors (p=0.002). Similarly, TNFR2 was also 
significantly higher in sporadic SVD compared to control when controlled for age and 
sex (p=0.001 (p=0.003 when adjusted for multiple comparisons)) and cardiovascular 
risk factors (p=0.002). There was no significant difference between CADASIL and 
control groups for TNFR1 or TNFR2.  
 
FAS was significantly higher in sporadic SVD compared to control when controlled 
for age and sex (p=0.020 (p=0.040 when adjusted for multiple comparisons)) and 
cardiovascular risk factors (p=0.019). There was no significant difference between 
CADASIL and control. 
 
IL1-RT1 was significantly higher in sporadic SVD compared to control when 
controlled for age and sex (p=0.002 (p=0.004 when adjusted for multiple 
comparisons)) and cardiovascular risk factors (p=0.001). Similarly IL-18BP was 
significantly higher in sporadic SVD compared to control when controlled for age and 
sex (p<0.001 (p<0.001 when adjusted for multiple comparisons)) and cardiovascular 
risk factors (p<0.001). There was no significant difference between sporadic SVD and 
control for IL-6Rα. There was no significant difference between CADASIL and 
control for IL1-RT1, IL-6Rα or IL-18BP.  
 
CRP was not significantly different between sporadic SVD and control or between 
CADASIL and control. Similarly, CHI3LT was not significantly higher in sporadic 





 Control Sporadic 
SVD 




Mean SD Mean SD Mean SD P value P value 
TNFR1 6.98 0.37 7.34 0.36 6.98 0.33 0.003 1.000 
TNFR2 6.00 0.39 6.35 0.28 6.03 0.41 0.003 1.000 
FAS 6.38 0.31 6.63 0.38 6.20 0.34 0.040 0.199 
IL1-RT1 6.67 0.31 6.97 0.30 6.62 0.34 0.004 1.000 
IL-6Rα 12.24 0.46 12.42 0.36 12.39 0.43 0.356 0.581 
IL-18BP 6.21 0.32 6.57 0.27 6.23 0.33 <0.001 1.000 
CRP 3.91 3.44 2.84 1.98 4.38 4.71 0.510 1.000 
CHI3L1 4.68 0.83 5.26 0.93 4.56 0.75 0.062 1.000 
 
Table 7.1: Group comparisons between the inflammatory markers were performed, 
controlling for age and sex. Comparisons were performed between the sporadic SVD 
and control groups, and the CADASIL and control groups. Significant p values are 





Mean values and group comparisons for each of the MMPs are shown in Table 7.3. 
MMP-2 was significantly higher in the sporadic SVD group compared to control 
when controlled for age and sex (p=0.016 (p=0.033 when adjusted for multiple 
comparisons)) and cardiovascular risk factors (p=0.014). There was no significant 
difference in MMP-2 levels between CADASIL and control. MMP-3 was not 
significantly different between sporadic SVD and control, or CADASIL and control. 
There was no significant difference in MMP-9 levels between sporadic SVD and 
control or CADASIL and control. Similarly, TIMP-4 was not significantly different 
between sporadic SVD and control or CADASIL and control. 
 
 
 Control Sporadic 
SVD 




Mean SD Mean SD Mean SD P value P value 
MMP-2 4.08 0.38 4.38 0.39 3.93 0.35 0.033 0.385 
MMP-3 8.30 0.64 8.37 0.72 8.26 0.69 1.000 1.000 
MMP-9 6.81 0.62 7.11 0.62 7.22 0.48 0.286 0.056 
TIMP-4 3.60 0.52 3.88 0.47 3.68 0.63 0.111 1.000 
 
Table 7.3: Group comparisons between the MMPs were performed, controlling for 
age and sex. Comparisons were performed between the sporadic SVD and control 
groups, and the CADASIL and control groups. Significant p values are shown in bold.  
 
 
7.3.3 Endothelial Cell Activation 
Mean values and group comparisons for each of the markers of endothelial cell 
activation are shown in Table 7.4. E-selectin was significantly higher in the sporadic 
SVD group compared to control when controlled for age and sex (p=0.007 (p=0.014 
when adjusted for multiple comparisons)) and cardiovascular risk factors (p=0.006). 
There was no significant difference in the CADASIL group. P-selectin and ITGB2 
both were not significantly different between the sporadic SVD and control or the 




vWF, CDH5 and JAM-A were not significantly different between the sporadic SVD 
and control groups or the CADASIL and control groups.  
 
PECAM-1 was significantly higher in the sporadic SVD group compared to control 
when controlling for age and sex (p=0.002 (p=0.003 when adjusted for multiple 
comparisons)) and cardiovascular risk factors (p=0.001). ALCAM was also 
significantly higher in the sporadic SVD group compared to control when controlling 
for age and sex (p=0.004 (p=0.007 when adjusted for multiple comparisons)) and 
cardiovascular risk factors (p=0.003). However, there was no significant difference in 
PECAM-1 or ALCAM in the CADASIL group compared to control.  
 
 
 Control Sporadic 
SVD 




Mean SD Mean SD Mean SD P value P value 
E-selectin 12.14 0.50 12.60 0.50 12.31 0.76 0.014 0.861 
P-selectin 10.93 0.53 11.14 0.40 10.94 0.48 0.293 1.000 
ITGB2 5.21 0.43 5.43 0.37 5.32 0.43 0.125 0.828 
vWF 8.45 0.75 8.46 0.73 8.00 0.66 1.000 0.090 
CDH5 4.88 0.43 5.05 0.30 4.94 0.36 0.302 1.000 
JAM-A 4.53 0.42 4.65 0.33 4.59 0.33 0.577 1.000 
PECAM-1 4.68 0.83 5.26 0.93 4.56 0.75 0.003 1.000 
ALCAM 7.70 0.40 8.02 0.33 7.76 0.32 0.007 1.000 
 
Table 7.4: Group comparisons between the endothelial cell activation markers were 
performed, controlling for age and sex. Comparisons were performed between the 
sporadic SVD and control groups, and the CADASIL and control groups. Significant 




7.3.4 Biomarkers and BBB permeability in the sporadic SVD group 
Linear models were used to investigate the association between the inflammatory 
biomarkers and the BBB permeability parameters in the sporadic SVD group (Table 
7.5). TNFR1 was significantly negatively associated with both global permeability (β 
=-0.792, p=0.009 (p=0.039 when adjusted for multiple comparisons)) and the volume 
of the permeability hotspots (β=-0.813, p=0.005 (p=0.028 when adjusted for multiple 
comparisons)) in the NAWM. When controlled for cardiovascular risk factors, the 
significance was still present with global permeability (β =-0.973, p<0.001) and 
hotspot permeability volume (β =-1.079, p=0.002).  Similarly, TNFR2 was 
significantly negatively associated with both global permeability (β =-0.785, p=0.008 
(p=0.039 when adjusted for multiple comparisons)) and the volume of the 
permeability hotspots (β=-0.759, p=0.007 (p=0.028 when adjusted for multiple 
comparisons)) in the NAWM. When controlled for cardiovascular risk factors, the 
significance was still present with the global permeability (β =-0.835, p=0.007) and 
hotspot permeability volume (β =-0.842, p=0.013). None of the other inflammatory 
biomarkers were significantly associated with the BBB permeability in the NAWM. 
None of the inflammatory biomarkers were significantly associated with BBB 
permeability in the WML.  
 
Linear models were used to investigate the association between MMPs and BBB 
permeability parameters in the sporadic SVD group (Table 7.6). There was no 
significant association between any of the MMPs and any of the BBB permeability 
parameters in the NAWM or the WML.  
 
Linear models were then used to investigate the association between the markers of 
endothelial cell activation and BBB permeability parameters in the sporadic SVD 
group (Table 7.7). There was no significant association between any of the markers of 






NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
TNFR1 -0.792 0.039 -0.260 0.740 -0.813 0.028 
TNFR2 -0.785 0.039 -0.147 0.740 -0.759 0.028 
FAS -0.303 0.437 0.244 0.740 -0.338 0.395 
IL1-RT1 -0.008 0.992 0.135 0.740 -0.071 0.892 
IL-6Rα -0.422 0.193 -0.451 0.479 -0.260 0.478 
IL-18BP -0.621 0.135 0.049 0.881 -0.679 0.060 
CRP 0.003 0.992 -0.167 0.740 0.033 0.892 
CHI3L1 0.201 0.601 0.392 0.479 -0.068 0.892 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
TNFR1 -0.756 0.086 -0.301 0.447 -0.759 0.080 
TNFR2 -0.700 0.086 -0.583 0.243 -0.632 0.088 
FAS -0.279 0.504 -0.273 0.447 -0.227 0.754 
IL1-RT1 0.016 0.956 -0.054 0.857 -0.032 0.912 
IL-6Rα -0.285 0.504 -0.259 0.447 -0.182 0.754 
IL-18BP -0.659 0.099 -0.619 0.243 -0.643 0.088 
CRP 0.135 0.676 0.213 0.447 0.109 0.865 
CHI3L1 0.151 0.676 0.319 0.447 -0.080 0.865 
 
Table 7.5. Linear models showing standardised β coefficients and p values for the 
associations between the inflammatory markers and the BBB permeability values in 
the NAWM (A) and the WML (B) for the sporadic SVD group. Significant p-values 





NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
MMP-2 -0.303 0.505 0.067 0.954 -0.359 0.229 
MMP-3 -0.187 0.505 0.351 0.609 -0.368 0.229 
MMP-9 -0.173 0.505 -0.248 0.609 -0.174 0.470 
TIMP-4 -0.340 0.505 -0.015 0.954 -0.461 0.229 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
MMP-2 -0.301 0.559 -0.271 0.680 -0.305 0.502 
MMP-3 -0.081 0.793 -0.092 0.744 -0.175 0.688 
MMP-9 -0.067 0.793 0.143 0.744 -0.082 0.736 
TIMP-4 -0.382 0.559 -0.257 0.680 -0.457 0.268 
 
Table 7.6. Linear models showing standardised β coefficients and p values for the 
associations between the MMPs and the BBB permeability values in the NAWM (A) 






NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
E-selectin 0.354 0.562 0.124 0.886 0.226 0.582 
P-selectin 0.162 0.727 0.275 0.886 -0.144 0.582 
vWF -0.257 0.727 0.131 0.886 -0.320 0.582 
ITGB2 -0.052 0.851 0.307 0.886 -0.197 0.582 
CDH5 -0.123 0.727 0.074 0.886 -0.140 0.582 
PECAM-1 -0.204 0.727 0.118 0.886 -0.332 0.582 
ALCAM -0.453 0.562 0.034 0.905 -0.474 0.523 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
E-selectin 0.417 0.476 0.456 0.302 0.258 0.482 
P-selectin -0.084 0.861 0.397 0.302 -0.351 0.390 
vWF -0.356 0.476 -0.246 0.672 -0.381 0.390 
ITGB2 0.049 0.861 -0.044 0.873 -0.048 0.858 
CDH5 -0.053 0.861 -0.149 0.767 -0.050 0.858 
PECAM-1 -0.215 0.861 -0.131 0.811 -0.302 0.482 
ALCAM -0.396 0.476 -0.465 0.302 -0.380 0.390 
 
Table 7.7. Linear models showing standardised β coefficients and p values for the 
associations between the endothelial cell activation markers and the BBB 
permeability values in the NAWM (A) and the WML (B) for the sporadic SVD group. 
Significant p-values are shown in bold. 
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7.3.5 Biomarkers and PK binding in the sporadic SVD group 
Linear models were used to investigate the association between the markers of 
inflammation and PK binding parameters in the sporadic SVD group (Table 7.8). 
There was no significant association between any of the markers of inflammation and 
the any of PK binding values in the NAWM or the WML.  
 
Linear models were then used to investigate the association between MMPs and PK 
binding parameters in the sporadic SVD group (Table 7.9). There were no association 
between any of the MMPs and any of the PK binding parameters in the NAWM. 
However, there was a significant positive association between MMP-3 and the mean 
value of the PK binding hotspots in the WML (β =0.568, p=0.012 (p=0.049 when 
adjusted for multiple comparisons)). This significance was still present when 
controlled for cardiovascular risk factors (β =0.850, p=0.010). There was no 
significant association between any of the other MMPs and any of the PK binding 
values in the WML.  
 
Linear models were then used to investigate the association between the markers of 
endothelial cell activation and PK binding parameters in the sporadic SVD group 
(Table 7.10). There was no significant association between any of the markers of 








NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
TNFR1 0.517 0.452 0.667 0.182 0.624 0.300 
TNFR2 0.450 0.452 0.650 0.182 0.537 0.300 
FAS 0.447 0.452 0.482 0.182 0.261 0.530 
IL1-RT1 0.648 0.360 0.167 0.604 0.046 0.883 
IL-6Rα -0.016 0.959 -0.225 0.479 -0.145 0.682 
IL-18BP 0.710 0.360 0.659 0.182 0.567 0.300 
CRP 0.300 0.452 0.360 0.270 0.449 0.300 
CHI3L1 -0.073 0.950 0.483 0.182 0.349 0.383 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
TNFR1 -0.013 0.976 0.648 0.149 0.594 0.270 
TNFR2 0.003 0.994 0.758 0.097 0.740 0.189 
FAS 0.243 0.439 0.558 0.097 0.705 0.105 
IL1-RT1 0.272 0.390 0.428 0.169 0.484 0.232 
IL-6Rα -0.303 0.266 -0.052 0.838 -0.172 0.622 
IL-18BP 0.267 0.504 0.554 0.169 0.694 0.189 
CRP -0.177 0.537 0.536 0.097 0.330 0.338 
CHI3L1 -0.126 0.685 0.353 0.228 0.088 0.783 
 
Table 7.8. Linear models showing standardised β coefficients and p values for the 
associations between the inflammation markers and the PK binding values in the 
NAWM (A) and the WML (B) for the sporadic SVD group. Significant p-values are 






NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
MMP-2 0.276 0.880 0.244 0.565 0.038 0.902 
MMP-3 0.074 0.880 0.387 0.565 0.258 0.902 
MMP-9 -0.045 0.880 -0.156 0.565 -0.188 0.902 
TIMP-4 0.159 0.880 0.310 0.565 0.109 0.902 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
MMP-2 0.175 0.800 0.335 0.376 0.271 0.510 
MMP-3 0.093 0.800 0.568 0.049 0.451 0.429 
MMP-9 -0.068 0.800 -0.261 0.376 -0.301 0.510 
TIMP-4 0.094 0.800 0.079 0.786 0.083 0.809 
 
Table 7.9. Linear models showing standardised β coefficients and p values for the 
associations between the MMPs and the PK binding values in the NAWM (A) and the 






NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β  P value 
E-selectin -0.337 0.529 0.168 0.814 0.015 0.969 
P-selectin -0.141 0.788 0.283 0.708 0.306 0.775 
vWF -0.186 0.788 -0.043 0.887 -0.277 0.775 
ITGB2 0.406 0.529 0.465 0.708 0.408 0.775 
CDH5 0.632 0.139 0.228 0.708 0.079 0.969 
PECAM-1 0.726 0.244 0.426 0.708 -0.015 0.969 
ALCAM 0.084 0.809 -0.079 0.887 -0.018 0.969 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker  β P value β P value β P value 
E-selectin -0.155 0.904 -0.234 0.549 -0.254 0.579 
P-selectin 0.008 0.980 -0.354 0.332 -0.403 0.368 
vWF -0.358 0.571 0.024 0.930 -0.201 0.613 
ITGB2 0.390 0.571 0.464 0.241 0.686 0.123 
CDH5 0.311 0.571 0.469 0.241 0.533 0.128 
PECAM-1 0.133 0.904 0.550 0.241 0.531 0.368 
ALCAM -0.090 0.904 0.049 0.930 -0.067 0.833 
 
Table 7.10. Linear models showing standardised β coefficients and p values for the 
associations between the endothelial cell activation markers and the PK binding 
values in the NAWM (A) and the WML (B) for the sporadic SVD group. Significant 
p-values are shown in bold. 
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7.3.6 Biomarkers and BBB permeability in the CADASIL group 
Linear models were used to investigate the association between the markers of 
inflammation and BBB permeability parameters in the CADASIL group (Table 7.11). 
There was no significant association between any of the markers of inflammation and 
the any of BBB permeability values in the NAWM or the WML. 
 
Linear models were then used to investigate the association between MMPs and BBB 
permeability parameters in the CADASIL group (Table 7.12).  There was a 
significant negative association between TIMP-4 and the mean value of the BBB 
permeability hotspots in the NAWM (β =-0.707, p=0.004 (p=0.014 when adjusted for 
multiple comparisons)). This significance was still present when controlled for 
cardiovascular risk factors (β =-0.825, p=0.001). There was no significant association 
between any other MMPs and BBB permeability in the NAWM, and there was no 
association with any of the BBB permeability parameters in the WML.  
 
Linear models were used to investigate the association between the markers of 
endothelial cell activation and BBB permeability parameters in the CADASIL group 
(Table 7.13). There was no significant association between any of the markers of 







NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
TNFR1 -0.380 0.338 -0.156 0.940 -0.214 0.567 
TNFR2 -0.247 0.586 -0.050 0.940 -0.258 0.567 
FAS -0.208 0.586 0.073 0.940 -0.069 0.799 
IL1-RT1 0.168 0.586 -0.021 0.940 0.207 0.567 
IL-6Rα -0.184 0.586 -0.119 0.940 -0.302 0.567 
IL-18BP 0.061 0.818 0.095 0.940 0.109 0.783 
CRP -0.558 0.188 -0.245 0.940 -0.381 0.567 
CHI3L1 -0.496 0.188 -0.379 0.940 -0.369 0.567 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
TNFR1 -0.161 0.760 0.025 0.950 -0.106 0.688 
TNFR2 -0.219 0.760 -0.112 0.950 -0.176 0.678 
FAS 0.083 0.760 0.134 0.950 0.145 0.678 
IL1-RT1 0.136 0.760 -0.016 0.950 0.190 0.678 
IL-6Rα -0.396 0.454 -0.255 0.950 -0.386 0.586 
IL-18BP 0.115 0.760 0.137 0.950 0.151 0.678 
CRP -0.334 0.580 -0.077 0.950 -0.295 0.678 
CHI3L1 -0.469 0.454 -0.253 0.950 -0.383 0.586 
 
Table 7.11. Linear models showing standardised β coefficients and p values for the 
associations between the inflammation markers and the BBB permeability values in 
the NAWM (A) and the WML (B) for the CADASIL group. Significant p-values are 






NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
MMP-2 0.181 0.485 -0.203 0.452 0.013 0.961 
MMP-3 -0.326 0.456 -0.557 0.156 -0.379 0.365 
MMP-9 -0.563 0.075 -0.432 0.156 -0.416 0.259 
TIMP-4 -0.537 0.075 -0.707 0.014 -0.448 0.259 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
MMP-2 -0.102 0.701 -0.291 0.318 -0.103 0.700 
MMP-3 -0.367 0.390 -0.339 0.318 -0.389 0.355 
MMP-9 -0.439 0.220 -0.341 0.318 -0.356 0.355 
TIMP-4 -0.598 0.083 -0.499 0.214 -0.525 0.196 
 
Table 7.12. Linear models showing standardised β coefficients and p values for the 
associations between MMPs and the BBB permeability values in the NAWM (A) and 





NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
E-selectin -0.561 0.114 -0.424 0.422 -0.489 0.316 
P-selectin 0.000 0.999 0.346 0.481 0.379 0.388 
vWF 0.109 0.999 -0.450 0.422 0.173 0.823 
ITGB2 -0.048 0.999 0.215 0.508 0.033 0.905 
CDH5 0.466 0.268 -0.020 0.946 0.435 0.373 
PECAM-1 0.063 0.999 -0.240 0.508 0.076 0.905 
ALCAM 0.115 0.999 0.276 0.503 0.139 0.823 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
E-selectin -0.378 0.468 -0.377 0.432 -0.315 0.515 
P-selectin 0.353 0.468 0.494 0.401 0.462 0.434 
vWF 0.162 0.761 0.137 0.860 0.125 0.737 
ITGB2 0.083 0.761 0.202 0.829 0.117 0.737 
CDH5 0.418 0.468 0.075 0.915 0.420 0.434 
PECAM-1 0.104 0.761 -0.003 0.991 0.094 0.737 
ALCAM 0.082 0.761 0.179 0.829 0.104 0.737 
 
Table 7.13. Linear models showing standardised β coefficients and p values for the 
associations between the endothelial cell activation markers and the BBB 
permeability values in the NAWM (A) and the WML (B) for the CADASIL group. 
Significant p-values are shown in bold. 
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7.3.7 Biomarkers and PK binding in the CADASIL group 
Linear models were used to investigate the association between the markers of 
inflammation and PK binding parameters in the CADASIL group (Table 7.14). There 
was no significant association between any of the markers of inflammation and the 
any of PK binding values in the NAWM or the WML. 
 
Linear models were then used to investigate the association between MMPs and PK 
binding parameters in the CADASIL group (Table 7.15).  There was no significant 
association between any of the MMPs and PK binding in the NAWM. There was a 
significant positive association between MMP-9 and the mean value of the PK 
binding hotspots in the WML (β =0.558, p=0.018 (p=0.037 when adjusted for 
multiple comparisons)). This significance was still present when controlled for 
cardiovascular risk factors (β =0.770, p=0.022). There was also a significant positive 
association between TIMP-4 and the mean value of the PK binding hotspots in the 
WML (β =0.499, p=0.018 (p=0.037 when adjusted for multiple comparisons)). This 
significance was still present when controlled for cardiovascular risk factors (β 
=0.516, p=0.047). There was no significant association between any of the other 
MMPs with the mean of the PK binding hotspots in the WML.   
 
Linear models were then used to investigate the association between markers of 
endothelial cell activation and PK binding parameters in the CADASIL group (Table 
7.16). There was a significant negative association between PECAM-1 and the mean 
value of the PK binding hotspots (β =-0.779, p=0.004 (p=0.031 when adjusted for 
multiple comparisons)). This significance was still present when controlled for 
cardiovascular risk factors (β =-0.773, p=0.006). There was no significant association 
between any of the other endothelial cell activation biomarkers and the PK binding in 
the NAWM. There was no significant association between any of the endothelial cell 





NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
TNFR1 0.118 0.892 -0.287 0.856 -0.104 0.898 
TNFR2 0.180 0.892 -0.180 0.856 -0.059 0.898 
FAS 0.216 0.892 -0.059 0.856 0.079 0.898 
IL1-RT1 0.171 0.892 -0.276 0.856 -0.087 0.898 
IL-6Rα 0.169 0.892 -0.074 0.856 -0.042 0.898 
IL-18BP -0.084 0.892 -0.387 0.856 -0.291 0.898 
CRP -0.044 0.892 0.076 0.856 -0.176 0.898 
CHI3L1 0.115 0.892 0.202 0.856 -0.122 0.898 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
TNFR1 -0.250 0.772 0.054 0.940 0.205 0.745 
TNFR2 -0.245 0.772 0.044 0.940 0.287 0.745 
FAS -0.067 0.815 -0.018 0.940 0.169 0.745 
IL1-RT1 -0.096 0.815 -0.086 0.940 0.285 0.745 
IL-6Rα -0.364 0.757 0.072 0.940 0.330 0.745 
IL-18BP -0.081 0.815 -0.145 0.940 0.045 0.903 
CRP -0.164 0.815 0.480 0.080 -0.035 0.903 
CHI3L1 -0.388 0.757 0.559 0.076 0.222 0.745 
 
Table 7.14. Linear models showing standardised β coefficients and p values for the 
associations between the inflammation biomarkers and the PK binding values in the 
NAWM (A) and the WML (B) for the CADASIL group. Significant p-values are 





NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
MMP-2 0.113 0.843 -0.305 0.439 -0.124 0.805 
MMP-3 0.277 0.843 -0.583 0.439 -0.544 0.805 
MMP-9 0.074 0.843 -0.015 0.968 -0.093 0.805 
TIMP-4 0.301 0.843 -0.425 0.439 -0.274 0.805 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
MMP-2 -0.309 0.259 -0.076 0.743 0.438 0.200 
MMP-3 -0.602 0.209 0.314 0.513 0.562 0.238 
MMP-9 -0.587 0.137 0.558 0.037 0.417 0.238 
TIMP-4 -0.494 0.137 0.499 0.037 0.483 0.200 
 
Table 7.15. Linear models showing standardised β coefficients and p values for the 
associations between the MMPs and the PK binding values in the NAWM (A) and the 






NAWM Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
E-selectin 0.067 0.963 -0.453 0.272 -0.226 0.872 
P-selectin 0.208 0.963 0.146 0.813 0.171 0.872 
vWF -0.367 0.963 -0.571 0.170 -0.778 0.032 
ITGB2 -0.015 0.963 -0.179 0.812 -0.106 0.872 
CDH5 -0.286 0.963 -0.534 0.170 -0.495 0.244 
PECAM-1 -0.246 0.963 -0.779 0.031 -0.558 0.244 
ALCAM 0.042 0.963 -0.039 0.901 0.043 0.894 
 
B 
WML Global Hotspot mean Hotspot volume 
Biomarker β P value β P value β P value 
E-selectin -0.466 0.625 0.326 0.609 0.333 0.983 
P-selectin 0.219 0.877 -0.040 0.884 0.130 0.983 
vWF -0.333 0.707 0.125 0.841 -0.156 0.983 
ITGB2 0.016 0.956 -0.193 0.793 -0.006 0.983 
CDH5 -0.131 0.902 -0.173 0.793 -0.012 0.983 
PECAM-1 -0.295 0.707 -0.052 0.884 0.042 0.983 
ALCAM 0.052 0.956 -0.297 0.609 0.109 0.983 
 
Table 7.16. Linear models showing standardised β coefficients and p values for the 
associations between the endothelial cell activation biomarkers and the PK binding 
values in the NAWM (A) and the WML (B) for the CADASIL group. Significant p-









This chapter reported an increase in the biomarkers TNFR1, TNFR2, IL1-RT1, IL-
18BP, FAS and MMP-2 in sporadic SVD compared to control, suggesting that 
inflammation, MMPs and endothelial cell activation are involved in sporadic SVD. 
None of the biomarkers were significantly increased in CADASIL compared to 
control. TNFR1 and TNFR2 were both negatively associated with BBB permeability 
in the NAWM of sporadic SVD patients, whilst MMP-3 was significantly associated 
with PK binding in the WML. In the CADASIL group, TIMP-4 was significantly 
negatively associated with BBB permeability in the NAWM, but positively associated 
with PK binding in the WML. MMP-9 was also positively associated with PK binding 
in the WML and PECAM-1 was negatively associated with PK binding in the 
NAWM in the CADASIL group.  
 
 
7.4.1 Inflammatory Biomarkers in sporadic SVD 
Five out of the eight inflammatory biomarkers tested were found to be significantly 
elevated in SVD compared to control (Table 7.1). These biomarkers were TNFR1, 
TNFR2, FAS, IL1-RT1 and IL-18BP. TNFR1 and TNFR2 were significantly negative 
correlated with the global permeability and volume of the permeability hotspots in the 
NAWM (Table 7.5). Interestingly, none of the inflammatory biomarkers were 
associated with any of the PK binding parameters (Table 7.8).  
 
TNFR1 and TNFR2 are the two cell membrane receptors of TNF-α (Faustman and 
Davis, 2010). We found both TNFR1 and TNFR2 were significantly elevated in our 
sporadic SVD group compared to controls. TNFR1 has not been previously studied in 
SVD, however, TNFR2 has been studied and has been significantly correlated with 
levels of CMBs, but not with lacunes or WMLs (Shoamanesh et al., 2015). Much of 
the previous SVD literature has focused on circulating levels of TNF-α itself and 
found it was significantly higher in lacunar stroke patients compared to non-stroke 
(Wiseman et al., 2014) and in vascular dementia patients compared to control 
(Tarkowski et al., 1999). Further, TNF-α has been associated with increased age and 
253 
 
hypertension in an SVD population (Wang et al., 2016) and with future vascular 
events in a longitudinal study (Boehme et al., 2016).  
 
We found also found TNFR1 and TNFR2 to be negatively associated with the global 
mean and hotspot volume of BBB permeability in the NAWM. These results would 
suggest that higher levels of TNFR1 and TNFR2 are associated with lower levels of 
BBB permeability. TNFR1 and TNFR2 have been shown to be the mediators of 
transport of TNF-α across the BBB (Pan and Kastin, 2002). Therefore, one 
explanation for our finding could be that when there are higher levels of BBB 
permeability, TNFR1 and TNFR2 may be down-regulated as they are no longer 
required to transport TNF-α into the brain. An alternative explanation comes from 
some interesting work, which suggests pre-treatment of TNF-α is neuroprotective in 
animal models of ischaemic stroke (Nawashiro et al., 1997). Further, knocking out 
TNFR1 and TNFR2 receptors in mice was shown to exacerbate damage after 
ischaemic stroke (Bruce et al., 1996, Gary et al., 1998, Marchetti et al., 2004). 
Therefore, this increase in TNFR1 and TNFR2 may actually be protective against 
increased BBB permeability. As this is the first study to show this association, we 
must be cautious not to over-interpret the findings. However, our study does suggest 
that there is a role for the receptors of TNF-α in SVD disease pathogenesis, and 
further studies with larger numbers should investigate this further and see if these 
results can be replicated.  
 
FAS levels were increased in sporadic SVD compared to control (Table 7.2). The 
increase in FAS suggests a role for apoptosis in sporadic SVD. FAS has not been 
previously investigated in SVD, but has been shown to be increased in mild ischaemic 
models (Wetzel et al., 2008). FAS had no association with BBB permeability or PK 
binding in sporadic SVD, suggesting it may not be involved in these pathogenic 
mechanisms and may instead by a resultant process of the ongoing damage occurring 
in SVD. 
 
IL1-RT1 is a receptor for IL-1 and was significantly increased in sporadic SVD 
compared to control. Animal studies have suggested that this receptor is rapidly 
upregulated after stroke (Wang et al., 1997). Blood levels of IL1-RT1 have not been 
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studied in SVD. However, IL-1 has been studied in both its α and β forms. 
Interestingly, WML and lacune count were not associated with IL-1α (Staszewski et 
al., 2018) or IL-1β (Baune et al., 2009). However, our results would suggest an 
upregulation of IL1-RT1 in SVD. 
 
IL-18BP, an antagonist of IL-18, was significantly increased in sporadic SVD 
compared to control. IL-18BP has not been reported in SVD, but IL-18BP was shown 
to improve neurological recovery in studies of experimental head injury (Yatsiv et al., 
2002) and hyperoxia-induced brain injury (Felderhoff-Mueser et al., 2005), through 
its effects of blocking IL-18. IL-18 itself has been seen to be increased in type 2 
diabetes (Aso et al., 2003), obesity (Esposito et al., 2002), stress (Sugama and Conti, 
2008) and Alzheimer’s disease (Ojala et al., 2009). IL-18 was also shown to be 
significantly associated with the number of CMBs (Miwa et al., 2011). Therefore, the 
upregulation of IL-18BP in SVD could be suggested to be a response of the immune 
system to act as natural protection against IL-18.  
 
CHI3L1 was not significantly elevated in sporadic SVD compared to control and was 
not associated with any of the BBB permeability or PK binding parameters. CHI3L1 
has never been investigated in sporadic SVD previously. However, it has been shown 
to have a role in type 2 diabetes (Di Rosa and Malaguarnera, 2016), large artery 
stroke (Chen et al., 2017) and intracerebral haemorrhage (Jiang et al., 2014). Further, 
elevated CHI3L1 in the general population was found to be associated with a two-fold 
increased risk of ischaemic stroke (Kjaergaard et al., 2015). It was also associated 
with worsened outcomes after ischaemic stroke (Rathcke et al., 2012) and heart 
failure (Harutyunyan et al., 2012). Therefore, CHI3L1 is likely to be a more general 
risk factor for cardiovascular disease rather than a marker for SVD specifically.  
 
Interestingly, CRP was not seen to be significantly elevated in sporadic SVD 
compared to control or associated with any of the BBB permeability of PK binding 
parameters. CRP is the most widely studied marker of systemic inflammation, shown 
to be elevated in lacunar stroke compared to non-stroke (Wiseman et al., 2014). 
Cross-sectionally, CRP has been associated with WML volume (van Dijk et al., 2005, 
Wright et al., 2009, Raz et al., 2012, Satizabal et al., 2012, Rizzi et al., 2014) and 
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lacune count (Hoshi et al., 2005, Yoshida et al., 2009, Mitaki et al., 2016, Hilal et al., 
2018), with greater progression of WML also associated with higher CRP levels at 
baseline (van Dijk et al., 2005). However, some studies have found that CRP is not 
associated with WMLs (Gunstad et al., 2006, Schmidt et al., 2006, Wada et al., 2008, 
Wersching et al., 2010, Wada et al., 2011, Rouhl et al., 2012, Aribisala et al., 2014) or 
with lacune count (van Dijk et al., 2005, Schmidt et al., 2006, Gottesman et al., 2009, 
Wada et al., 2011, Rouhl et al., 2012, Nylander et al., 2015, Shoamanesh et al., 2015). 
It is interesting that we did not see elevated CRP levels in the sporadic SVD group 
compared to control, as this is contradictory to the literature. It may be that the 
numbers from this study were too low to detect a difference; CRP is influenced by 
inflammatory responses occurring throughout the body and therefore it is possible that 
this noise makes it difficult to see the group difference with low numbers.  
 
IL-6Rα was not seen to be significantly elevated in sporadic SVD compared to 
control and was also not associated with BBB permeability or PK binding. IL-6Rα is 
part of the receptor for IL-6, which binds to IL-6 with low affinity but does not 
produce a signal. After ischaemic stroke, IL-6Rα was seen to remain unchanged 
whilst IL-6 concentration significantly rose (Acalovschi et al., 2003). IL-6Rα has 
never before been reported in an SVD population. IL-6 itself has been widely reported 
in the literature and associated with WMLs (Fornage et al., 2008, Satizabal et al., 
2012), lacunes (Hoshi et al., 2005, Yoshida et al., 2009) and CMBs (Shoamanesh et 
al., 2015, Miwa et al., 2011). However, not all studies have reported significant 
association between IL-6 and WMLs (Jefferson et al., 2007, Baune et al., 2009, 
Aribisala et al., 2014, Kim et al., 2014, Shoamanesh et al., 2015), lacunes (Baune et 
al., 2009, Satizabal et al., 2012, Shoamanesh et al., 2015) or CMBs (Lu et al., 2017). 
It has also been associated with SVD progression, defined as an increase in WMLs or 
development or new lacunes (Staszewski et al., 2018). The discrepancies with IL-6 
here can be explained by the fact we were measuring the IL-6Rα, which is a subunit 
of the receptor, and therefore may not upregulate in the same way IL-6 has been seen 
to.  
 
Our results suggest a role for TNFR1, TNFR2, FAS, IL1-RT1 and IL-18BP in 
sporadic SVD, suggesting that sporadic SVD is associated with a systemic 
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inflammatory response. Further, our results suggest a common pathogenesis between 
TNFR1 and TNFR2 with BBB permeability, which should be further explored.  
 
 
7.4.2 Inflammatory Biomarkers in CADASIL 
None of the inflammatory biomarkers were significantly increased in CADASIL 
patients compared to control (Table 7.1) and none of the biomarkers were 
significantly associated with BBB permeability (Table 7.11) or PK binding (Table 
7.14).  
 
CRP has been previously reported in CADASIL and the result mirrored that of our 
study, where levels were not significantly different from control (Campolo et al., 
2013). In vitro experiments of Notch3 signalling have suggested an associated with 
FAS-mediated apoptosis (Yamamoto et al., 2011). FAS signalling is a major 
apoptotic pathway in vascular smooth muscle cells, and therefore it has been 
suggested that, under normal conditions Notch3 signalling blocks FAS-mediated 
apoptosis (Wang et al., 2002). Therefore, Wang et al. suggested that in CADASIL, 
there may be increased FAS-dependent apoptosis of vascular smooth muscle cells. As 
TNF-α is the major activator of FAS-mediated apoptosis through TNFR1, then we 
may have expected to see an increase in TNFR1 and FAS in CADASIL. However, 
this was not the case in our study.  
 
The result that none of the inflammatory biomarkers were elevated in CADASIL or 
related to BBB permeability or PK binding could be related to the finding that BBB 
permeability is not significantly elevated in CADASIL (Figure 4.1-3), and therefore 
there may be neuroinflammatory responses occurring that are restricted to the CNS, as 
the BBB is too intact to allow them to spill into the periphery. It is also important to 
note that many of these inflammatory biomarkers have been associated with ageing, 
and are thought to increase with age (Singh and Newman, 2011). Our CADASIL 
group is significantly younger than our control group (Table 3.1) and therefore, 
although we did control for age in our analyses, they may not have taken into account 
all of this variation and an age-matched control group is important to validate this 
finding. Finally, it could be that inflammation is not as important in CADASIL 
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disease pathogenesis and so we do not see the same elevation of circulating 
biomarkers as we do in sporadic SVD.   
 
 
7.4.3 MMPs in sporadic SVD 
MMP-2 was significantly increased in sporadic SVD compared to control (Table 7.3). 
MMP-3 was positively associated with increased mean value of the PK binding 
hotspots in the WML (Table 7.9).  
 
MMP-2 was significantly increased in sporadic SVD in our study, but was not 
associated with BBB permeability or PK binding. Candelario-Jalil et al. previously 
investigated MMP-2 as an index in SVD, where CSF and plasma values were taken 
and indexed against albumin; they found a reduction in the MMP-2 index in vascular 
cognitive impairment patients (Candelario-Jalil et al., 2011). Another study found that 
MMP-2 could separate SVD from Alzheimer’s disease (Bjerke et al., 2011). MMP-2 
is known to affect the tight junctions of the BBB, increasing permeability. However, 
it was originally hypothesised to be most important in acute stroke, with less 
importance in chronic diseases, but this evidence would suggest that MMP-2 is still 
elevated and therefore is likely to be involved in SVD.  
 
MMP-3 was not upregulated in sporadic SVD compared to control, but it was 
significantly associated with the mean value of the PK binding hotspots in the WML. 
MMP-3 is an inducible MMP, along with MMP-9, and has been shown to be elevated 
in patients with vascular cognitive impairment (Candelario-Jalil et al., 2011). MMP-
3s role is predominantly tissue breakdown during the injury phase and angiogenesis in 
the recovery phase (Rosenberg, 2016). Importantly, it has also been shown to activate 
microglia (Connolly et al., 2016), which may explain the role between elevated 
MMP-3 and increased PK binding. The lack of increase in SVD compared to control 
suggests MMP-3 is not overly important in SVD pathology, but may still be useful as 
a general anti-inflammatory target to reduce microglia activation.  
 
We did not found a difference in TIMP-4 levels between sporadic SVD and control 
and no association with PK binding or BBB permeability. Interestingly TIMP-4 has 
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been investigated in SVD previously and was found to be associated with atrophy, 
WMLs and total SVD burden (Arba et al., 2019b). TIMP-4 inhibits a wide range of 
MMPs, with protective effects on remodelling of extracellular matrix (Leco et al., 
1997). However, our study would suggest that TIMP-4 does not have a large role in 
SVD.  
 
We did not find an increase in MMP-9 in our study and also found no association 
between MMP-9 and any of the BBB permeability of PK binding values. The role of 
MMP-9 in SVD is controversial in the literature. Early studies showed that MMP-9 
was elevated in vascular dementia compared to controls (Adair et al., 2004). MMP-9 
was also seen to be associated with WMLs (Kim et al., 2014, Romero et al., 2010) 
and CMBs (Koh et al., 2011, Lu et al., 2017). However, a more recent study in 
vascular cognitive impairment did not show an increase in MMP-9 compared to 
controls (Candelario-Jalil et al., 2011). Further, MMP-9 was not seen to be associated 
with lacunar infarcts (Yoshida et al., 2009, Romero et al., 2010). These negative 
results were then mirrored in a recent animal study of the SVD rat model, which 
showed no beneficial outcome of blocking MMP-9 (Raz et al., 2018). These results 
suggest that MMP-9 may not be as important in SVD as originally thought and may 
not be the best therapeutic target for SVD.   
 
Taken together, our results suggest there may be a role for MMP-2 and MMP-3 in the 
pathogenesis of sporadic SVD. However, the limited associations seen between 
MMPs and BBB permeability and PK binding is unexpected, as in the original 
hypothesis for this study, MMPs were the mediating factor between the inflammatory 
response and the opening of the BBB. These results suggest that potentially MMPs 
are not as important as originally thought, and some of the other more general 
inflammatory biomarkers may be more useful to target with therapeutics to slow 
down disease pathogenesis.  
 
 
7.4.4 MMPs in CADASIL 
None of the MMPs were significantly elevated in CADASIL compared to control 
(Table 7.3). TIMP-4 was significantly negatively associated with the mean value of 
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the BBB permeability hotspots in the NAWM (Table 7.12). MMP-9 and TIMP-4 
were then significantly positively associated with the mean value of the PK binding 
hotspots in the WML (Table 7.15). 
 
TIMP-4 was negatively associated with the mean BBB permeability of the hotspots in 
the NAWM, but positively associated with the mean PK binding of the hotspots in the 
WML. The TIMP-4 gene has been previously shown to be upregulated in CADASIL, 
and has been suggested to be important for its role in vascular inflammation (Pippucci 
et al., 2015). TIMPs are endogenous inhibitors of MMPs, so this result would suggest 
that when TIMP-4 is reduced, BBB permeability is increased, which could be due to 
the inhibiting effects of TIMP-4 on the MMPs being reduced.  
 
MMP-9 was seen to be significantly associated with increased mean of the PK 
binding hotspot in the WML. Previously, intense immune staining to MMP-9 has 
been seen in CADASIL (Dziewulska et al., 2017). MMP-9 is produced by microglia 
and therefore this could explain this finding (Könnecke and Bechmann, 2013). This 
result would suggest that MMP-9 potentially has more of a role in CADASIL than in 
sporadic SVD.  
 
MMP-2 and MMP-3 were not seen to be elevated in CADASIL or have a significant 
association with BBB permeability or PK binding. Interestingly, MMP-2 has 
previously been shown to have intense staining in CADASIL, whereas MMP-3 has 
not (Dziewulska et al., 2017). Our results would suggest that neither of them have a 
significant role in the pathogenesis of CADASIL. 
 
Overall, this evidence would suggest that MMP-9 and TIMP-4 might be involved in 
the disease pathogenesis, even though none of the MMPs were increased in 
CADASIL compared to controls. Similarly to discussed above, it could be that the 
lack of BBB permeability seen in CADASIL means that these processes cannot be 
picked up systemically, but may still be occurring centrally. Studies that investigate 
the CSF or perform post-mortem studies are required to explore if these processes are 




7.4.5 Endothelial Cell Activation Biomarkers in sporadic SVD 
Three out of the seven total endothelial cell activation markers were significantly 
elevated in sporadic SVD: E-selectin, PECAM-1 and ALCAM (Table 7.4). None of 
the endothelial cell activation markers were significantly associated with BBB 
permeability or PK binding (Table 7.10 and 7.13).   
 
We found increased E-selectin in sporadic SVD compared to control, but no increase 
in P-selectin. E-selectin and P-selectin are soluble adhesion molecules. E-selectin is 
expressed purely on endothelial cells, whilst P-selectin is expressed on both 
endothelial cells and platelets. Both E-selectin and P-selectin have previously been 
seen to be elevated in cerebrovascular disease, with P-selectin associated with 
severity of WMLs (Fassbender et al., 1999, de Leeuw et al., 2002). E-selectin was 
seen to be elevated in lacunar stroke patients compared to controls (Kozuka et al., 
2002), but this finding has not been replicated in other studies when comparing with 
control (Tuttolomondo et al., 2009b) or other stroke subtypes (Tuttolomondo et al., 
2009a, Beer et al., 2011). P-selectin results have been mixed, with some studies 
finding it to be increased in lacunar stroke patients compared to controls (Kozuka et 
al., 2002), and some finding no difference (Ilhan et al., 2010). The activation of P-
selectin is fast, whereas E-selectin is only activated 2 hours after ischaemic injury, 
suggesting that E-selectin may have more of a role in chronic disease, whereas P-
selectin may be more involved in acute injury. Our results suggest that E-selectin has 
a role in the pathogenesis of sporadic SVD and should be further investigated.  
 
We found a significantly higher circulating PECAM-1 in SVD patients compared to 
controls. PECAM-1 is expressed on leukocytes, platelets and endothelial cells and 
required for migration of leukocytes (Muller et al., 1993). Levels of PECAM-1 have 
been shown to be increased in both MS and ischaemic stroke (Kalinowska and Losy, 
2006). Further, circulating PECAM-1 has previously been associated with increased 
atherosclerotic cerebral infarction risk (Song et al., 2015). Early studies linked an 
increased PECAM-1 to an increase in BBB permeability (Kalinowska and Losy, 
2006). However, more recent studies in MS have built on this relationship, and 
suggested that PECAM-1 has a protective role of stabilising the BBB (Wimmer et al., 
2019). Interestingly, it was not directly associated with BBB permeability levels in 
261 
 
sporadic SVD in our study, which would suggest that there may be other factors 
mediating the relationship between PECAM-1 and BBB permeability. Nonetheless, 
the upregulation of PECAM-1 in SVD suggests an activation of the endothelium is 
occurring and it is a biomarker that could be explored further.   
 
We found a significantly higher circulating ALCAM in SVD patients compared to 
controls. ALCAM, also known as CD166, is upregulated substantially during 
inflammation and replaces VCAM-1 during transmigration of leukocytes across CNS 
endothelium (Cayrol et al., 2008). Studies of ischaemic stroke found that ALCAM 
levels measured during the stroke are associated with long-term mortality in those 
patients (Smedbakken et al., 2011). Follow-up data would be useful to see if ALCAM 
can predict similar outcomes in sporadic SVD patients.  
 
There was no significant difference between vWF in the sporadic SVD and control 
groups and no association between vWF and BBB permeability or PK binding. Meta-
analysis of vWF studies found that it was significantly higher in lacunar stroke vs. 
healthy controls, but was significantly lower compared to the non-lacunar stroke 
subtypes of atherothrombotic and cardioembolic stroke (Wiseman et al., 2014). vWF 
has also been associated cross-sectionally with WMLs (Kearney-Schwartz et al., 
2009, Wada et al., 2011) and lacunes (Kario et al., 1996, Gottesman et al., 2009). 
vWF was also associated with increased WML and lacunes longitudinally (Arba et 
al., 2019a). However, other studies have not seen an association with WMLs 
(Knottnerus et al., 2010) or lacunes (Wada et al., 2011). It may be that our group sizes 
were not large enough to detect a difference between sporadic SVD and control 
groups or it may be that vWF is not as important in the disease pathogenesis as 
suggested by these earlier studies.  
 
ITGB2 was not found to be significantly different between the sporadic SVD and 
control group or the CADASIL and control group. ITGB2 has not previously been 
investigated in SVD. However, ICAM-1 has been widely investigated. During an 
inflammatory response, ICAM-1 and ITGB2 form a complex to allow recruitment of 
leukocytes to the endothelial cells and therefore you would expect a relationship 
between these markers (Liu and Kubes, 2003). ICAM-1 has been associated with 
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increased WML (Hassan et al., 2003, Markus et al., 2005, Tchalla et al., 2015, 
Shoamanesh et al., 2015) and lacunes (Rouhl et al., 2012, Shoamanesh et al., 2015). 
One study also found ICAM-1 to be associated with longitudinal presence of WMLs, 
but not with lacunes (Arba et al., 2019a). However, not all studies have seen an 
association between ICAM-1 and SVD markers, with some showing no association 
with WMLs (de Leeuw et al., 2002, Jefferson et al., 2007, Rouhl et al., 2012) or 
lacunes (Hassan et al., 2003). Further studies are required that measure both ITGB2 
and ICAM-1 to see if they are upregulated in SVD. 
 
JAM-A, also known as soluble F11 receptor, was also found not to be significantly 
different between the sporadic SVD and control groups or CADASIL and control 
groups. It was also found not to be associated with BBB permeability or PK binding. 
JAM-A has been shown to redistribute from tight junctions to the apical cell surface 
where it mediates immune cell adhesion, upon inflammatory stimulation of 
endothelial cells, suggesting it may be detectable in circulation (Kummer and Ebnet, 
2018). It has been shown to have increasing circulating levels in hypertension (Ong et 
al., 2009), atherosclerosis (Cavusoglu et al., 2007) and haemodialysis patients (Salifu 
et al., 2007). However, a more recent study found that there was no increase in serum 
JAM-A in MS or ischaemic stroke patients, suggesting that JAM-A may not be 
released from endothelial cells in pro-inflammatory states, as originally thought 
(Haarmann et al., 2010). These results from MS and stroke patients would reflect our 
results, where JAM-A was not increased in the serum of sporadic SVD or CADASIL 
patients compared to control.  
 
CDH5, also known as VE-cadherin, was not significantly different between sporadic 
SVD and control groups. Circulating CDH5 has not been investigated in SVD, but 
was found to be elevated in patients with type 2 diabetes (Koga et al., 2005) and acute 
ischaemic stroke (Li and Qin, 2015). However, our results would suggest it does not 
have a role in SVD.  
 
Overall, there does seem to be a role for E-selectin, PECAM-1 and ALCAM in SVD. 
Interestingly, none of the endothelial cell activation markers were significantly 
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associated with BBB permeability or PK binding, which would suggest they may not 
be directly involved in the pathogenesis.  
 
 
7.4.6 Endothelial Cell Activation Biomarkers in CADASIL 
None of the endothelial cell activation biomarkers were significantly different 
between CADASIL and control (Table 7.4). PECAM-1 was significantly negatively 
associated with the mean value of the PK binding hotspots in the NAWM (Table 
7.16)  
 
PECAM-1 was the only endothelial cell activation biomarker to have any relationship 
in the CADASIL group, showing a negative association with PK binding in the 
NAWM. Elevated PECAM-1 is thought to be beneficial in MS, through contributing 
to the regulation of BBB integrity and T-cell migration, with absence of PECAM-1 
increasing the migration of T-cells across the BBB transcellular pathway (Wimmer et 
al., 2019). Therefore, potentially PECAM-1 is protective in CADASIL, and a 
reduction of it is leading to an increased activation of microglia.  
 
Interestingly, we found no difference between vWF in the CADASIL group compared 
to control. vWF has been studied previously in CADASIL specifically, in a post-
mortem study where they showed an accumulation of vWF in the small vessel walls, 
suggesting vWF permeates these sites and is involved in the pathogenesis of 
CADASIL (Zhang et al., 2012). More recently, a study of serum biomarkers in 
CADASIL found that vWF was significantly elevated in the serum compared to 
controls (Pescini et al., 2017). The lack of a difference found in this study is likely to 
be due to the low subject numbers used, and vWF should be further investigated in a 
larger samples size to see if this finding can be replicated.  
 
None of the other markers of endothelial cell activation have been previously 
investigated in CADASIL (Poggesi et al., 2016). The general lack of endothelial cell 
activation elevation in CADASIL was an unexpected finding. It would suggest that 
endothelial cells might not have an important role in CADASIL disease pathogenesis. 
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Further, combining this with the lack of increased BBB permeability seen in the 




The key limitation of this analysis is that the biomarkers were taken from serum 
samples, yet we are using them to hypothesise about mechanisms occurring in the 
vasculature and CNS. In reality, these samples are representing systemic increases in 
various biomarkers, and not any subtle changes that would be occurring in the CNS. 
Therefore, it is important to critique any generalisation to CNS mechanisms. Future 
work could omit some of these limitations by taking biomarkers from the CSF, to 
reduce the systemic processes, which interfere with biomarkers taken from the serum. 
 
Although this work was primarily focused on furthering our understanding of the 
disease pathogenesis, there is application of this work for disease diagnosis and 
progression, as we found many serum biomarkers were raised in our SVD cohort. 
Therefore, further studies should be carried out to see if any of these biomarkers are 
specific enough for this purpose, as this could reduce scan costs and increase the 





7.5 Summary of Findings 
 
Returning to the aims of this chapter, the following areas have been addressed:  
 
1. The inflammatory biomarkers of TNF-R1, TNF-R2, FAS, IL1-RT1 and IL-
18BP were significantly increased in sporadic SVD compared to control 
2. MMP-2 was significantly increased in sporadic SVD compared to control 
3. E-selectin, PECAM-1 and ALCAM, markers of endothelial cell activation, 
were significantly increased in sporadic SVD compared to control 
4. None of the biomarkers were increased in CADASIL compared to control 
5. TNFR1 and TNFR2 were significantly negatively associated with global mean 
BBB permeability and the volume of the BBB permeability hotspots in the 
NAWM in the sporadic SVD group 
6. MMP-3 was significantly positive associated with the mean value of the PK 
binding hotspots in the WML in the sporadic SVD group 
7. TIMP-4 was significantly negatively associated with the mean value of the 
BBB permeability hotspots in the NAWM and positively associated with the 
mean value of the PK binding hotspots in the WML in CADASIL 
8. MMP-9 was significantly positively associated with the mean value of the PK 
binding hotspots in the WML in CADASIL 
9. PECAM-1 was significantly negatively associated with the mean value of the 
PK binding hotspots in the NAWM in CADASIL 
 
This chapter has investigated blood biomarkers and their group differences and 
relevance to BBB permeability and PK binding. The next chapter will take all of the 
findings of this thesis and put them into context of the wider literature and 




Chapter 8: General Discussion and Future Work 
 
8.1 Summary of Work 
 
This thesis considers the pathogenesis of SVD and whether, using MR and PET 
imaging techniques, the underlying mechanisms of BBB permeability and microglia 
activation have a role in the disease. This thesis looks at both BBB permeability and 
microglia activation as separate concepts in comparison to imaging markers, cognitive 




8.1.1 Pathogenesis of sporadic SVD 
The mechanisms linking sporadic SVD to the parenchyma damage are heterogeneous 
and unclear. As outlined in Chapter One, the cardiovascular risk factors, 
environmental factors and genetic factors accumulated throughout life are thought to 
damage the small vessels, leading to inadequate blood supply to the brain regions 
(Marstrand et al., 2002, O'Sullivan et al., 2002). This hypoperfusion leads to a 
hypoxic response, causing free radical production, microglia activation, triggering of 
inflammatory cascades (including MMPs) and increased BBB permeability 
(Rosenberg et al., 2014). These mechanisms may then lead to further tissue damage 
through actions of the inflammatory molecules and increased extravasation of blood 
components through the BBB. This then leads to the characteristic SVD imaging 
markers that we see using conventional MRI and DTI, and the manifesting of clinical 
symptoms.  
 
Many studies have investigated the above mechanisms and found associations 
between them and the imaging or clinical outcomes. However, very few studies have 
looked at multiple pathogenic mechanisms simultaneously to understand their 
relationship with one another. Our study looked at microglia activation with BBB 
permeability, in combination with serum biomarkers, to try to understand how these 
complex mechanisms fit into the underlying disease pathogenesis. The exact methods 
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used are outlined in Chapter Two and the characteristics of the patient and control 
populations are described in Chapter Three.  
 
Chapter Four studied BBB permeability as an individual concept, in a similar way to 
how it had been studied previously (Cuadrado-Godia et al., 2018). Firstly, we 
provided evidence that there is an increase in BBB permeability in sporadic SVD 
compared to controls. We showed a significant increase in global BBB permeability 
in the NAWM and WML. Further, we showed increased focal permeability in 
sporadic SVD compared to control, by showing an increased volume of BBB 
permeability hotspots in the NAWM and WML.   
 
We then investigated whether BBB permeability was associated with current 
characteristic imaging markers of SVD. Within the sporadic SVD group, we did not 
find an association between BBB permeability and WMLs, lacunes or CMBs. 
However, we did find that increased volume of significant BBB permeability in the 
NAWM was associated with increased FA, suggesting that the presence of higher 
areas of permeability is associated with disruption of WM fibres in the NAWM. We 
also found higher levels of permeability in the NAWM compared to the WML. Taken 
together, this data suggests a role for BBB permeability in the NAWM, where it may 
precede WML formation. However, without follow-up data, this cannot be concluded.  
 
In Chapter Five, microglia activation was explored as an individual concept. PET 
imaging of PK binding was used to measure microglia activation. We found there 
were increased hotspots of microglia activation in sporadic SVD compared to control, 
with a significantly increased mean value and volume in the NAWM and WML.  
 
We found that microglia activation was not associated with any of the clinical SVD 
characteristics of WMLs, lacunes, CMBs or DTI parameters in the sporadic SVD 
group. Focal hotspots of microglia activation were consistently increased in the 
NAWM compared to the WML. Similarly to BBB permeability, this could again 
suggest that microglia activation is involved in the mechanism turning NAWM into 




The most interesting and unexpected result of the study came from Chapter Six, 
where we examined the relationship between the BBB permeability and microglia 
activation. We found no correlation between the two, and spatial analysis showed that 
voxels of significant BBB permeability and microglia activation were significantly 
independent of one another. This provides evidence that BBB permeability and 
microglia activation are occurring as distinct mechanisms within the pathogenic 
process within a single time-point. However, what we cannot determine from these 
results, is whether they are causative of one another; in other words, whether an area 
of high microglia activation will go on to become an area of high BBB permeability, 
or vice versa. Alternatively, they may be completely separate disease mechanisms, 
which are not involved in the same pathogenic pathway.  Follow-up studies are 
needed, which scan patients repeatedly to see the change in these dynamic processes 
over time, which will clarify whether they are causative of one other, of WML 
formation or of neither.  
 
Finally, Chapter Seven investigated various circulating biomarkers. We found 
evidence suggesting a role for the TNF-α receptors and cytokines within the IL-1 
family in sporadic SVD, representative of a systemic inflammatory response. Further, 
we found an increase in MMP-2 in sporadic SVD compared to control. There was 
also an increase in various markers of endothelial cell activation, including E-selectin, 
PECAM-1 and ALCAM, suggestive of endothelial cells in an inflammatory state, 
which may contribute to BBB permeability. TNFR1 and TNFR2 were negatively 
associated with BBB permeability, suggesting an opposing regulation between the 
TNF-α receptors and BBB permeability. MMP-3 was associated with microglia 
activation, suggesting a role in SVD.  
 
These markers show that there do seem to be underlying mechanisms occurring that 
may link BBB permeability and neuroinflammation together in SVD. They would 
therefore provide evidence that the results of Chapter Six, where BBB permeability 
and microglia activation were spatially distinct, are due to different brain regions 
being at varying stages in the pathogenic pathway, rather than the processes being 




Taken together, our results suggest a role for BBB permeability and microglia 
activation in sporadic SVD. They suggest that the processes are spatially independent 
at a single time-point. However, there do seem to be underlying inflammatory 
processes occurring that may be linking BBB permeability and microglia activation 
together, suggesting that they may be involved in the same mechanism.   
 
  
8.1.2 Pathogenesis of CADASIL 
The mechanism underlying CADASIL is also unclear. As described in Chapter One, 
CADASIL is a genetic disease and therefore the initial damage to the small vessels is 
predominantly due to genetic causes through a mutation in Notch3 (Papakonstantinou 
et al., 2019), although this can still be worsened by risk factors (Adib-Samii et al., 
2010). Studies have suggested that, although different initial processes damage the 
small vessels, the underlying mechanism that occurs as a result of the damaged 
vessels may be broadly similar to the sporadic condition (Poggesi et al., 2016). This is 
important to establish, as if a common mechanism exists then future treatments can be 
shared between sporadic SVD and CADASIL. Therefore, briefly, in CADASIL it is 
thought that Notch3 mutations lead to a degeneration of the vasculature through 
effects on many cells, predominantly vascular smooth muscle cells (Coupland et al., 
2018). Hypoxia then occurs and follows a similar pathway to sporadic SVD, with free 
radical production, microglia activation, activation of inflammatory cascades and 
increase in BBB permeability. However, very few studies have investigated the 
underling mechanism in CADASIL, making work within this area very novel. 
Chapter Two outlined the methods used in this study and Chapter Three described the 
CADASIL and control populations.  
 
In Chapter Four, we investigated BBB permeability in CADASIL and found that it 
was not significantly different from controls. This finding was in contrast to sporadic 
SVD, where BBB permeability was seen to increase compared to controls. BBB 
permeability had no relation to any of the characteristic SVD imaging markers of 
WMLs, lacunes or CMBs in the CADASIL group and no association with cognition. 





We then moved to investigate microglia activation in CADASIL in Chapter Five. We 
found there was a significantly higher mean and volume of hotspot microglia 
activation in the WMLs of CADASIL patients compared to control. The association 
was not significant in the NAWM, although there was a non-significant trend for the 
mean and volume of the hotspot microglia activation to be increased in CADASIL 
compared to control. We saw no associations between the amount of microglia 
activation and any of the SVD imaging markers of WMLs, lacunes or CMBs, and also 
no association with cognition within the CADASIL group. This work suggests that 
microglia activation is increased in patients with CADASIL; however, its role in the 
pathophysiology of the disease is unclear.   
 
Chapter Six compared the relationship between BBB permeability and microglia 
activation. This chapter showed a similar pattern across the sporadic SVD and 
CADASIL groups, which was that BBB permeability and microglia activation were 
not consistently correlated with one-another and that voxels of significant BBB 
permeability and microglia activation were significantly independent of one another 
spatially. This suggests that either the two mechanisms are not related, or that they are 
two parts of a dynamic process that occur at separate time-points, and therefore cross-
sectional data will be unable to establish the relationship.  
 
Chapter Seven then investigated circulating biomarkers in CADASIL. None of the 
biomarkers were significantly elevated in CADASIL compared to control. 
Additionally, none of the inflammatory markers were associated with any of the BBB 
permeability or microglia activation parameters. This could suggest that these 
inflammatory markers are involved in increasing BBB permeability, and their absence 
in CADASIL is why we do not see the same increase in BBB permeability as we see 
in sporadic SVD. Alternatively, it could be that, as we are measuring these markers 
systemically, the lack of increased permeability seen in CADASIL makes it more 
difficult for the markers to travel from their site of origin in the CNS, into the 
circulation. Therefore, the same inflammatory processes may be occurring in the CNS 
in sporadic SVD and CADASIL, but in sporadic SVD the increased permeability 
allows the markers to be picked up systemically, whereas in CADASIL they are 
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confined to the CNS. MMP-9 and TIMP-4 were shown to be associated with BBB 
permeability and microglia activation, suggesting MMPs may be involved in the 
pathogenesis. PECAM-1 was also negatively associated with microglia activation, 
suggesting a protective role against increasing inflammation. 
 
Further studies are required to understand the inflammatory response occurring in 
CADASIL, and why we do not see the same increase in BBB permeability as we do 
in sporadic SVD.  
 
Taken together, our results suggest that there is a role for activated microglia in 
CADASIL. They suggest that there is not an obvious role for BBB permeability, and 
there is a spatial independence between activated microglia and BBB permeability at 
a single time-point. The results also suggest that there are no systemic inflammatory 





8.2 Ongoing and future work 
 
8.2.1 Follow-up of Patients 
The fact that the data from this study is cross-sectional and taken at a single time-
point makes it impossible to be certain of the role of these mechanisms in SVD 
pathogenesis. The mechanisms of BBB permeability and activated microglia can only 
be proven to be pathogenic if they can be shown to lead to damage to the brain tissue 
at a later stage. Therefore, all the patients from this study will be followed up one year 
later, where they will undergo a further clinical MRI scan and cognitive tests. The key 
markers we are interested in monitoring the change of are WML volume and the DTI 
parameters FA and MD.  
 
WML growth and DTI changes over the follow-up period will be calculated. These 
will then be analysed in comparison to the baseline levels of BBB permeability and 
PK binding, to see if patients who had higher permeability or binding at baseline, 
seem to have increased progression of WMLs or increased FA and MD at follow-up.  
 
The analysis will then be expanded to see if the regions classified as hotspot BBB 
permeability or hotspot PK binding at baseline, have progressed to become WML or 
have obtained a significant change in FA or MD one-year on. This analysis will also 
be repeated in reverse, where follow-up MRI scans will be marked for WMLs, with 
baseline lesions subtracted, to create a mask of new WMLs that have occurred in that 
one-year period. The amount of BBB permeability and PK binding that was present at 
baseline in the new WMLs will be calculated to see if the levels were higher than in 
the rest of the brain.  
 
The cognitive decline seen over the one-year period will also be calculated and 
compared to baseline levels of BBB permeability and PK binding, to see if there is a 
clinical application to this.  
 
The greatest limitation of this is that the one-year period of follow-up is not a long 
amount of time, and therefore detectable changes in this time period may not be seen. 
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If this is the case, then a decision may be made to follow-up patients up again at a 
later time-point.  
 
Further, as these follow-up studies will not repeat the DCE-MRI or PK PET scans, 
they do not help to answer the question about the dynamics of the SVD pathogenic 
mechanism. If the follow-up scans do show BBB permeability and/or microglia 
activation to be pathogenic, a study investigating the dynamics of the processes could 
be very useful to improve our understanding and help with time-course and 
administration of future treatments.  
 
 
8.2.2 Clinical Trial 
This study has led to the start of a clinical trial utilising the same imaging techniques, 
cognitive tests and biomarkers used in this study. The clinical trial is based on an 
animal study of SVD, where minocycline was shown to reduce the size of WMLs 
(Jalal et al., 2015). The mechanism of action of minocycline is controversial, with 
Jalal et al. originally suggesting it acted through MMP-9, but later determining that 
this is unlikely to be the case (Raz et al., 2018). The many anti-inflammatory 
mechanisms of minocycline make it difficult to determine which action is protective 
in SVD. Therefore, if the drug is found to be effective in SVD patients, then further in 
vitro and in vivo studies will be required to fully understand the therapeutic 
mechanism of action.  
 
The clinical trial will scan patients with DCE-MRI and PK PET at baseline and after 3 
months of treatment with minocycline, to see if this reduces the amount of BBB 
permeability and microglia activation seen. The patients will then continue treatment 
for one year, where they will be scanned again with just a clinical MRI scan, to see if 
treatment with minocycline reduces WML growth and DTI changes in comparison to 
a placebo. If successful this trial could provide the first treatment for SVD that targets 







SVD is responsible for a third of all strokes and is the leading cause of vascular 
dementia (O'Brien and Thomas, 2015). Research is increasingly suggesting that SVD 
underlies age-related cognitive decline in the elderly, making it the most prevalent 
neurological disorder ever described (Thompson and Hakim, 2009). The growing 
ageing population of the UK means that this disease will continue to increase costs to 
the economy and affect the lives of hundreds of thousands of people. With no current 
treatments that treat the underlying mechanism, research into the pathogenesis of 
SVD is vital to discover new targets for therapeutics.  
 
The findings from this thesis have potential clinical and research implications. From 
an imaging perspective, we have shown that simultaneous PET/MR imaging can be 
carried out in an SVD patient population, and can provide quantification and spatial 
localisation of BBB permeability and microglia activation. Clinical trials investigating 
the impact of future therapeutics on these disease mechanisms can use this technology 
as suitable end-points to measure the therapeutic impact.  
 
The biological findings from this study have confirmed a role for BBB permeability 
and microglia activation in sporadic SVD, whilst paving the way for future research 
into the dynamics of these processes. This study has provided the first indication that 
microglia activation is an important mechanism in CADASIL, and the implications 
this may have for disease treatment. We have also shown an array of blood 
biomarkers that seem to be increased in sporadic SVD that provide new insights into 
the pathophysiology and have the potential to be utilised as clinical trial end-points or 
for both diagnosis and management of disease progression. Further, in vivo and in 
vitro work can build on these findings to understand the link between microglia 
activation and BBB permeability, which can then be translated into the clinic.   
 
SVD is a heterogeneous disease with an array of neuroimaging features and 
associated symptoms manifesting from a complex underlying mechanistic pathway. 
Improving our knowledge of the disease pathogenesis will allow for novel 
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therapeutics that target these mechanisms to be tested, and allow us to slow down, or 




Appendix A: Mean value of BBB permeability 
Hotspots - Analysis with Outliers Removed 
 
Two outliers were removed for the hotspot permeability mean values (both WM and 
NAWM), whilst three outliers were removed for the hotspot permeability mean 
penumbra values (both 3mm and 6mm penumbras). These outliers did not have an 
obvious reason to be removed but they were higher than can be reasonably expected 
and so are likely due to artifact.  
 
 
A.1 Statistical Analysis 
 
Statistical analysis was carried out in the same way as described in the main chapter. 
Briefly, group differences between hotspot mean values for sporadic SVD and control 
and CADASIL and control were analysed using the ANCOVA test and were 
controlled for age and sex. Pairs of comparisons were adjusted using Bonferroni. If 
there was a significant difference seen, an ANCOVA controlling for the 
cardiovascular risk factors of hypertension, hyperlipidaemia, type 2 diabetes and 
smoking was performed to see if the significance was still present.  
 






A.2.1 Group Differences 
There was no significant difference in the mean value of the BBB permeability 
hotspots in the WM between the sporadic SVD and control groups or the CADASIL 
and control groups (Figure A.1). There was also no significant difference in the mean 
value of the BBB permeability hotspots in the NAWM between the sporadic SVD and 





Figure A.1: There was no significant difference in the hotspot mean permeability in 
the WM of the sporadic SVD group compared to control (p=0.123) or the CADASIL 
group compared to control (p=1.000).  
 
 
Figure A.2: There was no significant difference in the hotspot mean permeability in 
the NAWM of the sporadic SVD group compared to control (p=0.090) or the 
CADASIL group compared to control (p=1.000).  
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A.2.2 WML Penumbra Group Difference  
There was a significantly higher mean value of the BBB permeability hotspots in the 
3mm penumbra of the sporadic SVD group compared to control (p=0.004 (p=0.007 
when adjusted for multiple comparisons) (Figure A.3). However, there was no 
significant difference in the mean value of the BBB permeability hotspots between 
the CADASIL and control groups.  
 
There was a significantly higher mean value of the BBB permeability hotspots in the 
6mm penumbra of the sporadic SVD group compared to control (p=0.009 (p=0.018 
when adjusted for multiple comparisons)) (Figure A.4). However, there was no 
significant difference in the mean value of the BBB permeability hotspots between 
the CADASIL and control groups.  
 
 
Figure A.3: There was a significant difference in the hotspot mean permeability in the 
3mm penumbra of the sporadic SVD group compared to control (p=0.007). However, 








Figure A.4: There was a significant difference in the hotspot mean permeability in the 
6mm penumbra of the sporadic SVD group compared to control (p=0.018). However, 





Appendix B: BBB permeability in CADASIL 
 
An analysis was carried out comparing the amount of BBB permeability in the 
CADASIL group between various symptoms.  
 
 
B.1 Statistical analysis 
Mann-Whitney U tests for non-parametric data were used to compare the imaging 
parameters and BBB permeability parameters for CADASIL patients by age, stroke 





Comparisons between the imaging markers for CADASIL patients over 55 vs. under 
55 are shown in Table B.1. Brain volume and GM volume were not significantly 
different between the groups. WML volume was significantly higher in the over 55 
group compared to under 55 (p=0.017). The groups had similar lacune volume, lacune 
number and CMB number. All of the DTI parameters of FA and MD were similar 
between the groups.  
 
Comparisons between the BBB permeability values between patients over 55 vs. 
under 55 are shown in Table B.2. There was no significant difference in any of the 
BBB permeability parameters of global mean, hotspot mean or hotspot volume 




Imaging Parameter Median [Q1, Q3] P 
value Over 55 (n=9) Under 55 (n=11) 
Brain volume (% of ICV) 76.03 [73.77, 79.96] 70.73 [68.48, 80.62] 0.470 
GM volume (% of ICV) 40.04 [35.59, 43.46] 40.85 [40.10, 46.54] 0.305 
WML volume (% of ICV)  5.25 [2.72, 6.91]  2.40 [1.54, 3.47] 0.017 
Lacune volume (% of ICV)  0.06 [0.02, 0.10]  0.00 [0.00, 0.05] 0.099 
Number of lacunes  3.00 [2.00, 8.00]  0.00 [0.00, 6.00] 0.157 
Number of CMBs  1.00 [0.00, 2.00]  0.00 [0.00, 6.00] 0.647 
FA NAWM median  0.28 [0.24, 0.33]  0.34 [0.31, 0.35] 0.053 
FA WML median  0.19 [0.18, 0.22]  0.20 [0.17, 0.23] 0.732 
MD NAWM peak height* 10.26 [8.79, 11.95] 12.43 [10.46, 13.71] 0.074 
MD WML peak height*  6.96 [6.17, 7.36]  6.43 [6.01, 7.38] 0.849 
FW NAWM median  0.35 [0.33, 0.37]  0.30 [0.28, 0.35] 0.063 
FW WML median  0.61 [0.56, 0.65]  0.54 [0.53, 0.57] 0.184 
FW FA NAWM median  0.21 [0.18, 0.23]  0.23 [0.23, 0.25] 0.063 
FW FA WMH median  0.18 [0.18, 0.19]  0.20 [0.18, 0.21] 0.342 
FW MD NAWM peak height*  2.31 [2.20, 2.66]  2.57 [2.37, 2.73] 0.305 
FW MD WML peak height*  2.78 [2.30, 2.91]  2.58 [2.15, 2.82] 0.425 
*(x103) 
Table B.1: Comparisons of imaging parameters of CADASIL patients over 55 years 






Median [Q1, Q3] P 
value Over 55 (n=8) Under 55 (n=11) 
Global mean 
(x103) 
NAWM 0.05 [0.02, 0.18] 0.05 [0.03, 0.15] 0.804 
WML 0.01 [0.01, 0.10] 0.04 [0.01, 0.11] 0.408 
Hotspot mean 
(x103) 
NAWM 2.46 [2.27, 2.89] 1.78 [1.55, 2.87] 0.160 
WML 2.07 [1.15, 2.85] 1.37 [1.10, 1.71] 0.408 
Hotspot 
volume 
NAWM 1.19 [0.39, 5.04] 2.85 [1.30, 8.26] 0.364 
WML 0.59 [0.19, 4.63] 1.71 [0.72, 5.40] 0.408 
 
Table B.2: Comparisons of permeability parameters of CADASIL patients over 55 




Comparisons were made for imaging markers between CADASIL patients who had 
experienced a stroke and those who had not in Table B.3. Brain volume, GM volume, 
WML volume, lacune volume, lacune number and CMB number were not 
significantly different between the groups. FA median in the NAWM was 
significantly lower in patients who had experienced a stroke compared to those who 
had not (p=0.017). FW adjusted FA median followed the same pattern and was 
significantly lower in those who had experienced a stroke (p=0.014). MD peak height 
in the WML was also significantly lower in patients who had experienced a stroke 
compared to those who had not (p=0.031). FW median in the WML was significantly 
higher in those who had experienced a stroke compared to those who had not 
(p=0.037).  
 
Comparisons between the BBB permeability parameters between CADASIL patients 
who had experienced a stroke and those who had not are shown in Table B.4. BBB 
permeability in the NAWM was significantly higher in those who had not 
experienced a stroke compared to those who had (p=0.021). None of the other 





Imaging parameter Median [Q1, Q3] P 
value Stroke (n=8) Non-Stroke (n=12) 
Brain volume (% of ICV) 73.43 [69.97, 77.94] 77.92 [70.06, 81.38] 0.589 
GM volume (% of ICV) 39.65 [35.36, 40.20] 44.27 [40.73, 46.19] 0.064 
WML volume (% of ICV)  4.40 [2.39, 7.31]  2.66 [1.04, 3.70] 0.143 
Lacune volume (% of ICV)  0.09 [0.01, 0.11]  0.00 [0.00, 0.03] 0.202 
Number of lacunes  8.00 [1.50, 10.00]  0.50 [0.00, 3.00] 0.188 
Number of CMBs  4.50 [0.00, 22.50]  0.00 [0.00, 1.25] 0.076 
FA NAWM median  0.28 [0.27, 0.30]  0.35 [0.32, 0.36] 0.017 
FA WML median  0.20 [0.18, 0.20]  0.21 [0.17, 0.24] 0.537 
MD NAWM peak height* 10.16 [9.36, 10.95] 12.56 [10.23, 13.50] 0.076 
MD WML peak height*  6.30 [5.65, 6.66]  7.34 [6.41, 8.00] 0.031 
FW NAWM median  0.35 [0.35, 0.37]  0.31 [0.29, 0.34] 0.076 
FW WML median  0.62 [0.58, 0.66]  0.54 [0.50, 0.57] 0.037 
FW FA NAWM median  0.21 [0.20, 0.22]  0.24 [0.23, 0.25] 0.014 
FW FA WMH median  0.19 [0.18, 0.20]  0.18 [0.18, 0.21] 0.643 
FW MD NAWM peak height*  2.34 [2.18, 2.61]  2.55 [2.30, 2.71] 0.355 
FW MD WML peak height*  2.47 [2.20, 2.87]  2.71 [2.19, 3.07] 0.700 
*(x103)  
Table B.3: Comparisons of imaging parameters of CADASIL patients who have and 






Median [Q1, Q3] P 
value Stroke (n=8) Non-Stroke (n=11) 
Global mean 
(x103) 
NAWM 0.02 [0.01, 0.06] 0.08 [0.04, 0.38] 0.021 
WML 0.01 [0.00, 0.06] 0.04 [0.02, 0.11] 0.116 
Hotspot mean 
(x103) 
NAWM 1.94 [1.72, 2.43] 2.36 [1.67, 3.90] 0.68 
WML 1.39 [0.90, 2.04] 1.63 [1.19, 2.64] 0.563 
Hotspot 
volume 
NAWM 0.89 [0.38, 3.35] 3.00 [1.63, 11.45] 0.099 
WML 0.45 [0.11, 3.26] 2.23 [1.09, 5.40] 0.215 
 
Table B.4: Comparisons of permeability parameters of CADASIL patients who have 




Comparisons of imaging parameters between CADASIL patients who had 
experienced a migraine vs. those who had not, is shown in Table B.5. Brain volume, 
GM volume and WML volume were not significantly different between groups. 
However, lacunes were significantly higher in those who had not experienced 
migraine compared to those who had in both volume (p=0.015) and count (p=0.031). 
Number of CMBs was not significantly different between the groups. None of the 
DTI parameters were significantly different between the groups.  
 
Comparisons of the BBB permeability values between CADASIL patients who had 
experienced a migraine and those who had not is shown in Table B.6. There was no 





Imaging parameter Median [Q1, Q3] P 
value Migraine (n=16) Non-Migraine (n=4) 
Brain volume (% of ICV) 75.40 [70.06, 80.26] 75.34 [64.15, 80.88] 0.925 
GM volume (% of ICV) 41.98 [38.93, 45.83] 39.65 [34.08, 44.05] 0.450 
WML volume (% of ICV)  2.53 [1.77, 4.10]  4.83 [3.34, 6.72] 0.131 
Lacune volume (% of ICV)  0.00 [0.00, 0.04]  0.13 [0.10, 0.15] 0.015 
Number of lacunes  0.50 [0.00, 4.25] 10.50 [6.75, 14.25] 0.031 
Number of CMBs  0.00 [0.00, 5.50]  1.00 [0.00, 16.50] 0.717 
FA NAWM median  0.33 [0.30, 0.35]  0.28 [0.27, 0.30] 0.219 
FA WML median  0.20 [0.18, 0.24]  0.19 [0.17, 0.20] 0.299 
MD NAWM peak height* 11.61 [9.75, 13.21] 10.97 [9.50, 11.56] 0.450 
MD WML peak height*  7.03 [6.29, 7.50]  6.01 [5.51, 6.58] 0.131 
FW NAWM median  0.32 [0.29, 0.36]  0.35 [0.35, 0.37] 0.108 
FW WML median  0.54 [0.52, 0.63]  0.60 [0.59, 0.64] 0.156 
FW FA NAWM median  0.23 [0.22, 0.25]  0.21 [0.20, 0.23] 0.299 
FW FA WMH median  0.19 [0.18, 0.21]  0.18 [0.17, 0.19] 0.219 
FW MD NAWM peak height*  2.55 [2.25, 2.67]  2.34 [2.11, 2.53] 0.345 
FW MD WML peak height*  2.68 [2.20, 3.00]  2.45 [2.19, 2.74] 0.571 
*(x103) 
Table B.5: Comparisons of imaging parameters of CADASIL patients who have and 






Median [Q1, Q3] P 
value Migraine (n=16) Non-Migraine (n=3) 
Global mean 
(x103) 
NAWM 0.06 [0.03, 0.16] 0.03 [0.02, 0.37] 0.911 
WML 0.03 [0.01, 0.11] 0.02 [0.01, 0.15] 0.823 
Hotspot mean 
(x103) 
NAWM 1.85 [1.56, 2.52] 3.96 [3.17, 194.48] 0.057 
WML 1.55 [1.15, 1.94] 2.77 [1.39, 2.93] 0.654 
Hotspot 
volume 
NAWM 2.47 [0.97, 7.93] 1.22 [0.61, 9.57] 0.823 
WML 1.55 [0.44, 4.38] 0.68 [0.34, 4.80] 0.654 
 
Table B.6: Comparisons of permeability parameters of CADASIL patients who have 
and have not experienced migraine. 
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Appendix C: 6mm WML Penumbra 
 
A 6mm penumbra was drawn around the WMLs to see if this followed the same 
patterns seen with the 3mm penumbra.  
 
 
C.1 Statistical Analysis 
Group differences in the penumbra values between sporadic SVD and control and 
between CADASIL and control were analysed using ANCOVA tests and were 
controlled for age and sex. Pairs of comparisons were adjusted using Bonferroni. If 
there was a significant difference seen, a further ANCOVA controlling for the 
cardiovascular risk factors was performed to see if the significance was still present.  
 
Comparisons between permeability or PK binding values for the NAWM and WML 
and the penumbra permeability or PK binding values were carried out using the 
Wilcoxon signed rank tests for paired non-parametric data. These tests were 
performed on the raw untransformed values. P values were corrected for multiple 
comparisons using FDR. 
 
All permeability penumbra values were transformed with a cube root to meet 
normality assumptions. Global mean PK binding values for the 6mm penumbra met 
normality assumptions. Hotspot mean PK binding values for the 6mm penumbra did 
not meet normality assumptions so were log transformed (base:10). Hotspot PK 
binding volumes for the 6mm penumbra also did not meet normality assumptions so 







C.2.1 BBB permeability Group Difference 
Global BBB permeability values within the penumbra were compared in Figure C.1. 
Global permeability in the sporadic SVD group was significantly higher than control 
when controlled for age and sex (p=0.003 (p=0.006 when adjusted for multiple 
comparisons)) and cardiovascular risk factors (p=0.004). The global BBB 
permeability values in the penumbra were not significantly different between 
CADASIL and control. 
 
Mean values of the BBB permeability hotspots were compared in Figure C.2. The 
mean value of the permeability hotspots was significantly higher than control when 
adjusted for age and sex (p=0.003 (p=0.007 when adjusted for multiple comparisons)) 
and cardiovascular risk factors (p=0.005). There was no significant difference 
between mean value of the hotspots in the penumbra between the CADASIL and the 
control groups.  
 
Finally, the volumes of the BBB permeability hotspots within the penumbras were 
compared, shown in Figure C.3. In the sporadic SVD group, there was a significantly 
higher volume of hotspots compared to control when adjusted for age and sex 
(p=0.009 (p=0.018 when adjusted for multiple comparisons)) and cardiovascular risk 







Figure C.1: Global mean values of BBB permeability from the 6mm penumbra region 
were compared between groups when controlled for age and sex. Global permeability 
mean was significantly higher in SVD compared to control (p=0.006). CADASIL was 
no different from control (p=0.263).  
 
Figure C.2: Mean values of the BBB permeability hotspots from the 6mm penumbra 
region were compared between groups when controlled for age and sex. The mean 
value of the hotspots was significantly higher in the sporadic SVD group compared to 
control (p=0.007). There was no difference between CADASIL and control 




Figure C.3: The volume of the BBB permeability hotspots for the 6mm penumbra 
were compared between the groups. The volume was significantly higher in sporadic 
SVD compared to control (p=0.018). There was no difference between CADASIL and 
control (p=0.932).  
 
 
C.2.2. BBB permeability NAWM vs. WML 
Penumbra values were then compared with corresponding NAWM and WML values, 
to see if they were significantly different in permeability to these regions, shown in 
Table C.1. 
 
Within the control group, penumbra values were similar to all corresponding NAWM 
and WML values except for the hotspot permeability in the WML. The mean value of 
the permeability hotspots in the penumbra was significantly higher than in the WML 
(p=0.011).  
 
In the sporadic SVD group, the penumbra values were similar to the corresponding 
NAWM and WML for the global permeability mean and the volume of the 
permeability hotspots. However, when comparing to the mean value of the 
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permeability hotspots, the penumbra values were significantly lower than the NAWM 
(p=0.037), but significantly higher than WML (p=0.001).  
 
Within the CADASIL group, the penumbra values were similar to the NAWM values, 
but significantly higher than the WML values. The global permeability mean of the 
penumbra was significantly higher than in the WML (p=0.004). The hotspot mean of 
the penumbra was also significantly higher than the WML (p=0.004) and the hotspot 














Median IQR Median IQR 
Control NAWM mean (x103) 0.046 0.071 0.063 0.061 0.976 
WML mean (x103) 0.009 0.062 0.063 0.061 0.072 
HS NAWM mean (x103)  1.977 1.183 1.652 1.588 0.684 
HS WML (x103) 1.033 1.943 1.652 1.588 0.011 
NAWM volume 2.074 2.314 1.811 2.372 0.976 
WML volume 0.543 3.661 1.811 2.372 0.105 
Sporadic 
SVD 
NAWM mean (x103) 0.295 0.620 0.290 0.529 0.713 
WML mean (x103) 0.161 0.361 0.290 0.529 0.146 
HS NAWM mean (x103)  3.397 3.036 2.955 2.968 0.037 
HS WML (x103) 2.376 2.624 2.955 2.968 0.001 
NAWM volume 10.660 14.480 9.780 13.400 1.000 
WML volume 9.314 10.518 9.780 13.400 0.598 
CADASIL NAWM mean (x103) 0.046 0.136 0.054 0.151 0.874 
WML mean (x103) 0.026 0.103 0.054 0.151 0.004 
HS NAWM mean (x103)  2.009 1.541 2.358 1.888 0.976 
HS WML (x103) 1.562 1.468 2.358 1.888 0.004 
NAWM volume 2.088 7.429 2.496 8.635 0.713 
WML volume 1.393 5.027 2.496 8.635 0.004 
 
Table C.1: Pairwise comparisons for the individual groups for the global mean 
permeability values, hotspot mean permeability values and hotspot permeability 




C.2.3 PK binding Group Difference 
Global PK binding in the penumbra was compared between sporadic SVD and control 
and CADASIL and control; there was no significant difference seen (Figure C.4).  
 
The mean value of the PK binding hotspots was then compared between the groups in 
Figure C.5. The mean binding o the hotspots was significantly higher in the sporadic 
SVD group compared to control when controlling for age and sex (p=0.014 (p=0.029 
when adjusted for multiple comparisons)) and cardiovascular risk factors (p=0.021). 
Further, the hotspot mean was significantly higher in CADASIL compared to control 
when adjusted for age and sex (p=0.005 (p=0.010 when adjusted for multiple 
comparisons)) and cardiovascular risk factors (p=0.005). 
 
The volume of the PK binding hotspots was not significantly different between the 
6mm penumbras (Figure C.6).  
 
 
Figure C.4: The global PK binding mean was compared between the groups. The 
mean was not significantly different between sporadic SVD compared to control 






Figure C.5: The mean value of the PK binding hotspots was compared between the 
groups. The mean was were significantly higher in sporadic SVD compared to control 




Figure C.6: The volume value of the PK binding hotspots was compared between the 
groups. The volume was not significantly different between sporadic SVD compared 
to control (p=0.783) or CADASIL and control (p=0.641). 
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C.2.4 PK binding NAWM vs. WML 
6mm penumbra values are shown in Table C.2. In the control group, the global mean 
PK values of the penumbra were significantly lower than the NAWM (p<0.001) and 
WML (p<0.001). The mean values of the PK binding hotspots were significantly 
lower then NAWM values (p<0.001), but significantly higher than WML values 
(p<0.001). The same pattern was seen for the volume of the PK binding hotspots; 
with 6mm penumbra values significantly lower than NAWM (p<0.001), but higher 
than WML (p<0.001).  
 
In the sporadic SVD group, global mean PK binding values in the 6mm penumbra 
were significantly lower than NAWM (p<0.001), but significantly higher than WML 
(p=0.003). The mean values of the PK binding hotspots in the penumbra were 
significantly lower than the NAWM value (p=0.002), but no different from the WML 
value. NAWM hotspot volume was significantly higher than 6mm penumbra 
(p=0.005), but no different from the WML value.   
 
In the CADASIL group, 6mm penumbra values were significantly lower than both 
NAWM (p<0.001) and WML (p<0.001) values for global mean binding. They were 
similar to NAWM (p=0.194) and WML (p=0.083) for the mean value in the PK 
binding hotspots. 6mm penumbra values were significantly lower than NAWM 
(p<0.001), but higher than WML (p=0.013) for the volume of the PK binding 






Mean PK binding  Mean Penumbra  P value 
Median IQR Median IQR 
Control NAWM mean  0.030 0.021 -0.046 0.033 <0.001 
WML mean  0.036 0.158 -0.046 0.033 <0.001 
HS NAWM mean  0.174 0.017 0.169 0.012 <0.001 
HS WML  0.000 0.146 0.169 0.012 <0.001 
NAWM volume 3.761 4.085 3.222 1.494 <0.001 
WML volume 0.000 0.671 3.222 1.494 <0.001 
Sporadic 
SVD 
NAWM mean  0.054 0.033 -0.075 0.037 <0.001 
WML mean  -0.003 0.045 -0.075 0.037 0.003 
HS NAWM mean  0.204 0.028 0.187 0.025 0.002 
HS WML  0.182 0.044 0.187 0.025 0.083 
NAWM volume 9.442 7.199 4.685 7.458 0.005 
WML volume 0.858 3.341 4.685 7.458 0.076 
CADASIL NAWM mean  0.052 0.045 -0.075 0.033 <0.001 
WML mean  0.013 0.044 -0.075 0.033 <0.001 
HS NAWM mean  0.196 0.030 0.191 0.020 0.194 
HS WML  0.180 0.023 0.191 0.020 0.083 
NAWM volume 6.805 10.004 3.514 5.021 <0.001 
WML volume 1.327 2.665 3.514 5.021 0.013 
 
Table C.2: Pairwise comparisons for the individual groups for the global PK binding 
values, hotspot PK binding mean and hotspot PK binding volume with equivalent 




Appendix D: Correlations between BBB permeability 
and PK 
 
Correlations were investigated between the BBB permeability and PK values for all 
of the patients combined.  
 
 
D.1 Statistical Analysis 
Spearman’s rank correlation test was used to test all of the correlations between BBB 
permeability and respective PK binding values. P values were adjusted for multiple 




Correlations between all of the BBB permeability and PK binding parameters for all 
of the participants combined can be found in Table D.1. In the WM, there was a 
significant correlation seen between the global mean value from the PK binding and 
the mean value of the BBB permeability hotspots (Spearman’s Rho = 0.41, p<0.05). 
There were no other significant correlations seen for any of the other WM values or 







Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.27 0.21 0.08 
Hotspot mean  0.41*    0.31 0.24 





Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.11 0.28 0.11 
Hotspot mean 0.11 0.28 0.21 





Global mean Hotspot mean Hotspot volume 
BBB 
Global mean 0.15 0.08 -0.02 
Hotspot mean 0.19 -0.02 -0.01 
Hotspot volume 0.1 0.05 0.01 
*p<0.05, **p<0.01, ***p<0.001 
 
Table D.1: Correlation matrices of Spearman’s Rho values for associations between 
BBB permeability and PK binding parameters in all the patients combined.  1) WM. 
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